Genetic disorders in the growth hormone-IGF-I axis by Walenkamp, M.J.E.
Genetic Disorders in the 
Growth Hormone – IGF-I Axis
Marie-José Walenkamp
Genetic Disorders 
in the Growth Hormone – IGF-I Axis
ISBN: 978-90-9022266-0
Printed by:  Pasmans Offsetdrukkerij BV, Den Haag
Cover adapted from design by Tercica Inc. (Brisbane, CA, USA), reproduced with permission
For publication of this thesis financial support from Novo Nordisk Farma B.V., Pfizer B.V. 
Ferring geneesmiddelen B.V., Ipsen Farmaceutica B.V. and Eli Lilly Nederland B.V. is grate-
fully acknowledged.
© 2007 M.J.E. Walenkamp
Genetic Disorders 
in the Growth Hormone – IGF-I Axis
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 8 november 2007
klokke 16.15 uur
door
Maria Josephina Elisabeth Walenkamp
geboren te Haarlem
in 1966
P r o m ot i e c o m m i s s i e
Promotor Prof. dr. J.M. Wit
Copromotores Dr. A.M. Pereira
 Dr. M. Karperien
Referent Dr. C. Camacho-Hübner (University of London)
Overige leden Prof. dr. S.L.S. Drop (Erasmus Universiteit Rotterdam)
 Prof. dr. J.A.Romijn 
If you can look into the seeds of time,
and say which grain will grow and which will not…..
William Shakespeare, Macbeth, Act 1 Scene 3
Aan mijn ouders,
Xavier, Fleur en Emilie

Ta b l e  o f  c o n t e n t s
Chapter 1  General introduction
Chapter 2 Genetic disorders in the Growth Hormone – Insulin-like 
Growth Factor-I axis. 
 Hormone Research 2006;66:221-230
Chapter 3 Large height gain by growth hormone therapy in combi-
nation with GnRH analog in two pubertal sibs with a GH-
releasing hormone receptor mutation. 
 Submitted
Chapter 4 Clinical and biochemical characteristics of a male patient 
with a novel homozygous STAT5b mutation. 
 The Journal of Clinical Endocrinology and Metabolism 2006; 91(9): 3482-3485
Chapter 5 Growth hormone secretion and immunological function of 
a male patient with a homozygous STAT5b mutation. 
 European Journal of Endocrinology 2007;156(2):1-12
Chapter 6 Homozygous and heterozygous expression of a novel 
Insulin-like Growth Factor-I mutation. 
 The Journal of Endocrinology and Metabolism 2005;90(5):2855-2864
Chapter 7 Structural and functional characteristics of the Val44Met 
Insulin-like Growth Factor-I missense mutation: correlation 
with effects on growth and development. 
 Molecular Endocrinology 2005;19(3):711-721
Chapter 8  A variable degree of intrauterine and postnatal growth 
retardation in a family with a missense mutation in the 
Insulin-like Growth Factor I receptor. 









Chapter 9 Successful long-term growth hormone therapy in a girl with 
haploinsufficiency of the IGF-I receptor due to terminal 
15q26.2->qter deletion. 
 Submitted
Chapter 10 General discussion
 Genetic disorders in the GH-IGF-I axis in mouse and man. 















Growth is a complex process leading to an increase in size. On a cellular level growth 
is determined by an equilibrium between hyperplasia (increase in cell number), 
hypertrophy (increase in cell size), and apoptosis (programmed cell death). These 
cellular processes are regulated by multiple factors. External factors, including 
nutrition, psychosocial factors and physical environment interact with internal 
factors as genetic make-up, hormones and growth factors (1). Despite this com-
plexity, most children grow in a remarkably predictable manner. Deviation from 
the normal growth pattern can be one of the first manifestations of a disruption of 
this growth process due to an underlying disorder. Accurate assessment of growth 
and knowledge of normal growth is therefore a prerequisite for optimal care of 
children (2). 
St a ge s  o f  g r ow t h 
Four distinct stages of growth can be considered: fetal, infant, childhood and 
puberty. 
With respect to fetal growth, the first trimester is characterized by forming of the 
organ systems, coordinated by the expression of various developmental genes. 
Major cellular hyperplasia takes place in the second trimester, in which peak 
growth velocity is reached (approximately 62 cm/year) (3). The third trimester is 
dominated by maturation of the organs and further body growth. The intrauterine 
environment, determined by maternal factors and placental function, has a large 
impact on fetal growth throughout gestation. The poor correlation between birth 
size (weight and length) and parental size reflects the dominant influence of this 
intrauterine environment over the genotype (3). Fetal factors associated with poor 
intrauterine growth consist of chromosomal abnormalities as trisomy 21, Turner 
syndrome and Cornelia de Lange syndrome. Endocrine factors that have been 
identified to play a role in intrauterine growth are IGF-I, IGF-II, and insulin.
In infancy (the first year of life) children grow rapidly (25 cm/year), but at a deceler-
ating rate. Besides nutritional input the GH-IGF-I system, as well as genetic factors 
play a role in this stage. In the first two to three years the child establishes its own 
growth channel, which is highly correlated with target height (gender-corrected 
mid-parental height). By four years of age average growth velocity is 7 cm/year. 




nant of growth. Puberty is the last growth phase, characterized by a growth spurt 
followed by a rapid decrease of growth velocity due to fusion of the growth plate. 
Besides GH and IGF-I, estrogen is the main determinant of pubertal growth and 
epiphysial fusion in boys and girls (1).   
As discussed above, various known and unknown factors play a role in the process 
of growth and development in different stages of life. This thesis will focus on the 
consequences of genetic defects in the GH-IGF-I axis on this complex process.
T h e  G H - I G F - I  a x i s  –  t h e  h i st o r i c a l  p e r s p e c t i ve
Sixty years ago a method for measuring growth hormone activity in human plasma 
still had to be discovered. At present, the molecular mechanisms underlying GH 
and IGF-I action are topics of intense research. In the next paragraph the mile-
stones in the history of the GH-IGF-I axis that lead to our current knowledge will 
be described (4).  With this knowledge we were able to identify new genetic defects 
in patients with short stature, that were previously diagnosed as idiopathic short 
stature. Consequently, these patients have helped us to further unravel the role of 
the GH-IGF-I axis in growth and development.
Until 1956, GH activity could only be measured with the “tibia test”: adminis-
tration of GH increases the thickness of the proximal epiphyseal cartilage of the 
tibia in hypophysectomized rats (5, 6). In 1957 Salmon and Daughaday measured 
the uptake of radioactive sulphate into costal cartilage in hypophysectomized rats 
and discovered that, if 10% normal rat plasma was added, there was a 200-300% 
increase in sulfate uptake. With the administration of increasing doses of GH, 
however, the sulphate uptake was only slightly increased (7). This laid the basis for 
their hypothesis that a GH dependent factor, which they termed sulfation factor 
(SF), was responsible for the stimulation of sulfate uptake. They found low levels 
of SF activity in patients with hypopituitarism, while patients with acromegaly had 
high levels of activity. Further proof came from administration of purified human 
GH to patients with hypopituitarism, which resulted in an increased serum SF level 
(8), while GH administered to a patient with Laron dwarfism failed to increase the 
low serum sulfation factor concentration (9). The findings that not only sulphate 
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uptake, but also protein and DNA synthesis was stimulated in a GH dependent 
way, and the observation that SF was active in muscle as well, led to the intro-
duction of the more general term: somatomedin, which reflected the expanding 
scope of SF action (10). The original somatomedin hypothesis was formulated, 
proposing that GH stimulates somatomedin synthesis and release from the liver 
and that somatomedin reaches the main target organs via the circulation to act as 
an endocrine agent (Fig. 1, left panel) (10). In the meantime, another research field 
showed that non-suppressible insulin-like activity (NSILA) fractions demonstrated 
somatomedin activity, when added to hypophysectomized rats. On the other hand 
somatomedin had NSILA action. This raised the suspicion that somatomedin and 
NSILA were identical. The primary structure of two components of NSILA was 
published in 1978, which were termed Insulin-like Growth Factor-I and –II  (IGF-I 
and IGF-II) (11, 12). In 1983, Klapper, and colleagues demonstrated that somato-
medin-C was identical to IGF-I (13). 
In the seventies, the IGF binding proteins (IGFBP’s) were discovered (14, 15). After 
isolation of IGFBP-1 (16) Furlanetto et al. showed that the major IGF-BP complex 
in serum was composed of three elements: somatomedin, an acid stable and an 
acid-labile subunit (17). The latter two components were IGFBP-3 and ALS. The 




binding proteins appeared to act as carrier proteins, prolonging the half life of the 
IGF’s by protecting them from proteolytic degradation, regulating the local action 
of  IGF’s and modulating IGF-I receptor activation. In addition, they seemed to 
regulate cell activity in various ways (18). 
In the 1980’s molecular biology allowed to determine that IGF-I was expressed in 
multiple tissues throughout embryonic and postnatal development and adult life, 
indicating that IGF-I also acts in a paracrine manner (19, 20). A revised version of 
the somatomedin hypothesis postulated that both endocrine and locally produced 
IGF-I are responsive to GH and therefore responsible for the effects of GH (Fig. 1, 
middle panel) (21). In addition, strong indications were found that GH also had a 
Table 1. Characterization of genes in the GH-IGF-I axis and the first clinical report on a genetic defect.
Gene Characterization First clinical report on genetic defect 
GH1 1979, Martial et al. Human growth hor-
mone: complementary DNA cloning and 
expression in bacteria (31)
1981, Phillips et al. Molecular basis for familial 
isolated growth hormone deficiency. (32)
GHR 1987, Leung et al. Growth hormone recep-
tor and serum binding protein: purification, 
cloning and expression (33)
1989, Godowski et al. Characterization of the 
Human Growth Hormone Receptor Gene and 
Demonstration of a Partial Gene Deletion in 
Two Patients with Laron-Type Dwarfism (34)
GHRH 1992, Mayo et al. Molecular cloning and 
expression of a pituitary-specific receptor 
for growth hormone-releasing hormone 
(35)
1996, Wajnrajch et al. Nonsense mutation in 
the human growth hormone-releasing hor-
mone receptor causes growth failure analo-
gous to the little (lit) mouse (36)
IGF-I 1983, Jansen et al.  Sequence of cDNA 
encoding human insulin-like growth factor I 
precursor (37)
1996, Woods et al. Intrauterine growth retar-
dation and postnatal growth failure associ-
ated with deletion of the insulin-like growth 
factor I gene (38)
IGF1R 1992, Abbott et al. Insulin-like growth factor 
I receptor gene structure (39)
2003,  Abuzzahab et al. IGF-I receptor muta-
tions resulting in intrauterine and postnatal 
growth retardation (40)
STAT5b 1996, Silva et al. Characterization and clon-
ing of STAT5 from IM-9 cells and its activa-
tion by growth hormone (41)
2003,  Kofoed et al. Growth hormone insensi-
tivity associated with a STAT5b mutation (42)
ALS 1988, Baxter RC. Characterization of the 
acid-labile subunit of the growth hormone-
dependent insulin-like growth factor binding 
protein complex (44)
2004, Domene HM et al. Deficiency of the 
circulating insulin-like growth factor system 
associated with inactivation of the acid-labile 
subunit gene (45)
GHSR 1996, Howard et al. A receptor in pituitary 
and hypothalamus that functions in GH 
release (30)
2006, Pantel et al. Loss of constitutive activity 
of the GHSR in familial short stature (43)
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direct effect on the epiphyseal growth plate (22). Experiments with IGF-I knockout 
mice, exhibiting a birth weight of only 60% of normal, indicated a direct, GH-inde-
pendent effect of IGF-I on prenatal growth (23-25). 
Tissue specific gene deletion experiments in mice resulted in the most recent, but 
undoubtedly not the final, revision of the somatomedin hypothesis, incorporating 
the role for IGF-I in glucose homeostasis and bone modeling (Fig. 1, right panel) 
(26). Mice with liver-specific IGF-I gene-deletion (LID) and consequently markedly 
reduced circulating IGF-I levels develop insulin resistance (27). In addition, these 
LID mice show a significant decrease in cortical bone volume (27). 
Genes encoding the different components of the GH-IGF-I axis have now been 
identified and in the last few years mutations and deletions in these genes have 
been described in the human. Table 1 shows the original reports on the character-
ization of the genes involved in the GH-IGF-I axis and the first clinical description 
of the genetic defect.   
T h e  G H - I G F - I  a x i s  –  p r e s e n t  v i e w
GH secretion is regulated by the hypothalamic factors GH releasing hormone 
(GHRH) and somatostatin. The pulsatile fashion of GH secretion is regulated 
by an interaction between these hormones. The release of GH is controlled by a 
wide range of other neurotransmitters and neuropeptides (28). The most potent 
GH secretagogue is ghrelin, a hormone predominantly produced by the stomach 
(29) whose plasma levels fluctuate with food intake. Ghrelin acts via the growth 
hormone secretagogue receptor (GHSR), which is highly expressed in the brain 
and in the pituitary (30). 
The biological actions of GH are mediated by the transmembrane GH receptor 
(GHR). The GHR is a cytokine receptor, subject to various modifications during 
synthesis of which the generation of a soluble GH binding protein (GHBP), consist-
ing of the extracellular domain of the GHR, is the most significant. The GHR uses 
the JAK-STAT signal transduction pathway (Fig. 2). Activation of the receptor ulti-
mately results in transcription of target genes, including IGF-I, IGFBP-3, and ALS. 
Binding of IGF-I to the IGF-I receptor type I results in activation of this tyrosine 
kinase receptor leading to the physiological actions of IGF-I (Fig. 3). 
Chapter 1
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Figure 2. GH signal transduction pathway (with permission from (21) copyright 2001, The Endocrine Society).
Figure 3. IGF-I signal transduction pathway (with permission from (21) copyright 2001, The Endocrine Society).
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O u t l i n e  o f  t h i s  t h e s i s
Alert physicians, collaborating with geneticists and molecular biologists have 
presented many reports on patients with genetically determined causes of short 
stature. This thesis, describing the phenotypical and molecular characteristics of 
patients with genetic defects in various components of the GH-IGF-I axis is the 
result of such collaboration. The aim of this thesis was to study the genotype-
phenotype relationship in these patients and to unravel the role of the GH-IGF-I 
axis in the complex process of growth and development throughout life. 
Chapter 1 offers a general introduction and is followed by a review on genetic 
disorders in the GH-IGF-I axis, including a proposal for the diagnostic evaluation 
of patients with severe short stature in chapter 2. 
Classical GH deficiency can be the result of mutations in the GHRH receptor gene, 
a defect in one of the genes involved in pituitary development or a mutation or 
deletion in the GH1 gene. Chapter 3 describes two sibs with a GHRHR mutation 
and this report is focused on the positive effect of the combined treatment of GH 
and GnRH analogue on final height.
GH insensitivity is caused by a genetic defect of the GHR (Laron syndrome) or a 
post GHR signaling defect. The first male patient with GH insensitivity caused by 
a homozygous STAT5b mutation is described in chapters 4 and 5: the clinical and 
biochemical features in chapter 4 and a detailed description of the growth hormone 
secretion pattern and immunological function in chapter 5. 
The first patient with a homozygous missense mutation of the IGF-I gene, resulting 
in a bioinactive IGF-I protein is described in chapter 6, followed by the structural 
and functional analysis of the mutant IGF-I in chapter 7. 
IGF-I resistance can be the result of genetic defect of the IGF-I receptor. In chapter 8 
a mother and daughter with a heterozygous missense mutation in the intracellular 
part of the IGF1R is described. A positive effect of GH treatment in a patient with 
a heterozygous terminal 15q deletion, including the IGF1R receptor, shows the 
clinical implications of this defect in chapter 9.  
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A b st r a c t
In the last few years our knowledge of genetically determined causes of short stature 
has greatly increased by reports of challenging patients, who offered the opportu-
nity to study genes that play a role in growth. Since the first paper that showed the 
etiology of Laron syndrome (1), many mutations in the growth hormone receptor 
have been identified. Recently, new mutations or deletions have been found in 
several components of the GH-IGF-I axis: a homozygous mutation of the GH1 
gene, resulting in a bio-inactive GH; mutations in the STAT5b gene, which plays 
a major role in the GH signal transduction; a homozygous missense mutation in 
the IGF-I gene; heterozygous mutations in the IGF1R gene and a homozygous 
deletion of the ALS gene. In this mini review we describe the clinical and biochemi-
cal features of these genetic defects.
Genetic analysis has become essential in the diagnostic workup of a patient with 
short stature.     
However, regarding the time consuming nature of molecular analysis, it is important 
to carefully select the patient for specific genetic evaluation. To help in this selection 
process we developed flowcharts, based on the recently described patients, that 
can be used as guidelines in the diagnostic process of patients with severe short 
stature of unknown origin.
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I n t r o d u c t i o n
Body growth is regulated by many genes, of which only a few have been clarified. 
However, in the last years our knowledge of genetically determined causes of short 
stature has greatly increased and genetic analysis is becoming essential in the 
diagnosis of short stature. 
A review article in this journal in 2003 described the most important genetically 
determined causes of short stature and the genes involved (2). Only two years 
later important papers were published presenting new diseases, caused by genetic 
defects in the GH-IGF-I axis. In this review we will give an overview of the clinical 
aspects and the biochemical parameters for these genetic defects in the GH-IGF-I 
axis and we present a flow chart for the diagnostic approach of these disorders. 
We will focus on those children, whose height is more than 2.5 SDS below the mean 
of the population reference. The first discriminating step in the diagnostic process 
of short stature is the presence or absence of dysmorphic features or disproportion-
ate stature. Hereditary causes of short stature in combination with dysmorphic or 
disproportionate features were reviewed by Kant et al. (2).  In summary, in case of 
dysmorphic features a chromosomal abnormality (numeric, structural, mosaic or 
uniparental disomy (UPD)) is suspected and karyotyping is indicated. Dysmorphic 
features may be minor, as seen in patients with Silver-Russell syndrome, who have 
in 10% of the cases UPD of chromosome 7. One can consider to look for Noonan 
syndrome, Prader Willi syndrome or 22q11 deletion in patients with short stature 
and subtle dysmorphic features. 
Disproportionate short stature is the result of skeletal dysplasia, a category of 
disorders affecting in most cases the epiphysis, metaphysis or diaphysis of the long 
bones, with specific radiological characteristics. The genetic basis of these disorders 
is emerging, as many skeletal dysplasia gene loci have been identified. More than 
half of all patients with skeletal dysplasias have a mutation at COL2A1 or FGFR3. 
Mutations in the SHOX gene are even more frequent, but do not always present 
with skeletal abnormalities. 2-3% of the children with idiopathic short stature have 
a SHOX deletion or mutation (3). It is particularly worthwhile to look for a SHOX 
deletion or mutation because treating these children with GH results in a similar 
catch-up growth as seen in girls with Turner syndrome treated with GH. Recently 
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deletions in the pseudoautosomal region downstream the SHOX gene were identi-
fied in patients with Leri Weill dyschondrosteosis (4). Phenotypically these patients 
were indistinguishable from patients with SHOX deletion. 
The child with proportionate short stature should be screened for organic, systemic 
and endocrine disorders. In children born small for gestation age (SGA) and a small 
head circumference chromosome disorders, congenital infections or exposure to 
toxins should be considered. After excluding organic and systemic diseases, IGF-I 
and IGFBP-3 measurements serve to focus on disturbances in the GH-IGF-I axis. 
As further diagnostic procedures heavily depend on IGF-I and IGFBP-3 concen-
trations, we would like to stress the importance of a reliable IGF-I and IGFBP-3 
assay.
G H - I G F - I  a x i s
The GH-IGF-I axis plays a key role in regulating somatic growth. Genetic defects in 
one of the components (pituitary GH secretion, GH receptor (GHR), postreceptor 
signaling and IGF-I) of this axis usually result in proportionate growth retardation. 
In the last years several patients with new genetic defects in the GH-IGF-I axis have 
been identified. We will summarize the genetic, biochemical and clinical aspects of 
these new findings (Table 1).
Pituitary GH secretion
Classical GH deficiency can be the result of a mutation in the GH releasing hormone 
receptor (GHRH-R) gene (5), a genetic defect in one of the genes playing a role 
in the ontogenesis of the GH producing cells in the anterior pituitary (POU1F1, 
PROP1, HESX1, LHX3, LHX4 etc.) (6) or a mutation or deletion of the GH1 gene 
(6). Dysfunctional GH variants, caused by heterozygous missense mutations in the 
GH1 gene, have been described by Takahashi et al. (7). Recently, the first homozy-
gous missense mutation in the GH1 gene (GH-C53S) has been described (8). This 
mutation leads to the absence of the disulfide bridge Cys-53 to Cys-165, resulting 
in reduced GHR binding and signaling. These genetic defects are comparatively 
rare causes of short stature.





















Birth weight LN LN LN ⇓ ⇓ ⇓ ⇓ N
Birth length LN ⇓ or LN LN ⇓ ⇓ ⇓ ⇓ LN
Birth head 
circ.
LN LN LN ? ⇓ ⇓ ⇓ ?
Parental 
height
N N N ? LN LN





N N ⇓ or N N N N ⇓ N
Milestones N N N N ⇓ ⇓ N or  ⇓ N
Psychomotor 
development
N N N N ⇓ ⇓ N or  ⇓ N
Immuno-
deficiency
- - + or - - - - - -
Physical 
exam
Height ⇓ ⇓ ⇓ -2 SD ⇓ ⇓ ⇓ -3.6 SD
Weight for 
height
N N ? N ⇓ ⇓ ⇓ ?

















GH peak ⇓ 
or N, 12hr. 
profile  ⇓
⇑ ⇑ N ⇑ ⇑ ⇑ or N ⇑
IGF-I ⇓ ⇓ ⇓ ⇓ ⇓ ⇑ N or ⇑ ⇓
IGF-II ⇓ ? N ⇓ N N N ?
IGFBP-3 ⇓ ⇓ ⇓ ⇓⇓ N N N ⇓
Insulin ⇓ N N ⇑ ⇑ N ? ?
ALS ⇓ ? ⇓ 0 N N ⇑ ?
Prolactin N N ⇑ N N N N N
Radiology
Skeletal age ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓
Table 1. Clinical and biochemical features of genetic defects in the GH-IGF-I axis.
N = normal, LN = lower normal range
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Recent studies demonstrate high diversity in the proximal promoter region of the 
GH1 gene, resulting in some haplotypes that are associated with a reduced level of 
gene expression, while other haplotypes were associated with increased expression 
(9). One can speculate that a haplotype, associated with reduced expression of 
GH, results in a condition with low spontaneous GH secretion and thus low levels 
of IGF-I, while stimulated GH secretion may be normal.
Growth hormone receptor and GH signaling
The biological effects of GH can only be reached in the presence of a normal 
functioning GHR, and an intact postreceptor signaling pathway. Deletions and 
mutations in the extracellular domain of the GHR gene result in classical GH insen-
sitivity (Laron syndrome). More recently, mutations in the transmembrane and 
intracellular domain of the receptor were identified, resulting in GH insensitivity 
syndrome with normal or high levels of GH binding protein (GHBP) (10-12). 
The first report of a specific molecular defect in the GH signal transduction was 
published by Kofoed et al. in 2003 (13). The authors described a patient with a 
homozygous missense mutation in the highly conserved SH2 domain of the STAT5b 
gene, which is essential for the GH signaling cascade and IGF-I transcription. At 
the moment of writing this review, several patients with homozygous mutations in 
the STAT5b gene have been described: a frame shift mutation (14, 15), a nonsense 
mutation (16), another frameshift mutation (17), and a splice site mutation (18). 
All patients appear to show hyperprolactinaemia; some of them have a serious 
immunodeficiency, while others show no such clinical symptoms.
Recently, a heterozygous mutation of the IκB gene was described (19, 20). IκB is 
part of the NFκB signaling pathway, playing a major role in immune responses. 
Besides severe immune deficiency, this patient also had signs of partial GH insen-
sitivity, suggesting that the NFκB pathway could play a role in the GH signal trans-
duction.
IGF-I
One of the biological effects of GH is stimulating IGF-I production, which is mainly 
taking place in the liver, but also in all other cells of the body. IGF-I has endocrine, 
paracrine and autocrine functions. IGF-I secretion is under control of many other 
factors than GH (e.g nutrition). IGF-I, IGF-II and insulin are the most important 
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regulators of prenatal growth. Postnatally, IGF-I remains important, while the 
role of IGF-II is still unclear. In 1996 one patient with a homozygous deletion of 
exons 4 and 5 of the IGF-I gene was described. Phenotypically he showed intra-
uterine growth retardation, postnatal growth failure, microcephaly, mental retar-
dation, sensorineural deafness and multiple dysmorphic features (21). In 2003, 
a patient with intrauterine growth retardation, short stature, delayed psychomo-
tor development and sensorineural deafness was described, with a homozygous 
mutation, changing the normal amino acid sequence of the E domain of the IGF-I 
precursor, resulting in low circulating levels of IGF-I (22).  In 2005, we described 
the first patient with a homozygous missense mutation of the IGF-I gene (23). The 
phenotype of this 55 year old patient was similar to that of the patient with an IGF-
I deletion (21). Family members with a heterozygous IGF-I mutation were shorter 
and had lower head circumferences than family members without the mutation. 
Recently, a boy was presented with a partial IGF-I deficiency due to a homozygous 
missense mutation of the IGF-I gene, resulting in pre- and postnatal growth retar-
dation, microcephaly, mild developmental delay and normal hearing tests (24). 
In the circulation IGF-I is bound to binding proteins (IGF-binding proteins, 
IGFBP’s). These proteins exhibit specific characteristics in relation to delivery 
of IGF-I to different tissues. IGFBP-3 production is strongly dependent on GH. 
IGFBP-3 forms with IGF-I and acid-labile subunit (ALS) a ternary complex in the 
circulation. A homozygous deletion of the ALS gene, resulting in a “circulating IGF-
I deficiency”,  was described in 2004 (25). This patient was not very short, but had 
a very delayed puberty. Later, a boy with a similar phenotype was reported (26).
IGF-I receptors (IGF1R) are widely spread through the body. Children with a 
deletion of the distal long arm of chromosome 15, which includes the IGF1R gene, 
are short (27). It was assumed that specific mutations/deletions of the IGF1R gene 
could result in growth retardation.
The first report on mutations in the IGF1R gene was published in 2003 by 
Abuzzahab et al. (28): a compound heterozygous mutation of the IGF-IR gene, 
resulting in reduced IGF-I binding and decreased receptor phosphorylation and a 
nonsense mutation in exon 2, resulting in reduced expression of  IGF1R. Recently, 
a heterozygous mutation in the cleavage site of the proreceptor of IGF1R was 
reported in a 6 year old Japanese girl and her mother (29). We described a mother 
and daughter with a heterozygous missense mutation in the intracellular part of 
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the IGF1R (30). A 13.6 year old girl was presented with a heterozygous missense 
mutation in the highly conserved N-terminal fibronectin type III domain of the 
IGF1R (31). Recently a new heterozygous missense mutation at the 
α subunit of the IGF-I receptor was described in a 4 year old girl with short stature 
(-3.6 SDS) and her mother (32).
P r o p o s a l  f o r  a  d i a g n o st i c  f l ow  c h a r t  f o r  p a t i e n t s  w i t h 
s e ve r e  s h o r t  st a t u r e  o f  u n k n ow n  o r i g i n
Although we acknowledge that undoubtedly future studies will show additional 
cases of the genetic defects described above, as well as new genetic disorders, we 
think that developing a diagnostic algorithm might be helpful in the evaluation of 
severely short children. For this purpose, we developed some flowcharts, based on 
the recently described patients, in combination with theoretical considerations. 
The flowcharts can be used as guidelines in the diagnostic process of patients with 
idiopathic short stature. As our knowledge of genetic causes of short stature is 
increasing rapidly, these diagrams undoubtedly will be subject of adaptation in the 
coming years. 
As main inclusion criterium for considering genetic evaluation we choose a height 
SDS of < -2.5, assuming that more pathology is found with a lower height SDS. 
We believe that deviation of growth is not a valuable parameter, as in some of 
the earlier described cases growth is far below, but parallel to, the –2.5 SDS line. 
Similarly, target height cannot be used as criterium, because in some cases parents 
are short due to the same genetic defect (as in the cases of heterozygous IGF1R 
mutations). 
Fig. 1 shows the first diagnostic step in a child with a height < -2.5 SDS. Propor-
tions should be measured and in case of disproportionate short stature a skeletal 
survey is performed and the child is referred to a clinical geneticist. Radiological 
abnormalities can point to a known skeletal dysplasia, requiring specific molecular 
analysis. If no or minimal radiological abnormalities are found, the SHOX and 
FGFR3 gene can be analysed, as in some cases mild disproportionate short stature 
is the only clinical feature (33, 34). 
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Karyotyping should be carried out, when dysmorphic features are found, but also 
in the absence of dysmorphic features karyotyping is usually carried out in all girls 
with unexplained short stature. Recently, it was argued that also in boys with short 
stature karyotyping should be considered, in order to diagnose a XY/X chromo-
somal pattern (35). In the dysmorphic child with a normal karyogram a genetic 
defect of the GH-IGF-I axis is still possible: e.g. the patient with a deletion of the 
IGF-I gene (21) and the patients with IGF1R gene mutation showed dysmorphic 
features (28). Obviously, if another cause for short stature is found by basic diag-
nostic screening, genetic analysis of the GH-IGF-I axis is not indicated. 
The next criterium in a child with proportionate short stature is the presence or 
absence of being SGA, defined as a birth weight or length of <-2 SDS. In case 
of SGA, further investigations will be focused on genetic defects of IGF-I produc-
tion or sensitivity. Indeed, children with classical GH deficiency or insensitivity are 
usually not born SGA. In case of SGA one should look for mutations or deletions 
in the IGF-I or IGF1R gene or a IGF-I signal transduction defect. In children with 
a normal birth weight and length additional testing should be focused on distur-
bances in GH secretion, GH sensitivity or GH signaling. 
Figure 1. Flow chart for the diagnostic approach of a child with short stature (< -2.5 SDS). 
Disproportionate/dysmorphic ? 
Basic diagnostic 
screening abnormal ? 













Yes  No 
FGFR-3







In children with short stature, born SGA, measuring the head circumference is 
essential. IGF-I plays a key role in intrauterine growth and cerebral development 
and prenatally IGF-I secretion is GH independent. Therefore, in SGA children with 
a small head circumference primary IGF-I deficiency or insensitivity should be con-
sidered (Fig. 2). The IGF-I level will determine the differential diagnosis. Undetect-
able IGF-I levels will indicate a homozygous IGF-I deletion or nonsense mutation 
with absolutely no production of IGF-I. Theoretically one can expect very low IGF-I 
levels in cases of a homozygous missense mutation in the IGF-I gene resulting in an 
abnormal IGF-I protein that can only be partially detected by the assay. IGF-I levels 
between –2 and 0 SDS could be the result of heterozygous mutations or deletions 
of IGF-I. It is conceivable that in the future polymorphisms in the promoter region 
of the IGF-I gene will be found that may explain the short stature in some of 
these cases. In case of a heterozygous mutation of IGF1R plasma IGF-I is usually 
elevated, but it can be low if the child is malnourished by extremely poor appetite 
(30). In spite of these theoretical possibilities, at present, we do not advise further 
genetic analysis, at least with the current tools available, in patients with IGF-I 
levels in the lower normal range. The differential diagnosis in patients with normal 
or high IGF-I levels consists of a homozygous IGF-I missense mutation, resulting in 
an abnormal IGF-I molecule, or a heterozygous IGF1R mutation with decreased or 
absent binding of IGF-I to the mutated receptor. In all these conditions IGFBP-3 
levels are within the normal range. 
With a normal head circumference these genetic defects are less probable, but they 
cannot be completely ruled out. Heterozygous mutations or deletions of the IGF-I 
or IGF1R gene could present with short stature, SGA and a head circumference 
>-2 SDS. One may consider to perform in vitro experiments with fibroblasts of 
patients, that meet these criteria. Depending on the sensitivity of the fibroblasts to 
IGF-I, the IGF-I gene or the IGF1R gene can be sequenced. 
We will now discuss the group of patients with short stature and a normal birth 
weight and length. The first diagnostic step in these patients is to determine the 
IGF-I and IGFBP-3 levels. If the IGF-I level is below the normal range (<-2 SDS) the 
interpretation of the GH peak in a stimulation test determines the next step (Fig. 
3). An MRI of the pituitary-hypothalamus region should be performed to demon-
strate or exclude anatomical defects.  
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GH deficiency is usually diagnosed if the GH peak is below 20 mU/L (equivalent 
to 6.6, 7.7 or 10 µg/L, depending on the standard used) in two tests. Depending 
on the presence of other pituitary hormone deficiencies analysis of transcription 
factors as HESX-1, PROP-1, and Pit 1 is required. In special cases analysis of LHX3 
or LHX4 can be considered. In case of isolated GH deficiency we advise to analyse 
the GH and GHRH-R gene, but one can argue that these tests could be restricted 
to those children in whom a positive family history for short stature or extremely 
short stature is found. 
A GH peak within the lower normal range (20-30 mU/L) can be the result of a 
disturbance in the GH secretion and one can consider to analyze the GH promoter 
gene. In several countries, including the Netherlands, the combination of very low 
IGF-I and borderline GH peaks after stimulation, is sufficient indication for GH 
therapy. A low 12- or 24 hr profile, which has been termed “neurosecretory dys-
function” by several investigators, could be used as criterium for analysis of the GH 
promoter gene.
Figure 2. Flow chart for the evaluation of a child with proportionate short stature, born SGA and a 
head circumference < -2 SDS. 
Height < -2.5 SDS 
SGA
Head circumference < -2 SDS 
IGF-I
Undetectable < -2 SDS > – 2 SDS and < 0 SDS > 0 SDS 
DD










IGF-I and IGF1R 
Polymorphism IGF-I promoter
DD
Heterozygous IGF1R mutation 
Homozygous IGF-I missense 
mutation
Mutation  analysis: 








A normal GH peak (30-40 mU/L) in combination with low IGF-I levels in patients 
with clinical features of GH deficiency and retarded skeletal maturation can be 
present. In these cases a low 12- or 24 hr GH profile could reflect a relatively inactive 
GH promoter haplotype. One should note, however, that in some cases with a GH 
signaling disorder very low IGF-I levels in the presence of normal GH peaks have 
been found.
The differential diagnosis of a low IGF-I  in combination with a high stimulated GH 
secretion (GH peak > 60 mU/L) consists of: bio-inactive GH, a GHR defect, a GH 
signal transduction defect (STAT5b mutation) or an ALS deficiency (Fig. 4). The 
response of IGF-I to increasing doses of GH (the IGF-I generation test, described in 
Table 2) will roughly distinguish the conditions characterized by an abnormal GH 
molecule from GH insensitivity states. We are aware that many different protocols 
for the IGF-I generation test have been described, and that the diagnostic value 
of all of them is still uncertain. Theoretically, in patients with a bio-inactive GH, 
IGF-I will reach normal levels with the lowest GH dose, while in patients with a GH 
Figure 3. Flow chart for the evaluation of a child with proportionate short stature, normal birth weight 
and length, low IGF-I levels (< -2 SDS) and a GH peak in a stimulation test < 40 mU/L. 
Height < -2.5 SDS 
Normal birth weight and length 
IGF-I < -2 SDS
GH stimulation test 
GH peak < 20 mU/L 
Other pituitary deficiencies ? 
Yes
All axes: HESX-1
GH, LH/FSH, TSH, prolactin: PROP-1 
GH, TSH, prolactin: Pit 1
 No 
Mutation GHRH-R gene 
Mutation/deletion GH gene 
Positive family history 
Extremely small stature 
Idiopathic isolated GH 
deficiency 
 No Yes
Analysis GH and GHRH-R
GH peak 20-30 mU/L 




Analysis GH promoter 
Idiopathic
GH peak 30-40 mU/L 
Analysis GH promoter gene
Figure 3 
GH promoter mutation 
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receptor or postreceptor problem IGF-I will not increase or only on the highest GH 
dose. 
Theoretically, an inactive GH promoter or partial GH insensitivity can result in low 
IGF-I levels with a normal GH peak in the stimulation test (40-60 mU/l). At his 
moment, however, we do not propose genetic analysis in these patients, as we 
think the time and money investment will not be balanced by the results. 
C o n c l u s i o n
In patients with short stature a systematic diagnostic approach may reveal the 
cause of the growth disorder. The medical history, including birth weight, length 
and head circumference, and physical examination, including body proportions, 
are necessary for the first differential diagnosis. Biochemical evaluation will point 
to a more specific diagnosis, which can be confirmed with molecular techniques. 
Figure 4. Flow chart for the analysis of a child with proportionate short stature, normal birth weight 
and length, low IGF-I levels (< -2 SDS) and a GH peak in a stimulation test > 60 mU/L. 
Height < -2.5 SDS 
Normal birth weight and length 
IGF-I < -2 SDS
GH stimulation test
GH peak > 60 mU/L 
IGF-I generation test 
> 1 SD increase of IGF-I 
with 0.7 mg/m2 GH
DD
Bio-inactive GH 
Analysis GH gene 
> 1 SD increase of IGF-I
with 1.4 mg/m2 GH
> 1 SD increase of IGF-I
with 2.8 mg/m2 GH
No increase of IGF-I 
with 2.8 mg/m2 GH
DD








Analysis GHR gene 
ALS deficiency 





In this review we discussed new genetic defects in the GH-IGF-I axis and proposed 
a practical flow chart for the diagnostic work-up. 
The proposed diagnostic pathways will lead to maximum results when pediatric 
endocrinologists, adult endocrinologists, clinical geneticists and molecular biol-
ogists cooperate. An unusual presentation of a patient with a growth disorder 
should alert the clinician to look for new abnormalities in the GH-IGF-I axis or 
other genes involved in growth. 
Table 2. IGF-I generation test.
Growth hormone dose Biochemical evaluation
Week 1 0.7 mg/m2/day IGF-I and IGFBP-3 at day 0 and day 8
Wash out period (at least 4 weeks)
Week 2 1.4 mg/m2/day IGF-I and IGFBP-3 at day 0 and day 8
Wash out period (at least 4 weeks)
Week 3 2.8 mg/m2/day IGF-I and IGFBP-3 at day 0 and day 8
The response criterium is defined as an increase of IGF-I of at least 1 SD on day 8. 
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A b st r a c t
Context: Patients with GHRH receptor (GHRH-R) mutations present with familial 
isolated GH deficiency, which untreated leads to a severely compromised adult 
height. Few data are available about the efficacy of treatment with GH in combina-
tion with a gonadotropin-releasing hormone (GnRH) analog (GnRHa) in adoles-
cence.   
Objective: To describe the evolution of growth and skeletal age of a brother and 
sister of Moroccan descent with a homozygous GHRH-R mutation who presented 
at an advanced age (16 and 14.9 years, respectively) and pubertal stage (Tanner 
stage G4 and B3, respectively) with a height of -5.1 SDS and -7.3 SDS on treatment 
with a combination of GH and GnRHa for 2.5 and 3 years followed by GH alone.  
Methods: GH was given in a dosage of 0.7 mg/m2/day (25 µg/kg/day) sc and 
triptorelin in a dosage of 3.75 mg/4 weeks im. Height and pubertal stage were 
measured three-monthly, bone age yearly. 
Results: Combined GH and GnRHa treatment resulted in a height gain of 24 cm 
and 28.2 cm respectively, compared to the initial predicted adult height by the 
method of Bayley-Pinneau. Adult height was within the population range and well 
within the target range. 
Conclusions: Our patients demonstrate that, in case of isolated GH deficiency 
caused by a GHRH-R mutation, combined treatment of GH and GnRHa can be 
very effective in increasing final height, even at an advanced bone age and pubertal 
stage
Large height gain by GH and GnRH therapy in GHRH-R mutation
41
I n t r o d u c t i o n
Growth Hormone Releasing Hormone (GHRH) and somatostatin are hypothalamic 
peptides that regulate the pulsatile GH secretion. GHRH stimulates GH synthesis 
and release, while somatostatin inhibits GH release (1). Binding of GHRH to the 
GHRH receptor (GHRH-R) activates the signaling cascade, resulting in cellular 
proliferation, GH synthesis, and secretion (2).
Several mutations in the GHRH-R gene have been identified, all showing an auto-
somal recessive inheritance pattern. Clinically, patients with homozygous GHRH-R 
mutations present with familial isolated GH deficiency (GHD), including propor-
tionate short stature, variable anterior pituitary hypoplasia, low IGF-I and IGFBP-
3 levels, subnormal stimulated GH levels and good response to exogenous GH 
(2-5). 
In 2001, we described the GH secretion in two patients with a novel homozy-
gous single base pair transition (G->C) at the splice donor site of intron VII of the 
GHRH-R gene (6). At the time of diagnosis, they were 14.9 and 16 years old and 
had reached an advanced stage of puberty. Both patients were treated with GH in 
combination with a gonadotropin-releasing hormone (GnRH) analog (GnRHa). 
We demonstrate that this combination can be highly effective in increasing final 
height, even at this advanced age and maturational stage.  
M e t h o d s
Auxological measurements
Height, body mass index (BMI) and target height were expresssed as standard 
deviation score (SDS) based on Dutch references for children of Moroccon descent 
(7). Sitting height/height ratio and head circumference were expressed as standard 
SDS based on Dutch references (8, 9). Target height was calculated from the 
parents heights corrected for sex and secular trend:  [height of father and mother 




Biochemical assays have been described previously (6). An arginine test was 
performed with 0.5 gr/kg arginine in 30 min.
Radiographic measurements
Bone age and predicted adult height was assessed by scoring the radius, ulna and 
short bones (RUS), using the Tanner and Whitehouse-2 (TW-2) method (10). 
In addition, bone age was assessed with the Greulich and Pyle method (11), and 
predicted adult height according to the tables of Bayley and Pinneau (12). 
Pa t i e n t s 
The patients were the third and fourth son and daughter of a Moroccan family 
with 6 children. The parents were not aware of consanguinity. The other four 
children were healthy. Father’s height was 170 cm and mother’s height was 156.4 
cm, resulting in a target height of 174.2 cm (0 SDS) for the brother and 161.2 cm 
(0 SDS) for the sister 
The boy was referred to our hospital because of short stature at the age of 16 yr. 
Three months before, he and his sister had immigrated from Morocco. No previous 
growth data were available. His medical history was uneventful and he had no 
other complaints. Auxological, biochemical, and radiological features are summa-
rized in Table 1. Total 24-h GH production was greatly diminished, as has been 
described earlier in detail (6). The maximal rise of TSH after 200 µg TRH was 5.7 
mU/liter after 20 min, which was considered a suboptimal response. A normal 
increase of prolactin was observed (from 4.5 to 15 µg/liter). Although computed 
tomography at the age of 16 yr showed a partial empty sella, a magnetic resonance 
imaging scan at the age of 25 yr showed no abnormalities of the pituitary and 
hypothalamus.
GH treatment was started at the age of 16.2 yr (Genotropin, Pharmacia, Stockholm, 
presently Pfizer, US) at a dosage of 0.7 mg/m2/day (25 µg/kg/day). After six weeks 
of GH treatment, a low level of total thyroxine was found (56 nmol/liter (normal 
value 70-160 nmol/liter)) with a normal T3 and TSH level. Substitution with levo-
thyroxine was initiated. Retesting 6 years later revealed a normal TSH response to 
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TRH  (6). Administration of 100 µg GnRH, showed a maximal increase of LH to 
10.1 U/liter, which was considered as a pubertal response. Plasma testosterone was 
32.4 nmol/liter (923 ng/dl). To prevent further progression of puberty and bone 
maturation, GnRH agonist (GnRHa) treatment was initiated one month after the 
start of GH (Decapeptyl CR, 3.75 mg every 4 wk im). GnRHa treatment resulted 
in prepubertal testosterone levels within one month and decreased the testicular 
volumes from 15 ml to 6 ml after 9 months of treatment. GnRHa was discontinued 
at the age of 18.7 yr (total duration of treatment 2.4 yr). Subsequently, the GH 
dose was increased to 1 mg/m2/day (34 µg/kg/day). Adult height was reached at 
Table 1. Auxological, biochemical and radiological characteristics of the patients.
Tanner stages: PH: pubic hair, G: genital, B:breast.
Variable Brother Sister
At start of GH therapy
Age (yr) 16 14.9
Height [cm (SDS)] 135.2 (-5.1) 116.9 (-7.3)
Weight (kg) 26.5 23
BMI [kg/m2 (SDS)] 14.5 (-2.9) 16.8 (-1.8)
Head circumference [cm (SDS)] 49.7 (-3.8) 50.3 (-2.7)
Sitting height/height [ratio (SDS)] 0.52 (0.2) 0.51 (-0.4)
Tanner stage PH4, G4 PH1, B3
IGF-I [ng/ml (SDS)] 14.5 (-7.0) 26.8 (-6.4)
GH maximum in exercise test (mU/liter) 2.8 0.5
GH maximum in arginine test (mU/liter) 5.0 1.3
Bone age - Greulich and Pyle (yr) 14 11.6
Predicted adult height – Bayley-Pinneau (cm) 144.2 127.4
Bone age – TW-2 (yr) 14.6 12.1
Predicted adult height – TW-2 (cm) 148.6 120.3
At final height
Age (yr) 21.3 20.5
Height [cm (SDS)] 168.2 (-1) 155.6 (-1)
Target height [cm (SDS)] 174.2 (0) 161.2 (0)
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Figure 1A. Growth chart for Dutch children of Moroccon descent of the boy with a GHRH-R mutation. 
The squares represent the bone age (TW-2 RUS).
Figure 1B. Growth chart for Dutch children of Moroccon descent of the girl with a GHRH-R mutation. 
The squares represent the bone age (TW-2 RUS).
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the age of 21.3 yr and was 168.2 cm (– 1.0 SDS), which was well within his target 
range (Fig. 1A). After reaching adult height he has received GH replacement at a 
dosage of 0.4 mg/day sc. 
The girl was referred to our hospital at the same time as her brother, at the age of 
14.9 years. Her medical history was also uneventful. Her auxological, biochemical, 
and radiological characteristics are summarized in Table 1. At physical examina-
tion she had a doll like face and increased abdominal fat. No dysmorphic features 
were noticed. Menarche had occurred, but it was uncertain at what age. She had 
regular menstrual cycles. Total 24-h GH production was greatly diminished, as was 
earlier described in detail (6). The maximal rise of TSH after 200 µg TRH was from 
0.8 to 6.7 mU/liter after 20 min, which was considered as a subnormal response. 
Prolactin increased from 3.6 to 21 µg/liter (normal). Computed tomography at 
the age of 15 yr showed an empty sella, which was confirmed on the magnetic 
resonance imaging scan at 23 yr of age. 
At the age of 15 yr GH treatment was started (Genotropin, 0.8  mg/m2/day = 28 
µg/kg/day sc) and one month after the start of GH a GnRHa was added (Deca-
peptyl CR 3.75 mg, every 4 wk im). Prior to treatment a GnRH test showed a 
pubertal response with a LH peak of 17.3 mU/liter 30 min after 100 µg GnRH iv. 
Plasma estradiol was 64 nmol/liter. On GnRHa treatment plasma estradiol was < 
40 pmol/liter and menstrual cycles stopped. Total thyroxin levels decreased after 6 
weeks of GH treatment (total thyroxine 61 nmol/liter), whereas T3 and TSH levels 
were normal, for which levothyroxine replacement therapy was initiated. Retesting 
at adult age showed a normal TSH response to TRH and levothyroxine was discon-
tinued (6). The GnRHa was stopped after 3 yr of treatment at the age of 17.1 yr. 
At that moment bone age was 12.9 yr according to TW-2 and 12 yr according to 
Greulich and Pyle. Subsequently, the GH dose was increased to 1.3 mg/m2/day 
(30 µg/kg/day). Puberty progressed normally after discontinuation of the GnRHa. 
At 20.5 yr she had Tanner stage B5 and regular menstrual cycles. Her final height 
was 155.6 cm (-1 SDS), which was well within the target range (Fig. 1B). After 
reaching final height, GH injections were discontinued for 4 yr, but after retesting 
GH treatment was reinstituted in a dosage of 0.4 mg/day. During uneventful preg-
nancies, at the age of 26 and 27 yr, GH was discontinued after the first trimester. 
She delivered two healthy babies, a girl and a boy, who are growing normally. 
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R e s u l t s
Result of GH and GnRHa treatment
Treatment with the combination of GH and GnRHa during 2.5 yr in the male sib 
resulted in a height gain of 24 and 19.6 cm according to the pretreatment predicted 
adult height determined by Bayley/Pinneau and TW-2, respectively. In the female 
sib a height gain of 28.2 and 35.3 cm was established after 3 yr of combination 
treatment compared with the pretreatment predicted adult height determined by 
Bayley/Pinneau and TW-2, respectively. 
D i s c u s s i o n
Mutations in the GHRH-R gene account for approximately 10% of the patients 
with familial isolated GHD. In both our patients a homozygous G-> C transition 
at the splice donor site of intron VII was found, altering the first basepair of the 
intervening intronic sequence after exon 7.  This mutation interrupts the signal 
transduction of GHRH, causes GHD and consequently severe postnatal growth 
retardation. Our patients were diagnosed at the ages of 16 and 14.9 years, respec-
tively, and they both showed signs of advanced puberty. We hypothesized that GH 
treatment alone at this advanced stage of puberty would accelerate bone matura-
tion progressively and thereby limit the effect on final height, while administration 
of GnRHa  might delay the process of epiphyseal fusion by inhibiting the secretion 
of gonadotropins and gonadal sex steroids. Our cases illustrate that severely GH 
deficient adolescents can greatly benefit from the combination GH and GnRHa 
treatment, even at an advanced age, bone age and pubertal stage.
The large height gain on GH and GnRHa treatment as we experienced in our 
patients is far beyond the average additional effect of GnRHa in group analyses 
(approximately 7 cm) (13-17). Also in individual patients with GH deficiency we 
are not aware of reports on such extremely good result. We speculate that, in our 
cases, who have a severe GH deficiency caused by a well-defined genetic disorder, 
the intact GH –IGF-I axis downstream the level of the GHRH-R resulted in maximal 
GH sensitivity.  This is supported by the significant rise of IGF-I seen in the IGF-I 
generation test in patients with a GHRH-R mutation (18) and the good growth 
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response to GH therapy in those patients (2-5, 18). The good sensitivity allows 
optimal catch-up growth, while the absence of estrogen restricts epiphyseal mat-
uration. The only report on GH and GnRHa therapy in a boy with a GHRH-R 
mutation also showed a positive effect on linear growth, but this was limited to a 
few centimeters (19). 
The TSH response to TRH was suboptimal in our patients, suggesting mild 
secondary hypothyroidism. A blunted TSH response was also reported in other 
patients with a GHRH-R mutation (18). One could hypothesize that hypoplasia 
of the pituitary is one of the contributing factors, however the pituitary size was 
normal in the brother. Another possible explanation for the blunted TSH response 
is that GHRH is necessary for maximal TSH production, although the normal TRH 
test at adult age argues against this. The low T4 levels after the start of GH therapy 
were probably the result of the positive effect of GH on 5’deiodinase activity, the 
enzyme converting T4 into T3 (20). In general, treatment is not necessary as T4 
levels recover spontaneously, but in our cases levothyroxine treatment was started 
to create optimal conditions for growth.  
In conclusion, this report shows that in patients with isolated GH deficiency due to a 
GHRH-R mutation, combined treatment of GH and GnRHa can have a great effect 
on adult height, even if started at an advanced bone age and pubertal stage. 
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A b st r a c t
Context: GH insensitivity can be caused by defects in the GH receptor (GHR) or 
in the postreceptor signaling pathway. Recently, two female patients with severe 
growth retardation and pulmonary and immunological problems were described 
with a defect in STAT5b, a critical intermediary of downstream GHR signaling. 
Objective: The objective was to determine the functional characteristics of a novel 
STAT5b mutation and describe the phenotype. 
Patients:  We describe an adult male patient with short stature (-5.9 SDS),  delayed 
puberty, and no history of pulmonary or immunological problems. GH-binding 
protein level as well as GH secretion characteristics were normal. Plasma prolactin 
level was elevated. Extremely low levels of IGF-I (-6.9 SDS), IGF-binding protein-3 
(-12 SDS), and acid-labile subunit (-7.5 SDS) were found.
Results: We found a homozygous frameshift mutation in the STAT5b gene (nucle-
otide 1102-3insC, Q368fsX376), resulting in an inactive truncated protein, lacking 
most of the DNA binding domain and the SH2-domain.
Conclusions: This report confirms the essential role of STAT5b in GH signaling in 
the human. We show for the first time that immunological or pulmonary problems 
or elevated GH secretion are not obligatory signs of STAT5b deficiency, whereas 
hyperprolactinemia appears to be part of the syndrome. Therefore, in patients 
with severe short stature, signs of GH insensitivity, and a normal GHR, analysis of 
the STAT5b gene is recommended. 
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I n t r o d u c t i o n
Primary GH insensitivity is characterized by severe postnatal growth failure, 
elevated levels of GH and decreased levels of  IGF-I. The majority of patients with 
GH insensitivity have mutations in the extracellular domain of the GH receptor 
(GHR), resulting in reduced GH binding. The first report of a mutation concerning 
the GH signaling pathway was published by Kofoed et al. (1) describing a female 
patient with a homozygous missense mutation in the STAT5b gene. Recently, Hwa 
et al. (2) described another female patient with a homozygous frameshift mutation 
of the STAT5b gene. In both patients short stature is associated with pulmonary 
problems and severe immunodeficiency.
STAT5b is a component of the Janus kinase-STAT signal transduction pathway. Of 
the seven STAT proteins, the GHR preferentially uses STAT5b for signal transduc-
tion. In the absence of STAT5b, the ability of GH to induce the expression of IGF-I 
mRNA is almost completely abrogated both in mice and man (1-3).
We now describe the clinical and biochemical characteristics of the first male with 
a homozygous frameshift mutation in the STAT5b gene, in whom short stature was 
not accompanied by immunodeficiency.
Pa t i e n t s  a n d  M e t h o d s
Clinical and molecular studies were performed after obtaining written informed 
consent.
Biochemical assays
Plasma GH was measured with time-resolved immunofluorometric assay (Wallac/
PE, Turku, Finland), using the WHO 80/505 as a standard (1 mg=2.6 IU). Plasma 
IGF-I, IGF-II, IGF-binding-protein (IGFBP)-1, IGFBP-2, IGFBP-3, and IGFBP-6 
were determined by specific RIAs (4). 
Acid-labile subunit (ALS) was measured by an ELISA (Diagnostics Systems Labo-
ratories, Inc., Webster, TX) (5). With the exception of  IGFBP-1, smoothed refer-
ences were available for all parameters, based on the LMS method (6), allowing 
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conversion of  the data of the patient to SD score (SDS) values. Plasma IGFBP-1 
concentration after an overnight fast was compared with a reference group of 6 
healthy adult controls. Prolactin was measured by electrochemical luminescence 
immunoassay (Roche Diagnostics, Almere, Netherlands). GH-binding protein was 
measured with the ligand immunofluorometric method (7).
Analysis of STAT5b
A skin biopsy was taken, and a culture of dermal fibroblasts was established. 
Genomic DNA was isolated from whole blood. STAT5b mRNA isolated from fibro-
blasts and STAT5b coding exons were amplified by PCR and subjected to direct 
sequencing. Primer combinations are available on request. 
Western blotting
Western blotting to detect phospho-Erk1, Erk2 and PKB/Akt was performed using 
fibroblast cultures from the patient and an age- and sex-matched normal subject 
as described in detail previously (8). Antibodies directed to inact STAT5b were 
obtained by Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
R e s u l t s
Phenotype
The index patient was born in the Dutch Antilles. His parents were not aware of 
any consanguinity. Paternal and maternal heights were 164.3 cm (-2.8 SDS) and 
165.6 cm (-0.8 SDS), target height was 176 cm (-1.1 SDS) (9). He was born after 
a full-term uncomplicated pregnancy. At birth, his weight was 3270 g (-0.7 SDS) 
and his length was 50 cm (-0.4 SDS) (10). Shortly after birth, congenital ichthyosis 
was diagnosed. 
At the age of 16 yr, he emigrated to The Netherlands. Shortly after arrival, he was 
admitted to the hospital because of hemorrhagic chickenpox. He made a full recovery 
after treatment with acyclovir. He was referred to a paediatric endocrinologist, for 
evaluation of growth retardation. His body proportions were normal, although his 
pubertal development was delayed (Tanner stage G1P1), testicular volume being only 
1 ml. Biochemical evaluation revealed a low IGF-I level (3.8 nmol/liter, -5.6 SDS) and 
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a slightly elevated prolactin level 1.4 U/liter (normal value < 0.3 U/liter). His maximal 
GH response to 50 µg GHRH iv was 25 µg/liter, which is considered to be a normal 
response. A computed tomography scan of the pituitary and hypothalamus revealed 
no abnormalities. His bone age was 9 yr. A 24-h plasma GH profile was normal. 
Nevertheless, a presumptive diagnosis of GH secretory dysfunction was made and a 
trial with recombinant human GH treatment (Genotropin) was started in a dose of 
1.5 IU (0.5 mg)/day for 25 months, followed by a dose of 3.0 IU (1.0 mg)/day for an 
additional 3 months. However, this treatment did not significantly improve growth 
rate, except for a slight growth acceleration probably due to pubertal development. 
IGF-I levels increased only slightly during treatment with recombinant human GH 
(5.8 nmol/liter, -4.7 SDS). At the age of 19.8 yr, bromocriptin was started (2.5 mg/
day) and serum prolactin decreased (<0.05 U/liter). Eight months later, he returned 
to the Dutch Antilles, and he was lost to follow-up for 10 yr. 
At the age of 30 yr, he was referred to our clinic for evaluation of his short stature 
(Table 1). He did not have any complaints and reported normal libido, erections, 
and ejaculations. He used to shave every four days. There was no history of infec-
tious diseases during the previous 16 yr. There was striking central obesity and 
pseudogynecomastia. He did not have galactorrhea. Secondary sexual charac-
teristics were typical for a male, facial hair was present, and body hair distribu-
tion showed a male pattern, although scarce. The ichthyosis was not active. There 
were no dysmorphic features. Testicular volume was 12 ml. The stretched penile 
length was 8 cm (P10-P90, 10.2-16.4 cm) (11). Cardiovascular, respiratory, and 
abdominal examinations were normal.  
Endocrine features at 30 yr of age
Circulating levels of IGF-I, IGF-II, IGFBP-3, and ALS were markedly reduced 
(Table 1). The concentration of prolactin was markedly elevated (i.e. five times the 
upper limit of normal). Basal GH level was normal (0.33 mU/liter). The maximal 
GH response after administration of insulin was 37.0 mU/liter (14.2 ng/ml), and 
after GHRH-arginine, 29.4 mU/liter (11.3 ng/ml), which are considered to be 
normal responses (12). 
Mutational analysis
Sequence analysis of STAT5b mRNA derived from dermal fibroblasts revealed the 
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Table 1. Clinical and biochemical features of the patient at the age of 30 yr.
Parameter Value
Age (yr) 30
Height [cm (SDS)] 141.8 (-5.9)
Weight (kg) 56
BMI (kg/m2) 28.2
Head circumference [cm (SDS)] 54 (-1.4)
Glucose (<110 mg/dl) 74
Insulin ( 0-20 mU/liter) 11
Prolactin (0-22 µg/liter) 110
TSH (0.3-4.8 mU/liter) 3.8
Free T4 (0.8-1.8 ng/dl) 0.84
LH (2-8 U/liter) 6.5
FSH (2-10 U/liter) 5.6
Testosterone (>230 ng/dl) 373
GH (mU/liter) 0.33
GHBP a (pmol/liter) 1524
IGF-I [ng/ml (SDS)] 8 (-8.2)
IGF-II [ng/ml (SDS)] 83 (-6.2)
IGFBP-1b (ng/liter) 31
IGFBP-2 [ng/ml (SDS)] 142 (-0.6)
IGFBP-3 [mg/liter (SDS)] 0.18 (-12.4)
IGFBP-6 [ng/ml (SDS)] 230 (1.3)
ALS [mg/liter (SDS)] 0.7 (-7.0)
Conversion factors: glucose x 0.0551 (millimoles per liter), free T4  x 2.87 
(picomoles per liter), and testosterone x 0.035 (nanomoles per liter)
a Normal range, 330-2437 pmol/liter
b  Normal range for non-fasting subjects, 24-58 ng IGFBP-1/ml. After overnight 
fasting, there was an average 5-fold rise in normal individuals
insertion of an extra C between nucleotide positions 1102 and 1103 (Fig. 1A). The 
parents, brother, and sister were carriers of the mutation (Fig. 1A). This resulted in 
a frame shift and premature truncation of the protein (Q368fsX376). The presence 
of the frame shift mutation was confirmed in genomic DNA. No other mutations 
were detected in the open reading frame of the STAT5b gene. The truncated 
protein lacked a large part of the DNA binding domain and completely lacked the 
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C-terminal SH2 domain required for dimerization with other STAT proteins and 
translocation to the nucleus, making this protein biologically inactive (Fig. 1, B and 
C). In line with this and in contrast to a normal control, total STAT5b could not 
be detected in protein extracts of the patient’s fibroblast using Western blot even 
after stimulation with 500 ng/ml GH (Fig. 1D). Although no abnormalities were 
present in the GHR, absence of STAT5b also resulted in impaired activation of the 
Figure 1: Identification of a homozygous frame shift mutation in STAT5b.
A. Electropherogram of the sequence analysis of the patient and his family members. The position of 
the extra C is indicated by the arrow.
B. Insertion results in a premature stopcodon in the N-terminal half of the protein. The truncated 
protein lacks the majority of the functional domains of STAT5b. The position of the mutation is 
depicted schematically by the arrow.
C. Alignment of part of the cDNA sequence corresponding to amino acids 359 to 378 of wild type 
(upper part) and patient’s STAT5b (lower part) showing the consequence of the frame shift mutation 
for the open reading frame.
D. Western blot analysis using protein extracts isolated from fibroblasts from the patient and an age- 
and sex-matched control after a challenge with 500 ng/ml human GH. No STAT5b protein could 
be detected in the patient’s cells. In addition, the activation of PKB/Akt and Erk1/2 was impaired. 
Total PKB was used to check loading efficiencies.
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PKB/Akt pathway by decreased phosphorylation on serine 473 and Erk1 and -2 
phosphorylation (Fig. 1D).
Because a stretch of eight consecutive Cs may be susceptible to replication errors, 
we carried out sequence analysis of this exon (PCR amplified from genomic DNA) 
of 71 individuals diagnosed with short stature. In four cases a heterozygous C>A 
transversion at the seventh C (nucleotide position 1101) was detected. This has no 
predicted effect on the coding sequence (Pro>Pro). No changes were found in any 
of the remaining 67 cases. 
D i s c u s s i o n
This is the first report of a male patient, homozygous for a frame shift mutation 
in the STAT5b gene, which induces a premature stopcodon at position 376 
(Q368fsX376). The resulting truncated protein lacks a functional DNA binding 
domain and misses the SH2 domain. The SH2 domain is critical for recruitment 
of STAT5b to the activated GHR complex and binding of STAT to the phosphory-
lated tyrosine residues. It also contains a conserved tyrosine residue at position 
699, which is critical for STAT dimerization and its subsequent translocation to 
the nucleus, where it can act as a DNA binding transcription factor (13, 14). Based 
on this analysis, the mutation is presumed to result in inactivation of the protein. 
Indeed, we could not detect any STAT5b in fibroblasts of the patient, at least not 
with the antibody available to us. 
The expression of IGF-I, IGF-II, IGFBP-3, and ALS is tightly controlled by GH. 
STAT5b appears to be the dominant transcription factor, mediating these effects 
of GH at the transcriptional level. In both the IGF-I and ALS genes, functional 
STAT5b response elements have been identified (15, 16). Fully in line with this, the 
serum levels of IGF-I, IGFBP-3,  and ALS are extremely low in all patients with a 
STAT5b mutation (1, 2).
Our patient is the first known male with a STAT5b mutation. He shows the same 
degree of postnatal growth retardation as the two female patients (-7 and -7.8 
SDS) (1, 2). Female STAT5b knockout mice are largely unaffected, whereas male 
knockouts, which are normally 30% larger than female mice, resemble females 
in size (17). Apparently, in humans, homozygous STAT5b mutations result in an 
equal pattern of growth retardation in males and females. 
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In line with the observations in STAT5b knockout mice (18), GHR gene-disrupted 
mice (19) and patients with Laron’s syndrome (20), our patient showed markedly 
increased serum prolactin levels. In STAT5b-deficient mice the high serum prolactin 
concentrations could be suppressed by bromocriptine (dopamine D2 agonist), 
suggesting absence of endogenous dopaminergic inhibition. Hyperprolactinemia 
might also be the result of elevated hypothalamic GHRH secretion, under the 
diminished feedback restraint from IGF-I and GH. Indeed, the elevated prolactin 
levels in Laron’s syndrome decrease upon IGF-I administration, in line with the 
inhibitory action of IGF-I on hypothalamic GHRH neurons (20).
The first reported patient with a STAT5b mutation had respiratory difficulties due 
to lymphoid interstitial pneumonia and a Pneunocystis Carinii infection (1). The 
second patient with a STAT5b mutation had primary idiopathic pulmonary fibrosis 
(2). In contrast, our patient has had neither pulmonary complaints nor signs of 
immunodeficiency. Our patient demonstrates  that STAT5b deficiency is not oblig-
atory resulting in a clinically immunodeficient state.
In conclusion, this report supports the essential role of STAT5b in GH signaling 
in the human and confirms that STAT5b deficiency leads to severe postnatal 
growth failure. In contrast with mice, the growth retardation in the human does 
not show a sexually dimorphic pattern. Hyperprolactinemia is apparently part of 
the syndrome, possibly by a deficient negative feedback loop in the hypothala-
mus. Although in earlier cases STAT5b deficiency was suggested to be associated 
with immunodeficiency, our patient shows that immunodeficiency is not an obliga-
tory feature in patients with a STAT5b mutation. In cases with postnatal growth 
retardation, a low IGF-I, IGFBP-3, and ALS, high or normal GH secretion, and 
an absence of mutations or deletions in the GHR, genetic analysis of STAT5b is 
warranted. Our case illustrates that the heterogeneity of clinical manifestations of 
this syndrome is larger than suggested by the first two cases.
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A b st r a c t
Objective: STAT5b is a component of the GH signaling pathway. Recently, we 
described a 31-year old male patient (height – 5.9 SDS) with a novel homozygous 
inactivating mutation in the STAT5b gene. The purpose of this study is to describe 
the phenotype in detail, including GH secretion and immunological function. In 
addition, we report four family members of this patient, all heterozygous carriers 
of the mutation. 
Design and methods: Twenty-four hour GH and prolactin secretion characteristics 
were assessed by blood sampling at 10-min intervals. An IGF-I generation test was 
performed. Monocyte function was tested by stimulation of whole blood with lipo-
polysacharide (LPS) in the presence or absence of Interferon-γ (IFN-γ). In addition, 
T cell function was determined by measuring proliferative responses of peripheral 
blood mononuclear cells (PBMC) after stimulation by various polyclonal activa-
tors and Interleukin-2 (IL-2). Clinical and biochemical characteristics were deter-
mined in the carriers of the mutation. 
Results: GH secretory parameters were comparable to that of healthy male 
controls (mean fat percentage 25), but likely increased in relation to the patient’s 
40% body fat. The regularity of GH secretion was diminished. Prolactin secretion 
was increased by sixfold. The IGF-I generation test showed a small increase of IGF-
I and IGFBP-3 on lower GH doses and an increase of IGF-I to –2.4 SDS on the 
highest dose of GH. In vitro, IL-12p40, IL 10 and TNF-α production rates by PBMC 
increased to values within the normal range upon stimulation of LPS. Heterozy-
gous carriers of the mutation did not show abnormalities, although the height of 
the males was below the normal range.
Conclusions: This report shows that GH and prolactin secretion was increased is 
this patient homozygous for a new  STAT5b mutation. Although STAT5b plays a 
role in signaling within immune cells, clinical immunodeficiency is not an obliga-
tory phenomenon of STAT5b deficiency per se. Heterozygous carriers of a STAT5b 
mutation show no signs of GH insensitiviy.
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I n t r o d u c t i o n
The growth hormone receptor (GHR) uses the JAK-STAT proteins as signal trans-
duction pathway. Out of the seven STAT proteins, STAT5b is preferred. Upon 
phosphorylation, STAT5b dissociates from the GHR, dimerizes and translocates 
to the cell nucleus, where it transcriptionally regulates the expression of a variety 
of target genes, including the gene coding for insulin-like growth factor-I (IGF-I) 
(1). In addition to the role of STAT5b in GHR signal transduction, clinical observa-
tions and studies in knock out mice have suggested that STAT5b is involved in the 
immune system (2, 3). 
To date, two immunodeficient females homozygous for a missense mutation and 
a frameshift mutation respectively, in the STAT5b gene, have been described (4, 
5). Recently, we reported the first male with a homozygous frameshift mutation, 
due to insertion of a C-residue at nucleotide position 1102-1103, that caused a 
premature truncation of the STAT5b protein (6). The patient presented with severe 
short stature (Fig. 1), low IGF-I levels and elevated prolactin levels. However, in 
contrast to the two previously reported females, he showed no overall signs of 
immunodeficiency.  
In this report of our male patient, we present the GH and prolactin secretion 
patterns. We have evaluated his immunological status in more detail and, in 
addition, we investigated the clinical and biochemical features of four family 
members who appeared to carry the mutation. 
M e t h o d s
All studies were performed after obtaining written informed consent from all 
subjects.
Clinical measurements and auxology
We measured height with a Harpenden stadiometer, and head circumference 
with a tape measure. Height and head circumference were expressed as standard 




Plasma GH was measured with time-resolved immunofluorometric assay (Wallac/
PE, Turku, Finland), using the WHO 80/505 as a standard (1 mg = 2.6 IU). The 
detection limit was 0.03 mU/l. Plasma IGF-I, IGF-II, IGF-binding-protein (IGFBP)-
1, IGFBP-2, IGFBP-3, and IGFBP-6 were determined by specific RIAs (8). Acid-
labile subunit (ALS) was measured by an ELISA (Diagnostics Systems Laborato-
ries, Inc., Webster, TX, USA) (9). With the exception of free IGF-I and IGFBP-1, 
smoothed references were available for all parameters, based on the LMS method 
(10), allowing conversion of the data of the patient to SDS values. Plasma IGFBP-1 
concentration after an overnight fast was compared with a reference group of six 
healthy adult controls. Prolactin was measured by a sensitive time-resolved immu-
nofluorometric assay (Wallac, Turku, Finland). The standards were calibrated 
against the WHO third International Standard for prolactin 84/500. The detection 
limit of the assay was 0.04 µg/l.
Twenty-four hours plasma hormone profiles 
Blood sampl ing protocol
Patients and controls were admitted to the hospital on the day of study. An indwell-
ing i.v. cannula was inserted into a vein of the forearm 60 min before sampling 
began and blood samples were withdrawn at 10-min intervals starting at 0900 h 
and for the next 24 h. A slow infusion of 0.9% NaCl and heparin (1 U/ml) was used 
to keep the line open. The subjects were free to ambulate, but not to sleep during 
daytime. Meals were served at 0800, 1230, and 1730 h and lights were turned off 
between 2200 and 2400 h. Plasma samples were collected on ice in heparinized 
tubes. The samples were centrifuged at 4°C for 15 minutes; the plasma was then 
separated, frozen and stored at -20°C until the assays were performed. 
Deconvolut ion analys is
Multiparameter deconvolution analysis was used to determine kinetic and secretory 
parameters of 24-h spontaneous GH secretion, calculated from GH plasma con-
centrations.  Initial parameters were created with Pulse 2, an automated pulse-
detection program. Subsequent  waveform-dependent analyses were performed 
as described previously (11). This technique estimates the rate of basal release, 
the number and mass of secretory bursts, and the subject-specific half-life. Daily 
pulsatile GH secretion is the product of secretory burst-frequency and mean mass 
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of GH released per event. Total GH secretion is the sum of basal and pulsatile 
secretion.
 Approximate entropy 
Approximate entropy (ApEn) is a scale- and model-independent statistic, applica-
ble to a wide variety of physiological and clinical time-series data. ApEn quantitates 
the orderliness or regularity of serial GH concentrations over 24 h. Normalized 
ApEn parameters of m = 1 (test range) and r = 20% (threshold) of the intraseries 
standard deviation  were used, as described previously (12). Hence, this member 
of the ApEn family is designated ApEn (1, 20%). The ApEn metric evaluates the 
consistency of recurrent subordinate (nonpulsatile) patterns in a time series and 
thus yields information distinct from and complementary to cosinor and deconvo-
lution (pulse) analyses (13). Higher absolute ApEn values denote greater relative 
randomness of hormone patterns. Data are presented as absolute ApEn values 
and normalized ApEn ratios, defined by the mean ratio of absolute ApEn to that of 
1000 randomly shuffled versions of the same series (14). 
Cluster  Analys is  
For the detection of discrete prolactin peaks, cluster analysis was used. This com-
puterized pulse algorithm is largely model-free, and identifies statistically signifi-
cant pulses in relation to dose-dependent measurement error in the hormone time 
series (15). A concentration peak is defined as a significant increase in the test peak 
cluster vs. the test nadir cluster. We used a 2 x 1 cluster configuration (2 samples in 
the test nadir and 1 in the test peak) and t-statistics of 2.0 for significant up- and 
down-strokes in prolactin levels to constrain the false positive rate of peak identi-
fication to less than 5% of signal-free noise. The locations and widths of all signifi-
cant concentration peaks were identified, the total number of peaks was counted, 
and the mean inter-peak interval was calculated in minutes. In addition, the 
following pulse parameters were determined: peak height (highest value attained 
within the peak), incremental peak amplitude (the difference between peak height 
and prepeak nadir), and area under the peak. Interpulse valleys were identified as 
regions embracing nadirs with no intervening upstrokes. The total area under the 




Whole blood was collected in endotoxin-free tubes (Endotube ET; Chromogenix, 
Milan, Italy), diluted in the ratio 1:5 and stimulated overnight with 0.1–100 ng/
ml lipopolysacharide (LPS)(Escherichia coli 0111 LPS) in the presence or absence of 
100 IU IFN-γ/ml. In several experiments either growth hormone or prolactin was 
added to a final concentration of 50–500 ng/ml, and 10 ng, respectively. After 18 
h, supernatants were collected and tested by ELISA for the presence of IL-12p40 
(R&D Systems), IL-10 and TNF-γ (Sanquin Research, Amsterdam)(16). PBMCs 
were incubated overnight with increasing amounts of IFN-gamma (0–100 IU/ml) 
in hydron-coated wells to prevent adherence of the monocytes. Cells were washed 
and stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD64 and PE-
conjugated anti-CD14 to analyze CD64 expression on CD14-positive cells using a 
FACSCalibur (16).
PBMCs were phenotyped by four color immunostaining using FITC-, PE-, 
PerCPCy5.5-, and activated protein C (APC)-conjugated antibodies, and analyzed 
by flow cytometry (FACSCalibur; Becton Dickinson, Baltimore, MD, USA). Data 
were analyzed using CELLQuest software (Becton Dickinson). 
R e s u l t s
Phenotype
The index patient was born in the Dutch Antilles. Paternal and maternal heights 
were 164.3 cm (-2.8 SDS) and 165.6 cm (-0.8 SDS), target height was 176 cm (-
1.1 SDS) (7). He was born after a full-term uncomplicated pregnancy with a birth 
weight of 3270 g (-0.7 SDS) and birth length of 50 cm (-0.4 SDS)(17). During 
childhood severe postnatal growth retardation was noticed (Fig. 1), although 
evaluation did not take place until the age of 16 years, when he emigrated to The 
Netherlands. 
Physical examination at 16 years revealed normal body proportions, although his 
pubertal development was delayed (Tanner stage G1P1), testicular volume being 
only 1 ml. His bone age was 9 years. He was treated with recombinant human GH 
(rhGH, Genotropin, Pharmacia) in a dose of 1.5 IU (0.5 mg)/day for 25 months, 
followed by a dose of 3.0 IU (1.0 mg)/day during an additional 3 months. However, 
this treatment did not significantly improve growth rate, except for a slight growth 
acceleration probably due to pubertal development (Fig. 1). 
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At the age of 30 years, he was referred to our clinic for evaluation of his short 
stature. Auxological parameters are summarized in Table 3. Basal endocrinologi-
cal parameters were within the normal range: free T4 10.8 pmol/l (10-24 pmol/l), 
TSH 3.8 mU/l (0.3-4.8 mU/l), LH 6.5 U/l (2-8 U/l), FSH 5.6 mU/l (2-10 U/l) and 
testosterone 13.1 nmol/l (8-50 nmol/l).
Twenty-four hour profiles of plasma GH and prolactin
The plasma GH concentration profile of the patient and that of a representative 
control subject are illustrated in Fig. 2. The results of the deconvolution analyis are 
shown in Table 1. Basal secretory rate and GH burst frequency were increased in 
the patient, but the other deconvolution parameters were comparable with that of 
the controls. It should be noted that although the body mass index (BMI) of the 
patient was within the range of that of the controls, his fat percentage was much 
higher. ApEn and ApEn ratio were increased in the patient, denoting decreased GH 
secretory regularity (Table 1). 
32Figure 1. Height for age chart of index patient, based on Dutch references (7). In the absence of local 
growth standards, we have assumed that inhabitants of the Dutch Antilles of African descent have a 
similar height as the Dutch population.
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The plasma prolactin profiles of the patient and a healthy control are displayed 
in Fig. 2. Cluster analysis revealed a five- to six fold increase in mean pulse height, 
mean pulse amplitude, mean pulse mass and pulsatile production. The prolactin 
secretory regularity was not decreased in the patient.
IGF-I generation test
At the age of 30 years an IGF-I generation test was performed with 12.5, 25.0 
and 50.0 µg GH/kg per day for 7 consecutive days for each dose, interrupted by 
washout periods of 2 weeks and 9 months respectively. The results of the IGF-I 
generation test are shown in Fig. 3. On the low and intermediate dose, a slight 
increase of IGF-I and IGFBP-3 was noted. However on the highest dose IGF-I level 
increased from -6.6 SDS to -2.4 SDS, IGFBP-3 from -11.6 SDS to -6.4 SDS and ALS 
from –7.2 SDS to –5.3 SDS. 
Figure 2. Plasma GH and prolactin profiles obtained by blood sampling at 10 min intervals in the 
patient and a representative healthy control subject.
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Table 1.  Deconvolution analysis and approximate entropy  of 24-h GH profiles in a  male patient 
with STAT 5b mutation and eight male healthy controls.
 
Patient Controls (n=8)
Basal secretory rate  (mU/l per min x 103) 3.25 1.6  (0.7-2.4)
Endogenous GH half-life (min) 13.0 16   (13.6-18)
No. of secretory bursts/ 24 h 16 10   (7-13)
Mean mass GH secreted/burst  (mU/l) 2.3 4.4  (2.2-6.5)
Pulsatile GH secretion (mU/l per day) 37 36  (25-47)
Total GH secretion (mU/l per day) 41 38  (27-49)
Age (years) 30 33  (30-36)
ApEn (1, 20%) 0.383 0.241 (0.189-0.335)
ApEn ratio 0.46 0.32  (0.27-0.36)
BMI (kg/m2) 28 26.0 (23.4-29.3)
Fat percentage 40 25 (21-28)
Data of the controls are shown as mean and (95% confidence interval). To convert mU/l into µg/l 
divide by 2.6. The fat percentage in the patient was measured by dual-energy X-ray absorptiometry 
(DEXA), and in the controls by BIA.
Table 2.  Cluster analysis and approximate entropy of 24-h prolactin profiles in a  male patient with 
STAT 5b mutation and eight male healthy controls.
Patient Male adult controls (n=8)
Pulse frequency (no./24 h) 17 15.8  (12-19.5)
Mean pulse height (µg/l) 20.5 4.4   (3.5-5.3)
Mean pulse amplitude (µg/l) 7.2 1.4   (1.0-1.7)
Mean pulse mass GH (µg/l) 340 67  (46-87)
Mean nadir concentration (µg/l) 19.1 2.9  (2.2-3.7)
Pulsatile production (µg/l per 24 h) 5750 1000  (700-1300)
AUC (µg/l/24 h) 36250 26.0 (23.4-29.3)
ApEn (1, 20%) 0.746 0.700 (0.590-0.810)
ApEn ratio 0.47 0.44  (0.38-0.50)
Age (years) 30 33  (30-36)




At least one of the first reported female patients with a STAT5b mutation was 
severely immunocompromised. The first suffered lymphoid interstitial pneumonia 
and had a Pneumocystis Jiroveci (previously, Pneumocystis Carinii) lung infection, and 
presented with severe hemorrhagic varicella and recurrent episodes of herpes 
zoster (4). The second female patient had primary idiopathic pulmonary fibrosis, 
a condition in which an infectious etiology cannot be ruled out (5). 
Our male patient has had neither pulmonary complaints nor signs of immunodefi-
ciency. Remarkably, he had a hemorrhagic varicella infection at the age of 16 years, 
but this could well be explained by lack of a history of chickenpox in the past and 
the fact that he developed the varicella secondary to his brother, who suffered a less 
severe case. Thus, we do not consider the severe case of chickenpox in this patient 
as sufficient evidence for immunodeficiency. Otherwise, the medical history of our 
Figure 3. Results of the IGF-I generation test, performed in the index patient. (A) IGF-I (SDS), (B) 
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patient was unremarkable for childhood infections, and response to vaccinations.  
Since the two previously reported patients with a homozygous STAT5b mutation 
appeared to be immunocompromized, we investigated various immunological 
functions of PBMCs.
IL-12p40, TNF-γ  and IL-10 production in response to LPS 
Monocyte function of the patient was determined by culturing whole blood in the 
presence of LPS. There was a LPS-dose dependent increase in IL-12p40 production 
that was similar to that in the control (Fig. 4A, grey and black bars). Similarly, 
IL-10 production increased in response to LPS, to a level somewhat higher than 
observed in the control, but the response was well within normal values (Fig. 4B). 
These findings indicated that IL-12p40 and IL-10 production in response to LPS 
was not impaired in the patient. Similar data were obtained for TNF-α produc-
tion (Fig. 4C). To investigate whether TNF-α and IL-12p40 production could be 
up-regulated and IL-10 production down-regulated by IFN-γ, the combination of 
LPS and a high dose of IFN-γ (100 IU/ml) was used to stimulate whole blood. In 
the patient, IL-12p40 and TNF-α production was increased, and IL-10 decreased, 
both in an LPS-dose-dependent fashion, and to a level similar to that observed 
in controls (Fig. 4A-C, hatched bars). Of note, incubation with neither GH nor 
prolactin influenced the IL-12p40, TNF-γ and IL-10 production after stimulation 
with LPS (data not shown).
IFN-γ responsiveness in PBMCs
To study the response to IFN-γ in more detail, monocytes were cultured in the 
presence of 0, 1, 10 and 100 U IFN-γ/ml and the increase in the expression of 
CD64 (FcγR1) was measured by FACS analysis. The CD64 promoter contains a 
STAT1 binding site and up-regulation of CD64, in response to IFN-γ stimulation, 
is a well-accepted marker of IFN-γ responsiveness of these cells (18). IFN-γ stimu-
lation of the monocytes of the patient resulted in a dose-dependent increase in 
CD64 expression, and at the highest (100 IU IFN-γ/ml) concentration was about 
equal to the maximal increase in CD64 expression for the healthy control: the 
cell-surface expression increased upon increasing concentrations of IFN-γ 1.2-, 
2.9- and 4.5-fold respectively, for monocytes of the patient and 1.3-, 2.9- and 5.3-
fold respectively, for  control monocytes, as compared to cell-surface expression 
without IFNγ. Neither GH nor prolactin influenced basal CD64 receptor expression 
(data not shown). 
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Figure 4. Production of (A) IL-12p40, (B) IL-10, and (C) TNF-α in whole blood of the patient and a 
healthy control. Whole blood was stimulated with lipopolysacharide (LPS) in the presence or absence 
of 100 U IFN-γ/ml. Supernatants were collected after 18 h and IL-12p40, IL-10 and TNF-α was 
measured by ELISA. Experiments were performed in duplicate.
Figure 4A 
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Cell surface expression of IFN-γ-receptors and lymphocyte proliferation
The expression of IFN-γR1 and TNF-γR1 and TNF-γR2-receptors on peripheral 
blood mononuclear cells did not differ from that in cells of healthy controls, as 
evident by the relative cell-surface expression of these receptors of 1.14, 1.69, and 
0.86 respectively, in the patient as compared with the control. 
To determine T cell function, phytohemagglutinin (PHA) blasts were obtained after 
2-week culture of PBMCs and proliferative responses were measured after stim-
ulation with various polyclonal activators and Il-2. Stimulation by anti-CD2/28 
mAbs or with phorbol-12-myristate-13-acetate (PMA) resulted in somewhat lower 
responses than in the controls, but this could be overcome by additional co-stimu-
lation with IL-2 (Fig. 5). It should be noted that also between healthy controls, 











































Figure 5. T-cell proliferative responses (top) and IFN-γ production (bottom). PHA blasts obtained 
after 14-day culture of PBMC were stimulated via TCR ligation by anti-CD2/28 mAbs or with PMA. 
The somewhat decreased response in the patient was well within normal range and could be overcome 
by additional co-stimulation with IL-2. 
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T cell reactivity may reflect the signaling defect due to the STAT5b mutation, but 
apparently the impaired intracellular signaling can be largely compensated by other 
mechanisms in the presence of a potent, combined stimulus like anti-CD2/28 with 
co-stimulation with IL-2. Although both the proliferative response and the IFN-γ 
production lagged behind the two controls used in this particular experiment, the 
patient’s values are within normal range, in particular to the combined stimulation 
by CD2/28 and IL-2, or PMA plus Ionomycin. 
Carriers of the STAT5b mutation
We investigated four family members of the index patient: his parents, brother 
and sister. They were all heterozygous carriers of the frameshift mutation in the 
STAT5b gene. All had a history of normal birth weight. Remarkably, his father and 
brother were short (height < -2 SDS; Table 3), while his mother and sister were 
not. They were all in good physical condition, except the father, who had type 2 
Table 3. Clinical and biochemical features of the index patient and family members. 
Parameter Patient Father Mother Brother Sister
Age (years) 31 65 58 33 27
Height (cm) (SDS) 141.8 (-5.9) 164.3 (-2.8) 165.6 (-0.8) 167.4 (-2.3) 165.7 (-0.8)
Weight (kg) 56 87 71 78.5 56
BMI (kg/m2) 28.2 32.2 25.9 28.0 20.4
Head circ (cm) (SDS) 54 (-1.4) 58 (0.1) 58 (1.6) 58.5 (0.4) 57 (1.0)
Hip/waist ratioa 0.94 1.05 0.86 0.94 0.68
GH (mU/l) 0.33 0.2 0.1 0.1 0.6
IGF-I (ng/ml) (SDS) 8 (-8.2) 102 (-0.3) 42 (-3.1) 147 (-0.3) 130 (-1.1)
IGF-II (ng/ml) (SDS) 83 (-6.2) 403 (-0.1) 396 (-0.3) 511 (0.9) 452 (0.2)
IGFBP-1b (ng/l) 31 68 18 4 26
IGFBP-2 (ng/ml) (SDS) 142 (-0.6) 247 (0.6) 193 (0.2) 102 [(1.3) 239 (1.0)
IGFBP-3 (mg/l) (SDS) 0.18 (-12.4) 1.58 (-0.8) 1.86 (-0.1) 1.72 (-1.1) 1.95 (-1.0)
IGFBP-6 (ng/ml) (SDS) 230 (1.3) 267 (1.2) 206 (0.8) 178 (0.3) 206 (1.5)
ALS (mg/l) (SDS) 0.7 (7.0) 9.5 (-1.9) 13.4 (-1.0) 16.3 (-0.2) 12.9 (-2.0)
a Normal value in men < 0.90, in women < 0.85 (WHO criteria).
b Normal range for non-fasting subjects: 24-58 ng IGFBP-1/ml. After overnight fasting there is an
  average fivefold rise in normal individuals.
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diabetes mellitus and prostate carcinoma. None of the family members reported 
any infectious problems and their plasma prolactin levels and thyroid function 
were normal. Basal GH levels were within the normal range. Plasma IGF-I levels 
were also normal with exception of the mother of the index patient, who had a low 
IGF-I value (Table 3). 
D i s c u s s i o n
The data described in this study indicate that total GH secretion is not obliga-
torily increased in patients with a mutation in the STAT5b gene when compared 
with healthy BMI-matched controls. In contrast, prolactin secretion was clearly 
enhanced. We also assessed immunological function in detail in the present patient, 
because the previous two patients with STAT5b mutations showed signs of immu-
nodeficiencies. With the exception of chickenpox contracted in adolescence (see 
below), the patient did not suffer any infections, and the data obtained in our 
patient indicate that a homozygous deleterious STAT5b mutation is not necessar-
ily accompanied by severe immunodeficiency. Finally, heterozygous carriers of an 
inactive STAT5b mutation are phenotypically normal.
All the three reported patients with STAT5b mutations (4-6) show the same growth 
pattern, resembling that of patients with classical GH insufficiency (GHI) (19). 
The degree of postnatal growth retardation is comparable to that of patients with 
an IGF-I deletion or mutation, who reached a final height of -6.9 and –8.5 SDS 
respectively (8, 20). The main difference is the intrauterine growth retardation that 
occurs in the patients with primary IGF-I deficiency, but not in those with STAT5b 
mutations, reflecting the GH-independent IGF-I gene expression in utero. 
The pubertal growth spurt that occurred in our patient (15 cm) during GH therapy 
is about half the magnitude that would be expected in a boy (Fig. 1). We hypoth-
esize, that this growth acceleration is mainly attributable to the rise in sex steroids 
during puberty, as GH treatment did not normalize IGF-I. This observation 
supports the hypothesis, that the full growth promoting action of testosterone can 
only be exerted in the presence of normal GH secretion (21). 
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The regulation of GH secretion is complex. Pulsatile secretion is important since 
most of the secretion occurs in bursts. The magnitude of GH bursts correlates 
with somatic growth and hepatic actions of the hormone. Decreased pulsatility 
may contribute to decreased IGF-I concentration as observed in aged subjects (22, 
23). Pulses are generated by interactions among GHRH, ghrelin and somatosta-
tin under negative feedback control by IGF-I and GH (24). A GH pulse autoregu-
lates hypothalamic-pituitary outflow in a biphasic mode, imposing initial inhibi-
tion which is followed by disinhibition of GH secretion (25). In animal models, the 
increase in GH leads to prompt somatostatin release, which inhibits GHRH and 
sensitizes the somatotrope to the next GHRH stimulus. In this perspective, ghrelin 
further amplifies GH release (26).
The diminished negative feedback signaling by IGF-I and GH in GHI leads to 
amplified GH secretion in many, but not all patients with GHIS (27, 28). IGF-I 
administration  in this syndrome diminishes GH secretion, indicating that feedback 
can be restored (28). The amplified GH secretion is likely mediated by increased 
hypothalamic GHRH output, while somatostatin release is not affected in view of 
the unchanged GH pulsatility (29-32). 
The magnitude of GH secretion is determined by age, gender, sex hormones and 
adiposity (24). Especially, adiposity decreases spontaneous and stimulated GH 
secretion (33, 34). Detailed studies have established that particularly visceral fat 
mass is correlated with GH secretion (35, 36). It is therefore of interest that patients 
with Laron’s syndrome have a greater total and regional fat mass than BMI- and 
gender-matched controls, showing that the normal  relation between these two 
measures as found in the general population is lost (37-39). We hypothesize that 
the seemingly normal GH secretion in our patient was severely suppressed by his 
(visceral) adiposity. The relatively unchanged  basal GH secretion and pulsatility 
argue against GH suppression by somatostatin. Detailed GH secretion studies in 
normal and adipose subjects point to decreased pituitary responsiveness to GHRH 
as a possible mechanistic explanation (36). Finally, the only moderately increased 
GH ApEn would fit with partly attenuated GHRH signaling.
It would seem that in our patient  altered responsiveness only affected the somato-
trophe but not the lactotrophe in view of the stimulated prolactin secretion. 
Increased prolactin secretion has also been found in other states of endogenous 
GHRH excess, such as ectopic GHRH-secreting tumors (unpublished data) and 
hGHRH-transgenic mice (40). 
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The IGF-I generation test in our patient showed a limited response of plasma IGF-I, 
IGFBP-3 and ALS levels on stimulation with the two lower doses of GH (Fig. 3). 
However, after administration of 0.05 mg GH/kg/day the concentration of IGF-I 
in plasma approached reference range values. Apparently, a high dose of GH can 
induce IGF-I transcription and secretion considerably, despite the absence of a 
functional STAT5b protein. Under this condition, possibly, other STAT proteins 
and/or alternative signal transduction pathways (e.g  Microtubule-associated 
protein kinase (MAPK)/Erk or Protein Kinase B (PKB)/Akt) may play a compensa-
tory role in the regulation of GH-dependent IGF-I expression. Indeed, we found 
some evidence for this in vitro (6). A high dose of GH could activate Erk1/2 and 
PKB/Akt although at a much lower level when compared with controls. Therefore, 
at high concentrations other mechanisms may partly compensate the loss of 
STAT5b, for example by recruitment of other STAT family members to the GHR 
(41). Since this effect is only seen at high GH concentrations, the affinity of other 
STAT proteins for the activated GHR appears much lower than of STAT5b. 
The first reported female patient with a STAT5b mutation had respiratory diffi-
culties due to lymphoid interstitial pneumonia and a Pneunocystis Jiroveci infection. 
At 8 years of age, she presented with severe hemorrhagic varicella and subse-
quently she had several episodes of herpes zoster (4). The second female patient 
with a STAT5b mutation also had pulmonary problems, characterized as primary 
idiopathic pulmonary fibrosis (5). In contrast, our male patient has had neither 
pulmonary complaints nor signs of immunodeficiency. Initially, we thought that 
the hemorrhagic varicella infection at the age of 16 years (6) could be a sign of 
immunodeficiency. However, the patient did not have a history of chickenpox in 
the past (a reliable surrogate of a lack of seroimmunity (42, 43)) and he developed 
the varicella secondary to his brother, who suffered a less severe case. Varicella 
secondary attack rate among susceptible household contacts is high and at higher 
age, e.g. above 10-14 years, the infection typically runs a more severe course than 
in infants (44, 45). For instance, adults with chickenpox, males in particular, have 
an about 25-fold higher risk of complications like pneumonitis or encephalitis, 
when compared with children with the disease (46). Thus, we do not consider 
the severe case of chickenpox in this patient as sufficient evidence for immunode-
ficiency, secondary to the STAT5b mutation. Moreover, with the exception of the 
chickenpox, the medical history of our patient was unremarkable for childhood 
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infections, and response to vaccinations. This was in line with additonal immuno-
logical investigations. 
The in vitro proliferative responses of T-cells to IL-2 and CD2/28 and the produc-
tion of IFN-γ upon IL-2 stimulation were within the normal range, although the 
latter cytokine response lagged somewhat behind those in controls. Although the 
present findings certainly cannot exclude some sort of subtle immunodeficiency, 
our patient demonstrates that STAT5b deficiency is not obligatory resulting in a 
severe immunocompromised state, which was suggested by at least one of the 
other two cases with STAT5b mutations, and findings in STAT5b -/- mice. This 
suggests a role for other factors in the expression of immunodeficiency in humans 
with STAT5b deficiency. Since our case is the first male patient described with 
STAT5b deficiency, it might be possible that the presentation of the immunophe-
notype of STAT5b deficiency is sex-dependent.
The heterozygous family members of the index patient did not exhibit signs of 
GH insensitivity. The short stature of the father and brother can not merely be 
explained by heterozygosity for the STAT5b mutation, as their IGF-I levels were 
normal. The mother had a low IGF-I level, but her normal IGFBP-3 and ALS levels 
argue against an effect of partial STAT5b deficiency.
In conclusion, STAT5b is essential for GH signaling and postnatal growth. GH 
secretion in our patient was likely attenuated by the visceral adiposity, but prolactin 
secretion was clearly amplified. Although STAT5b plays a role in signaling within 
the immune system, the clinical consequences of disrupting this signaling pathway 
appear limited, probably due to compensatory pathways, and immunodeficiency is 
not present in all patients with a STAT5b mutation. The heterozygous carriers show 
no signs of GH insensitivity. Other factors may contribute to the short stature of 
the male carriers. 
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A b st r a c t
IGF-I  is a key factor in intrauterine development and  postnatal growth and 
metabolism. The secretion of  IGF-I  in utero is not dependent on GH, whereas in 
childhood and adult life  IGF-I secretion seems to be mainly controlled  by GH, as 
revealed from studies on patients with GHRH-R and GH-receptor mutations. 
In a 55-yr-old male, the first child of consanguineous parents, presenting with 
severe intrauterine and postnatal growth retardation, microcephaly, and senso-
rineural deafness we found a homozygous G to A nucleotide substitution in the 
IGF-I gene changing valine 44 into methione (V44M). The inactivating nature of 
the mutation was proven by functional analysis demonstrating a 90-fold reduced 
affinity of recombinantly produced V44M for the IGF-I receptor. Additional inves-
tigations revealed osteoporosis, a partial gonadal dysfunction, and a relatively well 
preserved cardiac function. Nine of the 24 relatives studied carried the mutation. 
They had a significantly lower birth weight, final height and head circumference 
than noncarriers.
In conclusion, the phenotype of our patient consists of severe intrauterine growth 
retardation, deafness, and mental retardation, reflecting the GH-independent 
secretion of IGF-I in utero. The postnatal growth pattern, similar to growth of 
untreated GH deficient or GH-insensitive children, is in agreement with the 
hypothesis that IGF-I secretion in childhood is mainly GH-dependent. Remarkably, 
IGF-I deficiency is relatively well tolerated during the subsequent four decades of 
adulthood. IGF-I haploinsufficiency results in subtle inhibition of intrauterine and 
postnatal growth.
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I n t r o d u c t i o n
In mice, the GH-IGF-I system plays a key role in intrauterine development and 
postnatal growth and metabolism (1-3). Knockout models of the GH receptor 
(GHR) and IGF-I have indicated that in utero IGF-I, but not GH, is required for 
normal fetal growth (1, 3, 4). Postnatally, growth is mediated predominantly 
via GH-dependent IGF-I secretion. In mice the effects on bone accretion before 
puberty are mediated predominantly via mechanisms independent of GH whereas 
the pubertal and postpubertal changes are predominantly mediated via GH-
dependent mechanisms (5).
So far in humans only one adolescent male has been reported with a total IGF-I 
deficiency, resulting from a homozygous deletion of exons 4 and 5 of the IGF-I gene 
(6). This patient exhibited severe intrauterine growth retardation (birth weight –3.9 
SDS), severe postnatal growth failure (height in childhood –6.9 SDS), sensorineu-
ral deafness, and mental retardation. Recently two patients with mutations of the 
IGF-I receptor (IGF1R) were described (one compound heterozygote and one het-
erozygote) (7). Both had decreased intrauterine growth (birth weight -3.5 SDS), 
comparable with the birth weight of the IGF-I deficient boy, but postnatal growth 
failure was less severe (a final height of -4.8 SDS and a height in childhood of -
2.6 SDS, respectively). The patient who was compound heterozygous for missense 
mutations had signs of a nonverbal learning disorder and psychiatric anomalies. 
The patient with the heterozygous nonsense mutation had dysmorphic features, 
microcephaly, and mild retardation of motor development and speech. The het-
erozygous parents had heights of -1.6, -2.8 and -2.6 SDS. 
The severely compromised intrauterine growth of the patients with IGF-I deficiency 
and (partial) IGF-I insensitivity is in contrast with the slightly diminished intrauter-
ine growth of patients with either congenital complete GH deficiency (GHD) (8) 
or GH resistance (9-11) suggesting that, as observed in mice, in utero the produc-
tion of IGF-I is largely independent of GH. Postnatally, IGF-I insufficiency leads to 
a persistent and severe growth retardation, of approximately equal magnitude as 
observed in complete GHD or GH resistance, implying that postnatal growth is the 
result of GH dependent IGF-I production 
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We describe a 55-yr-old patient with severe pre-and postnatal growth retardation, 
deafness, and mental retardation. He and his younger brother were described in 
1969 as a familial syndrome of prenatal dwarfism, associated with elevated GH 
levels and end-organ unresponsiveness (12). We show that this clinical picture is 
caused by a homozygous missense mutation in the IGF-I gene, resulting in an IGF-I 
polypeptide with strongly decreased binding affinity to the IGF-I receptor in vitro 
and a lack of bioactive IGF-I in vivo. This unique patient enables us to study the 
effects of nearly complete primary IGF-I deficiency in adulthood. Investigations 
in 24 family members, of  whom nine proved heterozygous for the mutation, have 
also enabled us to characterize for the first time the phenotype of IGF-I haploinsuf-
ficiency in detail.
M e t h o d s
The guardian of the index case, and all relatives who underwent investigations, 
provided written informed consent.
Clinical measurements and auxology
Height and sitting height were determined with a Harpenden stadiometer, and 
head circumference was assessed with a tape measure. Height was expressed as 
standard deviation score (SDS) based on Dutch references (13), after correction 
for shrinking (age) and secular trend (birth cohort) (14). Sitting height, sitting 
height/height ratio and head circumference were also expressed as SDS for the 
Dutch population (13, 15). Blood pressure was measured with a Dynamap and 
testicular volume with the Prader orchidometer.
Radiological and sonographic measurements
Bone mineral density (BMD) was measured by dual energy X-ray absorptiom-
etry (QDR 4500; Hologic Inc., Bedford, MA) at the lumbar spine and femoral 
neck. Bone mineral apparent density (BMAD) of the lumbar spine was calculated 
using the formula BMAD=BMD x [4 / (π x width)]. The validity of this model has 
been tested using volumetric data obtained from magnetic resonance imaging 
of lumbar vertebrae (16). Cardiac ultrasound was performed (GE System 7, 
Vingmed, Milwaukee, WI) and routine images (for assessment of left ventricular 
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systolic function) and color Doppler data (to detect valvular abnormalities) were 
obtained. In addition, tissue Doppler imaging was performed for detailed evalua-
tion of diastolic function (17). 
Biochemical measurements
Plasma GH was measured with time-resolved immunofluorometric assay (Wallac/
PE, Turku, Finland). Spontaneous GH secretion was assessed after an overnight 
fast by sampling every 20 min from 0900 to 1300 h. A fasting combined GHRH (1 
µg/kg iv at 0 min) and arginine test (0.5 g/kg iv over 30 min, from 0 to +30 min) 
was performed. 
Plasma IGF-I, IGF-II, IGF-binding-protein (IGFBP)-1, IGFBP-2, IGFBP-3, IGFBP-4, 
IGFBP-5, and IGFBP-6 were determined by specific RIAs (18-22). Acid-labile subunit 
(ALS) was measured by a commercially available ELISA  (Diagnostics Systems Lab-
oratories, Inc., Webster, TX) (23). With the exception of  IGFBP-1 and -5, for all 
parameters smoothed references were available, based on the LMS method (24), 
allowing conversion of  patient data to SDS values. Plasma IGFBP-1 concentration 
after an overnight fast was compared with a reference group of  six healthy adult 
controls. We compared IGFBP-5 with a reference population (5). The proportion 
of intact IGFBP-3 was determined by a ligand immunofunctional assay (25). The 
different molecular-size classes of endogenous IGF-IGFBP complexes in plasma 
were determined by neutral gel filtration (26). IGF-I bioactivity was assessed by an 
IGF-I kinase receptor activation assay based on cells transfected with the human 
IGF1R gene (KIRA) (27).
Molecular studies
A skin biopsy was taken, and a culture of dermal fibroblasts was established. These 
cells were used for a thymidine incorporation assay in response to IGF-I (28). Total 
RNA was isolated and reversed transcribed into cDNA. Full length IGF-I cDNA was 
isolated by PCR using the following primer combination (forward 5’-GCTTCAT-
TATTCCTGCTAAC-3’; reverse 5’-AACTCGTGAGAGCAAAGGATC-3’), cloned, and 
subjected to direct sequencing, using routine procedures. The V44M mutation 
was introduced into Escherichia coli codon optimised human IGF-I cDNA by Qui-
kChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Expression and 
purification of recombinant V44M IGF-I was performed as previously described 
(29). Folding patterns of V44M IGF-I and native IGF-I were very similar. Purified 
Chapter 6
90
V44M IGF-I was shown to be more than 95% pure by N-terminal sequencing and 
of the correct mass by mass spectroscopy. IGF1R binding affinity was determined 
using an europium-labeled IGF-I binding assay, essentially as described previously 
for epidermal growth factor binding to the epidermal growth factor  receptor (30) 
but using IGF1R from lysed P6 cells. 3T3 cells overexpressing IGF1R (gift from 
Professor Renato Baserga, Thomas Jefferson University, Philadelphia, PA) captured 
with antibody 24-31 (a gift from Professor Ken Siddle, University of Cambridge, 
UK). Europium labeled IGF-I (DELFIA Eu-labeling kit, Perkin Elmer, Norton, OH) 
was added with competing IGF-I or V44M  IGF-I and the amount of labeled IGF-I 
bound was measured by time-resolved fluorescence.
IGF-I binding to bovine placenta membrane fractions was performed using acid 
Sep-Pak C18 extracts of the sera. Sep-Pak C18 extraction is a well-established 
technique that effectively removes interfering IGF-binding proteins from both 
normal and chronic renal failure patient sera or plasma (the latter contain elevated 
levels of various IGF-binding proteins) as we have verified previously by [125I] IGF-I 
or [125I] IGF-II probed Western ligand blots of chromatographed materials (31-
33). In addition, experiments were performed in which 125I radiolabeled (30,000 
cpm) wild-type IGF-I was incubated (overnight at 4 oC) with an aliquot (200 µl) 
of pooled normal serum. In a similar way, other 200 µl-aliquots of pooled normal 
serum were incubated with the same amount of 125I radiolabeled wild-type IGF-I 
in the presence of either 200 ng recombinant wild-type IGF-I or 200 ng recombi-
nant V44M IGF-I. The distribution of [125I]IGF-I among the various molecular-size 
classes (i.e. 150 kD, 40-50 kD, and free IGF-I) in each aliquot of serum was deter-
mined after separation by S200 gel filtration and counting of 125I activity in each 
fraction.
Statistical analysis 
Data were analyzed with SPSS for Windows (version 11.0; SPSS Inc., Chicago, IL). 
Independent-samples t tests were used to compare the data of the carriers with the 
non-carriers. P < 0.05 was considered significant.
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R e s u l t s
Subjects
The index case, RV, was born in 1947 as the first of five children of a consanguine-
ous marriage (Fig. 1). His grandfathers were brothers. At birth after 8 months’ 
gestation, weight was 1420 g (-3.9 SDS) and length 39 cm (-4.3 SDS) (34). Postna-
tally there was a persistent progressive growth failure (Fig. 2) with normal propor-
tions, retarded skeletal maturation, microcephaly, deaf-mutism, and severe mental 
retardation. At 11.4 yr, a 6-month trial with a testosterone depot preparation (75 
mg im once a month) was given, which caused a slight acceleration of growth 
velocity, but also a clear advance in skeletal maturation. At 15 yr of age he had 
to be institutionalized because of severe mental retardation (IQ < 40) and motor 
unrest. Pubic hair and testicular growth occurred at the age of nearly 20 yr. Studies 
performed at the age of 21 yr (1968) revealed elevated basal [13 ng/ml (20 mU/
liter)] and stimulated [127 ng/ml (191 mU/liter)] plasma GH levels in response to 
insulin-induced hypoglycemia (12). Adrenal and thyroid function was normal. He 
had a history of a right radial fracture following a minor trauma.
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Figure 1. Pedigree of the family. The arrow points at the index case. Height SDS of the familymembers 
is added in italic. Heterozygotes are marked with a central dot. 
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Figure 2. Growth chart of RV. Target height (TH) corrected for secular trend is calculated as: [height 
father + height mother + 13 cm] /2 + 4.5 cm.
Figure 2 
Figure 3 
Figure 3.  RV at 55 yr of age, together with one of his brothers (168.2 cm).
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At 55 yr of age he came again to our attention because of a request for genetic 
counseling by one of his healthy younger brothers (Fig. 3). The auxological findings 
are summarized in Table 1. Abdominal fat mass was increased. There were several 
dysmorphic features, including deep-set eyes, flat occiput, a columella extending 
beyond the alae nasi and a striking micrognathia. His extremities showed broad 
end phalanges and convex nails. There was hypermobility of the interphalangeal 
joints but not of the other joints. The mobility of both elbows was restricted. 
Blood pressure was 172/93 mm Hg. Neurological examination was normal. Audio-
logical analysis demonstrated severe bilateral hearing loss confirmed by absent 
brainstem evoked potentials. Testicular volume was 7 (left) and 1 ml (right). The 
stretched penile length was 8 cm (P10-90: 10.2-16.4 cm) (35). Bilateral inguinal 
scars were seen. In 1975 an operation for a bilateral inguinal hernia with ileus had 
been performed. Cardiovascular, respiratory, and abdominal examinations were 
normal. His IQ was less than 40. Ophthalmological examination revealed cataracts 
of both eyes and shallow anterior chambers. Vision was 0.63.
His youngest brother, AV, was born at term with a birth weight of 1900 g (-4.5 
SDS) (34). His clinical phenotype strongly resembled that of RV. He too showed 
deaf-mutism and severe retardation (12). At the age of 12 yr (1968) endocrine 
investigations were performed. At baseline GH was 3 ng/ml and after insulin-
induced hypoglycemia, plasma GH exhibited an exaggerated response [maximum 
206 ng/ml (309 mU/liter)] (36). An oral glucose tolerance test showed an elevated 
baseline plasma insulin (15 mU/liter) (37), an insulin peak of 46 mU/liter with a 
maximum glucose of 125 mg/dl (6.9 mmol/l) [normal according to the American 
Diabetes Association (38)], and a normal suppression of plasma GH (<1 ng/ml). 
Prolonged fasting resulted in a physiological rise of GH (up to 56 ng/ml) and free 
fatty acids. Human pituitary GH was administered im for 4 d  in a dose of 5 mg 
(≈ 4 IU) once daily, which did not result in a reduction of urinary excretion of 
nitrogen, potassium, and phosphate or an increase of hydroxyl-proline excretion 
(12).  He died at 32 yr of age of aspiration pneumonia and severe gastritis with 
reflux oesophagitis after orthopedic surgery (triple athrodesis of left ankle).
Radiological features
BMD at the right femoral neck was 0.57 gr/cm2 (-3.7 SDS) and 0.51 gr/cm2  at 
the left femoral neck (-4.3 SDS). Lumbar spine BMD (L2-L4) was 0.52 gr/cm2 
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Table 1. Auxological and biochemical characteristics of RV at 55 yr of age 
Variable Value SDS
Height (cm) 117.8 - 8.5a
BMI (kg/m2) 17.9 - 2.0b
Height/sitting height ratio 0.51 - 0.3b
Head circumference (cm) 44.2 - 8.0 b
GH maximum (ng/ml) after GHRH/arginine stimulation 91.9
GH maximum (ng/ml) in 3-h GH profile 1.8
Total IGF-I (ng/ml) 606 + 7.3
IGF-II (ng/ml ) 454 + 0.5
ALS (µg/ml) 28.9 + 3.4
IGFBP-1 (ng/ml) 12 Lowc
IGFBP-2 (ng/ml) 106.3 - 1.0
IGFBP-3 (µg/ml) 1.98 + 0.1
IGFBP-4 (ng/ml) 145.6 + 0.6
IGFBP-5 (ng/ml) 347.7 - 0.4
IGFBP-6 (ng/ml) 121.8 - 1.5
Normal value
Testosterone (ng/dl)  271 >230
Inhibin B (ng/liter) 64 >150
LH (U/liter) 3.5 2-8
FSH (U/liter) 19.2 2-10
To convert GH to milliunits per liter, multiply by 2.6; to convert IGF-I to nanomoles per liter,  multiply 
by 0.131; to convert IGF-II to nanomoles per liter, multiply by 0.134; to convert ALS to nanomoles 
per liter, multiply by 15.8; to convert IGFBP-1 to nanograms per milliliter, multiply by 0.033; to 
convert IGFBP-2 to nanamoles per liter, multiply by 0.032; to convert IGFBP-3 to nanomoles per liter, 
multiply by 33.3; to convert IGFBP-4 to nanamoles per liter, multiply by 0.038; to convert IGFBP-5 to 
nanomoles per liter, multiply by 0.035; to convert IGFBP-6 to nanomoles per liter, multiply by 0.034; 
to convert  testosterone to nanomoles per liter, multiply by 0.035
a See Ref. 60
b See Ref. 13
c Normal range for nonfasting subjects: 24 - 58 ng IGFBP-1 per liter. After overnight fasting there is an 
  average 5-fold rise in normal individuals.
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(-5.2 SDS). BMAD was 0.2 gr/cm3 (-3.5 SDS) (16). Cardiac ultrasound showed a 
left ventricular ejection fraction of 60%, without regional wall motion abnormali-
ties. Left ventricular mass was normal. Diastolic function was impaired (abnormal 
relaxation), with an E (early flow) to A (late flow) ratio of  0.53, and the E’ (early 
diastolic myocardial velocity assessed by tissue Doppler imaging) being 4.5 cm/sec 
(normal value >12 cm/sec).
Biochemical features
The results of the biochemical analysis are shown in Table 1. Maximum GH con-
centration after stimulation was in the upper normal range (36). Serum IGF-I was 
markedly elevated. After an overnight fast, the IGFBP-1 level remained low. Circu-
lating levels of IGFBP-2, -3, -4, -5, and -6 were within the normal range whereas ALS 
was increased. The proportion of intact IGFBP-3 did not differ from that encoun-
tered for age- and gender-matched normal controls. As with normal plasma, in the 
patient’s plasma, most of IGF-I (> 90%) (Fig. 4A) and IGF-II (>70%) (Fig. 4B) was 
associated with the 150 kD complex. The distribution of IGFBP-3 and IGFBP-5 
over the various molecular weight classes in serum appeared normal as did IGFBP 
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Figure 4. IGF-I (A) and IGF-II (B) in serum of RV are normally distributed over the various molecular 




Considering the increased level of IGF-I in our patient, we reasoned that the clinical 
symptoms could be caused by either an inactivating mutation in the IGF1R or in 
IGF-I itself. The wild-type (wt) IGF-I induced stimulation of 3H-thymidine incor-
poration by cultured fibroblasts of the patient was comparable with the average 
response observed in cells obtained from 10 healthy control subjects. Considering 
the variation observed in IGF-I responses using dermal fibroblast cultures (28), 
the presence of an inactive IGF1R appeared unlikely (Fig. 5A). Subsequently, IGF-
I cDNA was isolated by RT-PCR from fibroblasts. Sequence analysis identified a 
homozygous G>A nucleotide substitution at position 274, changing valine at 
position 44 of the mature IGF-I protein to methionine (Fig. 5B). The same nucleo-
tide substitution was also present in the genomic DNA but not in a control panel 
of 87 individuals. V44 is located in the first α helix of the A domain of  wt IGF-I and 



























A. Fibroblasts of RV respond normally to wt IGF-I in a thymidine incorporation assay. An asterisk 
indicates a statistical difference from unstimulated cells (P < 0.01). 
B. Sequence analysis of wt IGF-I (upper panel) and IGF-I of RV (lower panel). Arrow indicates the homo-
zygous G>A nucleotide alteration.
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Functional analysis
We subsequently used the mutant cDNA for the synthesis of mutant IGF-I (V44M). 
V44M had an approximately 90-fold lower affinity for the IGF1R compared with 
wt IGF-I measured in both europium (Fig. 6A) and 125I-labeled IGF-I competition 
receptor binding assays (Fig. 6B). Competition binding studies with 125I-labeled 
IGF-I and serum of our patient or an age-and sex-matched control revealed that 
serum of the patient displaced 125I-wt IGF-I with an ED50 of 11.3 µl serum equiva-
lents (Fig. 6B). This volume of serum contained 5.3 ng IGF-II (serum value of  454 
ng/ml, Table 1) that also competed for binding to the receptor. This is close to the 
deduced ED50 value of purified human IGF-II (4.3 ng) in this assay. Thus, these cal-
culations demonstrate that the displacement of 125I-wt IGF-I in the bovine placenta 
membrane assay can be explained by the presence of IGF-II and that V44M in 
serum did not significantly contribute to this process, in agreement with the data 
obtained for recombinant V44M providing further support for the inactivating 
nature of the mutation. In addition, a competition experiment was performed in 
which 125I-wt IGF-I was incubated with normal serum in the absence or presence 
of unlabeled wt and V44M IGF-I. As shown in Fig. 6C wt IGF-I and V44M IGF-
I competed with equal affinity for 150 kD and 40-50 kD complex forming with 
radiolabeled ligand. This suggests that the V44M mutation has only minor effect 
on binding to IGFBPs in marked contrast to binding to the IGF1R.
Carriers of the IGF-I mutation
We investigated a total of 24 relatives of the index patient. Nine of them carried the 
heterozygous V44M IGF-I mutation. Their birth weight and head circumference 
were lower in comparison with noncarriers (Table 2). Their height SDS was lower 
as shown in Fig. 7. Testicular volume was normal. 
Except for one diabetic individual and the 87-yr-old mother, fasting glucose levels 
were normal. Fasting insulin levels were significantly higher in carriers (Table 2). 
Serum LH, FSH, testosterone, and estradiol were normal (data not shown). Basal 
GH levels (a single fasting sample) were within the normal range. Carriers had higher 
total IGF-I levels (Fig. 7) and lower IGF-I bioactivity than noncarriers (Table 2).
We measured BMD at the femoral neck and lumbar spine in all carriers. They had 
values within the normal range for their age and sex. In 21 relatives (three young 
children were excluded), we performed audiometry, revealing hearing abnormali-
ties in seven individuals. However, no statistically significant association with car-




A Receptor binding assay showing 90-fold reduced binding affinity of V44M  IGF-I to the IGF-I 
receptor.
B. Competition binding assay using 125I-IGF-I as tracer and IGF1R-expressing membranes of bovine 
placenta. Competition is performed with wt hIGF-I, wt hIGF-II, V44M, serum of the patient, or 
an age- and sex-matched control. The ED50 of a Sep-Pak C18 extract of RV is 11.3 µl, which cor-
responds to 5.3 ng IGF-II, being close to the deduced ED50 of IGF-II (4.3 ng). The values of IGF-I 
and IGF-II of the age- and sex-matched control were 185 ng/ml and 386 ng/ml.
C. 125I radiolabeled wt IGF-I was incubated with an aliquot of pooled normal serum, in either the 
absence or presence of 200 ng recombinant wt IGF-I or 200 ng recombinant V44M IGF-I. wt IGF-I 
and mutant IGF-I efficiently competed for 150 kD and 40-50 kD complex forming with iodinated 
IGF-I.
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Figure 7: Height SDS and IGF-I SDS of  heterozygous and nonheterozygous family members (dots) and 
95% confidential interval (bars). 
Table 2. Auxological and biochemical characteristics of the carriers of the heterozygous 
IGF-I mutation (n = 9) vs. noncarriers (n = 15).
Variable Carrier Noncarrier P value
Age (yr) 44.2 ± 7.8 27 ± 5.7 0.08
Male/female 5/4 8/7
Height (SDS)a -1.0 ± 0.2 -0.4 ± 0.2 0.04
Head circumference (SDS) -1.0 ± 0.3 0.5 ± 0.3  < 0.01
BMI (SDS) b 0.5 ± 0.3 0.7 ± 0.3 0.62
Birth weight (g)c 3048 ± 101 3358 ± 85 0.04
Fasting insulin (mU/liter)d 16.5 ± 1.9 12.1 ± 0.7 0.03
Total IGF-I (SDS)   0.6 ± 0.3 -0.3 ± 0.2 0.04
Bioactive IGF-I (ng/ml) 0.9 ± 0.09 1.6 ± 0.16 < 0.01
Data are expressed as mean values ± SEM.
To convert insulin to picomoles per liter, multiply by 7.175; to convert bioactive IGF-I to nanomoles 
per liter, multiply by 0.131.
a For the calculation of mean height SDS, height of the father of the index cases was included (n=10). 
b For the analysis of BMI, one noncarrier (obese and type 2 diabetes) was excluded.
c Birth weight data were available from eight carriers and 15 noncarriers. 





























D i s c u s s i o n
There are two principal, novel findings in our study. It is the first report on a homo-
zygous missense mutation in the human IGF-I gene resulting in an IGF-I protein 
that is hardly capable of interacting with the IGF1R  but with relatively unaf-
fected binding capacity for IGFBPs. This leads to severe effects on growth and 
development in utero and during  childhood. It provides an opportunity to evaluate 
the effects of primary IGF-I insufficiency in adulthood, in comparison with the 
secondary IGF-I deficiency present in severe GH resistance or deficiency. Second, 
we have shown for the first time that IGF-I haploinsufficiency results in a subtle, 
but statistically significant, inhibition of intrauterine and postnatal statural and 
cranial growth and increased fasting insulin concentrations.
From observations on analogous peptides in the human as well as in other species, 
one can predict that a change in V44 should lead to a severe loss of function. 
V44 is not conserved only in IGF-I of all species except one (40) available in the 
National Center for Biotechnical Information database, but also in the two struc-
turally related proteins IGF-II and insulin. In insulin, amino acid VA3, structurally 
homologous to V44 in IGF-I, is involved in binding to the insulin receptor (41). 
Interestingly, a germline mutation of VA3 to leucine (insulin Wakayama) resulting 
in a variant that poorly binds to the insulin receptor has been associated with 
diabetes mellitus (42). 
Proof for the inactivating nature of V44M was provided by demonstrating a 90-
fold lower binding affinity for the IGF-I receptor in receptor binding assays using 
recombinantly produced protein. In addition, total receptor binding activity of 
the patient’s serum was equivalent to a level that would be achieved by the same 
concentration of IGF-II found in his serum. This observation indicated that V44M 
did not contribute significantly to receptor binding despite the increased circulat-
ing levels of V44M in serum. Thus, the phenotype of our patient is caused by a 
complete lack of bioactive IGF-I. Furthermore IGF-II, although in the upper normal 
range, cannot compensate for IGF-I deficiency in utero, in childhood and neither in 
adulthood, in agreement with earlier reports (1-3, 6, 7).
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Remarkably, gel filtration experiments revealed that the relative distribution of 
V44M over the various molecular weight classes in serum is not different from wt 
IGF-I in normal serum. This suggests normal binding of V44M to IGFBPs and is 
indicative of a relatively small impact on overall structure of V44M. It also implies 
that V44M can compete normally with IGF-II in the formation of complexes with 
the binding proteins and ALS. This was supported by our observation that V44M 
efficiently competed with wt IGF-I for 150- and 40-50 kD complex formation in 
serum, and was recently confirmed by BIAcore analysis showing normal binding 
of V44M to human (h)IGFBP-2, hIGFBP-3 or hIGFBP-6 biosensor surfaces. In 
addition, nuclear magnetic resonance analysis demonstrated only subtle changes 
in overall structure of V44M (43).
Considering the respective roles of IGF-I and GH in utero and in childhood, the 
clinical presentation of these two sibs with a dysfunctional IGF-I generally confirm 
the observations made in the single previously reported case of the IGF-I-deficient 
adolescent (6) and the two patients with partial IGF-I insensitivity (7). In utero, 
biologically active IGF-I is necessary for normal intrauterine growth, brain devel-
opment, development of the inner ear, and mandibular growth, similarly to the 
phenotype of IGF-I knockout mice (44, 45). The functional effects of a partial IGF-
I insensitivity on the brain are much milder, but the head circumference at birth 
of the heterozygote was severely decreased (-4.6 SDS). No effects were seen on 
inner ear development. This suggests that the heterozygous and compound het-
erozygous mutations in the IGF1R do not completely preclude IGF-I signaling. The 
variation in dysmorphic features in the different cases of IGF-I deficiency and IGF-I 
insensitivity may be partially due to a tissue-specific expression of IGF1R alleles 
(7). The absence of intrauterine growth retardation, mental retardation, hearing 
problems, and micrognathia in GH-deficient and GH-insensitive infants implies 
that in the fetal stage IGF-I secretion is GH-independent. 
In childhood and adolescence, a complete lack of IGF-I function seems to lead to 
a qualitatively similar postnatal growth pattern as seen in a complete lack of GH 
effect: severe proportionate growth retardation accompanied by retarded skeletal 
maturation and delayed pubertal development. In our case and the case with IGF-
I deletion growth was extremely retarded, and led in our male patients to a final 
height of 118 cm (about 8.5 SD below the mean). In the two patients with partial 
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IGF-I insensitivity short stature was less extreme (final height -4.8 SDS and a height 
in childhood of -2.6 SDS, respectively). Patients with GH insensitivity due to a GHR 
mutation reach an average height varying from –5.3 to -12 SDS (46-48). Mean 
height of patients with GHRH-R mutations is –7.2 SDS. So the effect of primary or 
secondary IGF-I insufficiency on postnatal growth is similar. 
Whereas IGF-I deficiency leads to specific detrimental consequences for growth 
and development of various organs in utero and during childhood, IGF-I deficiency 
appears to be tolerated relatively well during  the subsequent four decades. We 
found  a low BMD  and decreased testicular function in our patient, but both 
findings might be explained by other factors than IGF-I deficiency. The severe 
osteoporosis in our 55-yr-old patient could be explained by hypomuscularity and a 
low level of physical activity. Because our patient had a normal serum testosterone 
level, it is unlikely that his osteoporosis is due to hypogonadism. Our findings are in 
contrast with the absence of osteoporosis in the adolescent with the IGF-I deletion, 
and in the 12-yr-old girl with IGF1R mutation. They are also in contrast with the 
normal BMAD values observed in patients with Laron syndrome (GH insensitiv-
ity) and in patients with untreated GHD due to GHRH receptor mutations (49-
51). Similar observations in future cases with primary IGF-I deficiency are needed 
before it can be assumed that maintenance of normal bone density is dependent 
on GH-independent IGF-I secretion.    
At 55 yr of age, secondary sex characteristics and plasma testosterone level were 
normal, but FSH was elevated and inhibin was low in our patient. This suggests that 
mainly Sertoli cell function and spermatogenesis are impaired, probably resulting 
in infertility. The significance of the partial gonadal failure that we observed in 
our patient is most probably the result of  testicular damage due to the bilateral 
inguinal hernia operation. This speculation is strengthened by the observation that 
the adolescent with IGF-I deletion has normal basal and GnRH-stimulated LH and 
FSH values. Furthermore, in patients with a secondary IGF-I deficiency due to a 
GHR or GHRH receptor mutation, fertility is normal. 
IGF-I deficiency appears noncritical for adult cardiac function because only 
diastolic function was mildly impaired, a nonspecific finding observed frequently 
in individuals of 50 yr and older. The hypertension we found is in line with the 
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findings in IGF-I deficient mice. IGF-I has growth-promoting effects on smooth 
vascular muscle and has potent vasodilator effects, suggesting a possible role for 
IGF-I in the regulation of vascular tone (52). In our patient, with probably life-long 
exposure to increased GH levels, the absence of cardiac abnormalities is striking, 
compared to the findings in patients with untreated acromegaly who are exposed 
to GH and IGF-I excess for years before diagnosis. In these patients the devel-
opment of both ventricular hypertrophy and valvular abnormalities are strongly 
dependent on the duration of exposure to increased GH production (53, 54). We 
speculate that the cardiomyopathic changes found in patients with acromegaly are 
caused by increased levels of IGF-I due to GH-excess. 
One of the clinical characteristics of our patient is a restricted mobility of both 
elbows. This feature was also described in patients with GHR deficiency and GH 
deficiency caused by Prophet of Pit-1 (PROP 1) gene mutation (55, 56). This 
suggests that the effect of GH on the development of a normal joint mobility is 
mediated through IGF-I.
With regard to the IGFBPs, the normal IGFBP-3 level in RV and the patient with 
the IGF-I deletion supports the notion that the production of IGFBP-3 is controlled 
independently of IGF-I in humans (57). ALS is increased, which suggests that ALS 
is primarily GH dependent, and in this case may predominantly circulate in an 
unbound form. Also in the case of IGF-I deficiency, an elevated plasma ALS was 
reported, which decreased after IGF-I therapy (57).
In contrast to patients with GHD and GH insensitivity, in whom IGFBP-1 is usually 
elevated, IGF-I deficiency is associated with a low fasting IGFBP-1. IGFBP-1 has 
an inhibitory effect on the growth-promoting and anabolic effects of IGF-I. It is 
primarily regulated by insulin, but also IGF-I, IGF-II, and GH have specific inhibi-
tory effects on IGFBP-1 expression (58). We speculate that the persistently low 
IGFBP-1 levels are caused by the direct suppressive effect of high GH levels (59). 
Finally, it is of interest that heterozygous carriers of the mutation have a lower 
birth weight, height, and head circumference than noncarriers. Although height 
SDS was significantly lower than in the noncarriers, it was still within the normal 
range. The clinical findings are in line with the elevated IGF-I, and lower IGF-I bio-
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activity. We hypothesize that a gene-dose effect may explain this mild effect on 
growth. The carriers had higher fasting insulin levels than the noncarriers support-
ing the role of IGF-I bioactivity in insulin sensitivity (57). Fertility in heterozygous 
carriers appears normal, considering the offspring of the obligate heterozygous 
parents of the index cases and the fact that four other adult heterozygotes had 
children. This observation is supported by normal testosterone, estradiol, LH, and 
FSH levels in carriers.
In conclusion, this homozygous missense mutation in the human IGF-I gene results 
in an abnormal IGF-I molecule with low receptor binding. In contrast to the severe 
effects on pre- and postnatal growth and development,  IGF-I insufficiency is well 
tolerated in adulthood. IGF-I haploinsufficiency results in decreased IGF-I bioac-
tivity, a subtle, but statistically significant, inhibition of intrauterine and postnatal 
statural and cranial growth, and elevated fasting insulin levels.
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A b st r a c t
We have previously described the phenotype resulting from a missense mutation 
in the IGF-I gene, which leads to expression of IGF-I with a methionine instead of 
a valine at position 44 (Val44Met IGF-I). This mutation caused severe growth and 
mental retardation as well as deafness evident at birth and growth retardation in 
childhood, but is relatively well tolerated in adulthood. We have conducted a bio-
chemical and structural analysis of Val44Met IGF-I to provide a molecular basis for 
the phenotype observed. Val44Met IGF-I exhibits a 90-fold decrease in type 1 IGF 
receptor (IGF1R) binding compared with wild-type human IGFI and only poorly 
stimulates autophosphorylation of the IGF1R. The ability of Val44Met IGF-I to 
signal via the extracellular signal-regulated kinase 1/2 and Akt/protein kinase B 
pathways and to stimulate DNA synthesis is correspondingly poorer. Binding or 
activation of both insulin receptor isoforms is not detectable even at micromolar 
concentrations. However, Val44Met IGF-I binds IGF-binding protein 2 (IGFBP-2), 
IGFBP-3, and IGFBP-6 with equal affinity to IGF-I, suggesting the maintenance 
of overall structure, particularly in the IGFBP binding domain. Structural analysis 
by nuclear magnetic resonance confirms retention of near native structure with 
only local side-chain disruptions despite the significant loss of function. To our 
knowledge, our results provide the first structural study of a naturally occurring 
mutant human IGF-I associated with growth and developmental abnormalities 
and identifies Val44 as an essential residue involved in the IGF–IGF1R interaction. 
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I n t r o d u c t i o n
The IGF system plays an important role in normal growth and development. Acti-
vation of the type-1 IGF receptor (IGF1R) by IGF-I or IGF-II results in potentiation 
of growth, survival and differentiation. The action of IGFs is modulated by IGF 
binding proteins (IGFBPs), which regulate the availability to bind to the IGF1R. 
The importance of IGF-I in normal growth has been demonstrated experimentally 
in mice with  IGF-I knockout (1). These mice exhibit a deficiency in intrauterine 
growth, and those that survive continue to show restricted growth. At birth they 
are 60% of normal weight, but fall to 30% normal weight in adulthood (1, 2). 
The significance of IGF-I in normal growth is also demonstrated by disease states 
in which a disruption in circulating IGF-I levels occurs. Overexpression of IGF-I 
resulting from overproduction of GH leads to acromegaly, whereas low IGF-I levels 
resulting from an inactive GH  receptor lead to Laron dwarfism (3, 4).  
We have recently described the phenotype resulting from a homozygous missense 
mutation in the human IGF-I gene (5). The mutation (G274A) leads to the expres-
sion of IGF-I with a methionine instead of a valine at residue 44 (Val44Met IGF-I). 
This was the first description of the effect of IGF-I deficiency in adulthood; the indi-
vidual carrying the homozygous mutation is now 55 yr old. We observed several 
similarities between this individual and an earlier report of an IGF-I gene deletion 
described in a young male (6). Both patients suffered severe pre- and postnatal 
growth retardation, deafness and mental retardation. In adulthood, however, the 
lack of functional IGF-I is well tolerated, with effects mainly on bone mass and 
gonadal function (5).  
In this study we describe biochemical and structural analysis of Val44Met IGF-I and 
provide an explanation for the growth and developmental abnormalities observed. 
Native IGF-I is a single polypeptide chain of 70 amino acid residues, that contains 
three α-helical regions surrounding a hydrophobic core (7, 8). Residues 3-29 of 
IGF-I, which are homologous to the B chain of insulin, include helix 1 (Ala8-Cys18), 
and residues 42-60, which are homologous to the insulin A chain, include helices 
2 (Ile43-Cys48) and 3 (Leu54-Tyr60). Residues 30-41 make up the C  region loop, 
which is missing in insulin, and residues 61-70 make up the C-terminal D region 
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tail. We show that substitution of Met for Val at residue 44 of IGF-I results in 
a 90-fold reduced affinity for the IGF1R and a correspondingly lower activation 
of downstream signaling pathways. Remarkably, Val44Met IGF-I binds with equal 
affinity to IGFBP-2, -3 and -6, suggesting maintenance of overall structure. This 
was confirmed by nuclear magnetic resonance analyses revealing only local side 
chain disruptions compared with IGF-I. Our study identifies Val44 as an essential 
residue involved in IGF-IGF1R interaction.
R e s u l t s
Receptor binding [IGF1R and Insulin Receptor (IR)] and activation
Purified IGF-I and Val44Met IGF-I were analyzed for their relative abilities to bind 
and activate the IGF1R and both isoforms of the IR (IR-A and IR-B). Competition 
binding curves for binding to the IGF1R are shown in Fig. 1A and 50% inhibitory 
concentration (IC50)  values are summarized in Table 1.  As reported previously (5), 
the affinity of Val44Met IGF-I is approximately 90-fold lower than that of IGF-I for 
the IGF1R. IGF1R activation on P6 cells was assessed using IGF-I, IGF-II, insulin 
and Val44Met IGF-I (Fig. 1B). Although IGF-I activates the IGF1R with an IC50 of 
3.9 ± 0.43 nM, IGF-II at the same concentration is only able to induce IGF1R phos-
phorylation equal to 35% that of IGF-I. In addition, activation of the IGF1R by 
insulin can only be detected at concentrations greater than 50 nM. Here we show 
that Val44Met IGF-I is only slightly more potent than insulin in IGF1R activation as 
a result of decreased receptor binding affinity. 
Competition binding curves for binding to the two isoforms of the IR (IR-A and 
IR-B) are shown in Fig. 2, and IC50 values are summarized in Table 2. No competi-
tion by Val44Met IGF-I for europium-labeled insulin (Eu-insulin) binding is detected 
using either IR-A or IR-B, even at micromolar concentrations. IGF-I is a relatively 
poor binder to both IR isoforms and binds with a 3-fold higher affinity to the IR-A 
(IC50 = 120 nM) than to IR-B (IC50 = 366 nM). In contrast, insulin binds with high 
affinity to both IR isoforms, with a slightly higher affinity to the IR-B isoform in 
our assay (IR-A, IC50 = 1.4 nM ; IR-B, IC50 = 2.8 nM) (9). IGF-II also competes with 
high affinity (IC50 = 18nM) for Eu-insulin binding to the IR-A and has a 3.7-fold 
lower affinity for the IR-B. In addition, activation of the IR by concentrations of up 
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Figure 1
Figure 1. Binding and Activation of Human IGF1R by Val44Met IGF-I
A. Immunocaptured IGF1R was incubated with Eu-IGF-I in the presence or absence of increasing con-
centrations of IGF-I or Val44Met IGF-I as described in Materials and Methods. The graph shown is a 
representative of two independent experiments. Results are expressed as a percentage of Eu-IGF-I 
bound in the absence of competing ligand, and the data points are the mean ± SEM of triplicate 
samples. Errors are shown when they are greater than the size of the symbols. The ligands are as 
follows: A, IGF-I (∆); Val44Met IGF-I (); 
B. IGF1R phosphorylation by IGF-I, IGF-II, insulin, and Val44Met IGF-I. P6 cells overexpressing the 
human IGF1R were serum-starved for 4 h, followed by stimulation with various concentrations 
of ligand for 10 min. Cells were lysed with ice-cold lysis buffer containing phosphatase inhibitors 
and activated receptors were immunocaptured with the anti-IGF1R antibody 24-31 as described in 
Materials and Methods. Receptor autophosphorylation was measured by time-resolved fluorescence 
using Eu-PY20 to detect phosphorylated tyrosines. The graph shown is a representative of three 
experiments and data points are the mean ± SEM of triplicate points. Errors are shown when they 
are greater than the size of the symbols. The ligands are as follows: B, IGF-I (), IGF-II (), insulin 
(), and Val44Met IGF-I ().
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Figure 2. Competition Binding Curves of Eu-Insulin Binding to Immunopurified Human IR-A or IR-B.
Immunocaptured IR-As or IR-Bs were incubated with Eu-insulin in the presence or absence of increas-
ing concentrations of insulin, IGF-I, IGF-II, or Val44Met IGF-I as described in Materials and Methods. The 
graphs shown are a representative of three experiments.
A. competition for binding to IR-A
B. competition for binding to the IR-B. Results are expressed as a percentage of Eu-insulin bound in 
the absence of competing ligand and the data points are the mean ± SEM of triplicate samples. 
Errors are shown when they are greater than the size of the symbols. The ligands are as follows in 
A and B, insulin (); IGF-II (); IGF-I (); Val44Met IGF-I (). 
Figure 2
to 1 µM Val44Met IGF-I is not detectable (data not shown), whereas the extent of IR 
phosphorylation by the other ligands correlates with receptor binding affinities (9). 
In summary, IGF1R binding affinity of Val44Met IGF-I is 90-fold lower than that of 
IGF-I and activation is correspondingly lower. IR binding and, therefore, activation 
are disrupted very significantly by substitution of valine for methionine at residue 
44. 
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Receptor signaling and biological activity in fibroblasts
To examine the effect of the Val44Met-mutation on the ability to activate signal 
transduction in cells with a more physiological number of IGF1R, activation of 
the extracellular signal-regulated kinase 1/2 (Erk1/2) and Akt/protein kinase B 
(PKB) pathways was analyzed in cultures of dermal fibroblasts. After a 10-min 
stimulation by IGF-I or Val44Met IGF-I, a dose-dependent activation of Erk1/2 was 
detected (Fig. 3). Approximately 100-fold more Val44Met- IGF-I was required to 
induce detectable Erk1/2 phosphorylation. The maximal stimulation reached with 
Val44Met IGF-I was about half of the activation level reached by IGF-I. In contrast, 
approximately 200-fold more Val44Met IGF-I was required to activate Akt/PkB on 
Ser473 and Thr308 compared with IGF-I. Again, the maximal stimulation of Akt/PKB 
reached with Val44Met IGF-I varied between 70% and 40% of the levels induced 
by IGF-I (Fig. 3). In summary, the reduced activation of downstream signaling by 
Val44Met IGF-I corresponds with its reduced affinity for the IGF1R compared with 
Table 1. Inhibition of Eu-IGF-I binding to the IGF1R by IGF-I and Val44Met IGF-I 







The IC50 relative to that of IGF-I is also shown. Values are the mean ± SEM from two independent 
experiments.






IC50 (nM) IC50 relative to 
IGF-I
IGF-I 120.4 ±34.1 1 366 ±15 1
Val44Met IGF-I >1000 ND >1000 ND
Insulin  2.8 ±0.3 0.02  1.4±0.1 0.004
IGF-II 18.2 ±2.4 0.15 68 ±11 0.19
The IC50  relative to that of IGF-II binding to the IR-A is also shown. Values are the mean ± SEM from 
three independent experiments. ND, not determined.
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IGF-I. However, there appears to be a greater effect on signaling via the Akt/PKB 
pathway than on Erk1/2 signaling, indicating a differential ability to stimulate 
signaling outcome after binding by Val44Met IGF-I. 
Subsequently, the ability of Val44Met IGF-I to stimulate DNA synthesis was 
measured in primary cultures of skin fibroblasts isolated from the patient and a 
normal age- and sex-matched subject. IGF-I was able to stimulate DNA synthesis 
in both the patient and the normal fibroblasts to a similar extent. In contrast, 
Val44Met IGF-I was unable to stimulate DNA synthesis in either cell type in the 
Figure 3
Figure 3. Activation of PKB/Akt and Erk1/2 in Skin Fibroblasts by Val44Met IGF-I.
A. Western blot analysis of fibroblasts stimulated for 10 min with a dose-response range of IGF-I and 
Val44Met IGF-I. The blots were probed with phospho-specific antibodies for activation of PKB at 
Ser473 and Thr308 and Erk1/2. Total Erk was used to check for equal loading. Pictures are a repre-
sentative example of a duplicate experiment.
B. Quantification by densitometric scanning of the blots shown in A. Values were expressed as a 
percentage of the maximal activation level reached with IGF-I, which was set to 100%, and were 
corrected for loading efficiency using total Erk. 
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physiological dose-response range of IGF-I (1-100 ng/ml; Fig. 4). When 100-fold 
higher concentrations of Val44Met IGF-I were used (>1000 ng/ml), small induc-
tions of [3H]thymidine incorporation were observed, which leveled off at about 
45% of the levels reached by IGF-I. These experiments indicate that the patient’s 
IGF-1Rs were functioning normally, but the Val44Met IGF-I was unable to elicit a 
biological response in the normal dose-response range of IGF-I action. 
IGFBP binding
We previously reported that neutral gel filtration of the patient’s serum showed that 
endogenous Val44Met IGF-I predominantly associates with the 150-kDa complex 
(comprised of Val44Met IGF-I, IGFBP-3, and the acid labile subunit) as seen with 
wild type IGF-I in control serum (5). Additional IGFBP binding was assessed using 
BIAcore analysis with IGFBP-2, IGFBP-3 and IGFBP-6 biosensor surfaces (Fig. 5). 
There was no difference in binding affinities between IGF-I and Val44Met IGF-I for 
any of the surfaces. IGFBP-2 and IGFBP-3 exhibit similar affinities for IGF-I and 
Val44Met IGF-I (0.7 nM), whereas IGFBP-6 bound IGF-I and Val44Met IGF-I with a 
much lower affinity (6.6 nM; see Fig. 5). Because IGFBP binding was not perturbed 
we can conclude that Val44Met IGF-I is correctly folded. 
Figure 4
Figure 4. Stimulation of DNA synthesis in Normal and Patient Skin Fibroblasts by Val44Met IGF-I.
Increasing concentrations of Val44Met IGF-I (gray lines) and IGF-I (black lines) were used to stimulate 
DNA synthesis in fibroblasts from the patient ( and ) and a normal age- and sex-matched indi-
vidual ( and ). Amount of incorporation of [3H]thymidine is expressed as the fold change over that 
in unstimulated fibroblasts and represents the mean of a triplicate experiment ± SEM.
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Structural analysis of Val44Met IGF-I by NMR
To determine whether there were any significant structural differences between 
Val44Met IGF-I and wild-type IGF-I, NMR spectra of mutant IGF-I were compared 
with those of the native protein (supplemental Fig. 1, published on The Endocrine 
Society’s Journals Online web site at http://mend.endojournals.org). 1H and 15N 
NMR resonance assignments for Val44Met IGF-I were made from a three-dimen-
sional nuclear overhauser effect spectroscopy heteronuclear single quantum 
coherence (NOESY-HSQC) spectrum. The assignment process was assisted by 
comparison of two-dimensional 15N-1H HSQC spectra of Val44Met IGF-I with those 
of IGF-I in the presence of excess IGF-F1-1 peptide (8), long-[Arg3]IGF-I (10) and 
long-[Leu60]IGF-I (11), although some significant discrepancies exist among the 
Figure 5. Surface Plasmon Resonance Analysis of Val44Met IGF-I Binding to IGFBP-2, -3, and -6.
 Sensorgrams represent binding to IGFBP-2 (A), IGFBP-3 (B), and IGFBP-6 (C) surfaces at 50 nM IGF-
I (black line) or Val44Met IGF-I (gray line). Kinetic studies with a range of analyte concentrations were 
determined at a flow rate of 40 µl/min to minimize mass transfer effects, allowing 300 sec for associa-
tion and 900 sec for dissociation. Dissociation constants (Kd) were derived using BIAevaluation 3.2 
software an a 1:1 Langmuir binding model.  
Figure 5
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assignments for these three proteins, as summarized in supplemental Table 1, 
published on The Endocrine Society’s Journals Online web wite at http://mend.
endojournals.org. One group of residues, including Cys6, Gly7, Leu10, Val11, Phe16, 
Arg50, and Leu54, is affected by F1 peptide binding to IGF-I (8), so their chemical 
shifts differed from those of Val44Met IGF-I, long-[Arg3] IGF-I and long-[Leu60] 
IGF-I. A second group, including Ala8, Phe25, Ile43, Ser51, Arg55, and Tyr60, differed 
in the Val44Met IGF-I mutant as a direct consequence of the mutation. Resonances 
from Gly7, Leu10, Glu58, and Cys61 were not found in spectra of Val44Met IGF-I even 
at lower temperatures (15° and 20°C). 
Chemical shift differences between Val44Met IGF-I and IGF-I were small, except 
for Cys6, Ala8, Phe23, Ile43, Asp45, Ser51, Arg56, Leu57 and Tyr60 (Fig. 6). The largest 
changes were for Ile43 and Asp45, which flank the site of substitution, and Arg56, 
which is located in the middle of second helix of the A region, about 9.1-11.2 Å 
away from Val44 (NH-NH distance) in the long-[Arg3]IGF-I structure (12) and 11.5-
12.6 Å away in the IGF-I plus F1 peptide structure (8). Two of the residues strongly 
affected, Phe23 and Tyr60, are implicated in IGF-I binding to IGF1R (13, 14) (Fig. 7). 
Thus, although the structure of Val44Met IGF-I is similar to that of native, chemical 
shift comparisons suggest that the mutation has caused local structural changes 
around the mutant site and in surrounding regions, some of which are involved in 
binding to the IGF-I receptor
This conclusion is supported by a detailed analysis of nuclear overhauser effects 
(NOEs) from the backbone amide resonances. If the distance between two protons 
is less than 6 Å in the structure, an NOE between those two protons should be 
observable in NMR spectra. Most of the observed NOEs to Met44 (Table S2) are 
consistent with the native structure, although the NOE between Met44 Hγ 
 
and Thr41 
NH is new, suggesting that the side-chain of Met44 has a different orientation from 
that of Val44 in native IGF-I. The relative intensities of the backbone NOEs to Met44 
in Val44Met IGF-I indicate that the native helix encompassing residues 43-48 is 
maintained, with HN-HN NOEs from Met44 to Ile43 and Asp45 being observed, as 
expected for an α-helix (15). One difficulty in making a detailed comparison with 
native IGF-I is that neither of the two high-quality solution structures for IGF-I cor-
responds precisely to IGF-I. Long-[Arg3]IGF-I has a substitution at position 3 and 
an N-terminal extension (although this is not shown in Fig. 7), and the other has 
a peptide from phage display bound to it (again, not shown in Fig. 7). It is clear 
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from Fig. 7 that these structures are not identical. From inspection of the pattern 
of chemical shift perturbations and NOEs observed for Val44Met, it appears that 
the structure of long-[Arg3]IGF-I may be more representative of Val44Met. 
Deviations from random coil chemical shifts for backbone 15N, NH, and Hα
  
reso-
nances are a valuable indicator of ordered secondary structure in proteins (16). 
These plots for Val44Met IGF-I (Fig. S2) are consistent with the secondary structure 
of native IGF-I. Plots of 15N backbone relaxation parameters R1, R2, and NOE for 
Val44Met IGF-I as a function of residue number (Fig. S3) are similar to those for 
long-[Arg3]IGF-I (12), with the regions of ordered secondary structure showing 
positive NOEs and faster spin-spin relaxation (larger R2 values) and the N- and C-
termini and the C region having smaller NOEs (in some cases negative) and smaller 
R2 values. The mean R1, R2 and NOE values for Val
44Met IGF-I are 1.40 ± 0.12 s-1, 
10.05 ± 0.46 s-1, and 0.42 ± 0.02, respectively, compared with values of approxi-
mately 1.39 s-1, 7.69 s
 
-1 and 0.55 ± 0.12, respectively, in long-[Arg3]IGF-I. Detailed 
comparisons are difficult because of differences in protein concentration and state 
Figure 6
Figure 6. Weighted Average Chemical Shift Differences between Val44Met IGF-I and Native IGF-I
The average chemical shift differences derived from our spectra were calculated for 15N and 1H reso-
nances using ∆δav = (∆δNH
2 + 0.17∆δN
2)1/2(66). Residues Gly1, Gly7, Leu10, Glu58, and Cys61 were not 
assigned. Residues 2, 28, 39, 63 and 66 are proline and Asp12, Lys27, Gly30, Gly32, Ser33, Ser34, Arg37, 
and Thr41  had zero ∆δav values. The locations of the three helices of native IGF-I are indicated above 
the plot. 
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of aggregation, but one significant difference between the two data sets occurs at 
residues 52 and 53, which have low NOEs and smaller R2 values in Val
44Met IGFI 
than long-[Arg3]IGF-I. This suggests that the loop connecting helices 2 and 3 in the 
native structure (arrowed in Fig. 7) may be somewhat more flexible in Val44Met. 
Figure 7
Figure 7. Backbone Ribbon View of IGF-I with Side-Chains of Key Residues Indicated
Long-[Arg3] IGF-I (12) (PDB accession no. 3LRI) is shown on the left, and IGF-I + F1 peptide (8) 
(PDB accession no. 1PMX) is shown on the right (with the peptide not shown for clarity); in each case 
the closest to average structure over the family is shown. Side chains are colored as follows: Met44 in 
red; Ile43, Asp45, and Arg56, which have the largest chemical shift changes between mutant and native 
IGF-I, in blue; Cys6, Ala8, and Leu57, which have smaller chemical shift changes between mutant and 
native IGF-I, in green, and Phe23, Tyr24, and Tyr60, which are implicated in IGF-I binding to the type 1 
IGF receptor (13, 22, 27, 67) in magenta. The upper and lower views of each structure are related by an 
80° rotation around the horizontal axis. The loop connecting helices 2 and 3 in the native structure is 
arrowed; note that the last five residues in the lower view of IGF-I + F1 peptide, and the first two residues 
in the upper view, are not shown in order to avoid overlap. The N-terminal extension in long-[Arg3]IGF-
I is not shown, so the chain begins at the equivalent of Gly1 of IGF-I.
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D i s c u s s i o n
We have conducted a comprehensive biochemical and structural analysis of Val44Met 
IGF-I in order to explain the phenotype described of a patient carrying a point 
mutation in the IGF-I gene. A similar phenotype was previously described resulting 
from a deletion in the IGF-I gene (6). The phenotype is not due to a defective 
IGF1R as IGF-I can stimulate the same biological response in fibroblasts derived 
from the patient or from a normal individual. However, we demonstrate that the 
Val44Met mutation results in a significant reduction (~90-fold)  in IGF1R receptor 
binding affinity and undetectable binding to either IR isoform. As a consequence, 
phosphorylation of the IGF1R and downstream-acting signaling proteins, i.e. 
Erk1/2 and Akt/PKB, is diminished. Remarkably, Val-Met substitution at position 
44 seems to affect the Akt/PKB pathway to a greater extent than one would expect 
on the basis of receptor binding affinities. It is possible that these differences are 
a direct consequence of the changed kinetics of receptor-ligand interaction, which 
may have a greater impact on activation of the PKB/Akt-pathway than on the 
Erk1/2 pathway. This interesting finding is the subject of ongoing investigations. 
Despite a large effect on receptor binding Val44Met IGF-I is still able to bind 
IGFBP-2, IGFBP-3, and IGFBP-6 with equal affinity to IGF-I. This suggests that 
the common IGFBP-binding site is not disrupted. In support of this conclusion we 
see that Val44Met IGF-I shows a normal association with the 150-kDa complex in 
serum (5). Dubaquie and Lowman (17) reported a small disruption in IGFBP-1 
and IGFBP-3 binding by Val44Ala IGF-I (2.3- and 1.4-fold lower binding than IGF-I, 
respectively), but did not report IGF1R binding. A recent crystal structure of IGF-I 
in complex with the N domain of IGFBP-5 shows that Val44 is not included in the 
N domain binding site (18). Headey et al. (19) reported that binding of IGFBP-
6 C domain to IGF-II affects the two residues adjacent to Val43, namely Ile42 and 
Glu44. Although Val43 could not be assessed because of peak overlap, it seems that 
this region of the IGF-II surface is involved in interaction with the C domain of 
IGFBPs. Therefore, the lack of effect of the Val44Met substitution in IGF-I on IGFBP 
binding may be attributable to the fact that the hydrophobic nature of the surface 
is preserved. The C domain of the IGFBPs is apparently less sensitive to the nature 
of the side-chain at position 44 than is the IGF-I receptor. 
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Interestingly, the results of the NMR analysis of the Val44Met IGF-I structure 
suggest relatively little disruption of the overall structure. The marked effect on 
IGF1R binding could be explained by either local structural disruption around 
the mutation site and in surrounding areas or by a direct interaction of Val44 with 
the receptor. Analysis of chemical shift comparisons shows differences in local 
structure at residues Cys6, Ala8, Phe23, Ile43, Asp45, Ser51, Arg56, Leu57, and Tyr60. Of 
these residues, Tyr60 has previously been implicated as important for IGF1R and IR 
binding (13, 20). Tyr60Leu IGF-I has a 20-fold reduction in IGF1R binding affinity 
and Tyr60Phe IGF-I has 2.6-fold reduced IR binding affinity. In addition, Maly and 
Luthi (21) showed that Tyr60 was protected from iodination in the presence of 
the IGF1R. Interestingly, iodination experiments with Val44Met IGF-I revealed an 
approximately 10-fold reduced incorporation of 125I compared with wild type (data 
not shown). These iodinations predominantly occur on tyrosine residues including 
Tyr60. Reduced incorporation of 125I is compatible with the local differences in 
structure at Tyr60, which could make this residue less accessible for iodination. 
Phe23 has also been identified as important for IGF1R binding as mutation to Gly 
results in a 48-fold reduction in receptor binding affinity compared with IGF-I (14). 
Whether this mutation is causing a structural perturbation has not been inves-
tigated. The neighboring residue, Tyr24, has been identified in several studies as 
being important for IGF1R binding (22). We have also previously demonstrated 
decreased IGF1R binding (~ 6-fold) by mutation of Ala8 to Leu (23). Only relatively 
small effects of mutating Ser51 and Arg56 have been reported (24, 25).
Val44 is conserved in all but one (catfish brain)(26) of the IGF-I sequences reported 
to date and is also found in the corresponding position in the two structurally 
related proteins, IGF-II and insulin. Interestingly, mutation of Val43 of IGF-II (which 
corresponds to Val44 in IGF-I) to Leu results in a 220-fold lower IGF1R binding 
affinity while maintaining IGFBP binding affinities similar to IGF-II (27). This obser-
vation confirms the importance of this residue in maintaining IGF1R binding. 
A point mutation in the insulin gene (guanine to thymine at position 1298) resulting 
in the ValA3 to Leu mutation in the A chain has been termed insulin Wakayama (28, 
29). ValA3 corresponds to Val44 of IGF-I. The expression of ValA3Leu insulin leads to 
hyperinsulinemia and in some cases diabetes (29) resulting from severely defective 
IR binding. It has been suggested that ValA3 and IleA2 make direct contact with the IR 
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after a structural change in insulin (30). Removal of contact between the beginning 
of the A chain and the C terminus of the B chain (involving residue B24) exposes 
residues IleA2 and ValA3 and thereby allows their interaction with the IR (30-34). 
Substitution of IleA2 with allo-IleA2 leads to a 50-fold reduction in IR binding affinity 
while maintaining overall structure (32). Direct evidence for interaction with the 
receptor has recently been provided by a cross-linking study using a p-azido-Phe 
derivative of ValA3 and suggests an interaction with the insert domain (35). 
Several substitutions have been made at ValA3 including ValA3Leu insulin, which has 
only 0.14% of IR binding affinity compared with insulin (29, 36). Nakagawa and 
Tager (37) reported a similar helical content in ValA3Leu insulin and native insulin 
after circular dichroism spectral analysis. Interestingly, NMR analysis of ValA3Leu 
insulin revealed no significant change in structure (Weiss, M., unpublished obser-
vations) despite the significant effect on IR binding (29, 36). Structural analyses of 
ValA3Ile (37) and ValA3Thr (38) by far ultraviolet light circular dichroism show little 
disruption to the overall structure, whereas mutation to Gly leads to a complete 
disruption of the first A chain α-helix, as shown by NMR analysis (39). Further-
more, substitutions at residue IleA2 highlight the importance of the beginning of 
the A domain helix in IR binding. Substitution of IleA2 with Val reduces the helical 
content and destabilizes the first A domain helix (40). As with ValA3Leu insulin (37), 
our data show that Val44Met IGF-I maintains all helical structures. This is perhaps 
not surprising, because Met is a residue of reasonable helical propensity (41, 42) 
and is commonly found in the same position in proteins as Val (43). However, we 
did find that the loop connecting helices 2 and 3 in the native structure (Fig. 7) 
is somewhat more flexible in Val44Met IGF. Despite this minor structural pertur-
bation, both Val44Met IGF-I and ValA3Leu insulin have severely disrupted receptor 
binding properties. It seems likely that Val44 in IGF-I plays a similar role in IR binding 
to ValA3 in insulin. 
In conclusion, we describe a biochemical and structural analysis of the first naturally 
occurring mutant of IGF-I. The mutant, Val44Met IGF-I, exhibits large reductions 
in IGF1R and IR binding affinities and correspondingly lower potential to activate 
signaling events downstream of the IGF1R, while preserving native affinity to 
several binding proteins. Biological activities of Val44Met IGF-I are only observed 
when supraphysiological concentrations (at least 100-fold higher) are used. In 
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the normal physiological dose-response range Val44Met substitution is completely 
inactivating. These data led us conclude that the homozygous patient with the 
Val44Met substitution is effective null for IGF-I. This fully explains the phenotype of 
our patient, and is in line with the observed similarities in developmental defects 
observed in our patient and in one previously described adolescent man with a 
homozygous IGF-I gene deletion, as well as in IGF-I knockout mice (1, 6). The lack 
of binding to the IR by Val44Met IGF-I probably plays a minor role in the overall 
phenotype of our patient, because the affinity of IGF-I for either the IR-A or IR-B 
isoform is relatively low compared with that of insulin. Our structural analyses 
reveal only minor perturbations in the local structure of residues known to be 
involved in IGF1R binding and the overall structure is remarkably well preserved. 
Finally, our analysis identifies Val44 as a critical residue involved in receptor-ligand 
interactions, and further mutational analysis of this residue could provide valuable 
insight into the mechanism of IGF1R binding by IGF-I. 
M a t e r i a l s  a n d  M e t h o d s
Materials
Oligonucleotides were purchased from Geneworks Pty Ltd. (Adelaide, Australia). 
Restriction enzymes were from New England Biolabs (Hitchin, UK) or Geneworks 
Pty Ltd. (Adelaide, Australia). 15N-Labeled NH4Cl was purchased from Sigma-
Aldrich Corp. (Castle Hill, Australia). Human IGF-I for Eu labeling and human 
IGFBP-2 were purchased from GroPep Pty. Ltd. (Adelaide, Australia). Human 
IGFBP-3 and IGFBP-6 were from R&D systems (Minneapolis, MN). Human insulin 
was purchased from Novo Nordisk (Bagsværd, Denmark). Greiner Lumitrac 600 
96-well plates were obtained from Omega Scientific (Tarzana, CA). DELFIA Eu 
labeling kit, DELFIA enhancement solution, and Eu-conjugated antiphosphotyro-
sine antibody PY20 were purchased from Perkin Elmer (Turku, Finland). Eu-IGF-I 
and Eu-insulin were produced as described by Denley et al. (9) according to the 
manufacturer’s instructions.  
Antibodies 83-7 and 24-31 were gifts from Prof. K. Siddle (Cambridge, UK). P6 
cells (BALB/c3T3 cells overexpressing human IGF1R) (44) and R- cells (mouse 3T3-
like cells with a targeted ablation of the IGF1R gene) (45) were gifts from Prof. R. 
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Baserga (Philadelphia, PA). Cells overexpressing the exon 11-/IR-A and exon 11+/
IR-B isoforms of the IR (R-IR-A and R-IR-B cells, respectively) were created as previ-
ously described (9). Total Erk1/2, Phospho-p44/42 MAPK, Phospho-Akt (Ser473) 
and Phospho-Akt (Thr308) antibodies were obtained from Cell Signaling Technol-
ogy (Beverly, CA). 
Construction of expression plasmids encoding human IGF-I and Val44Met IGF-I
Human IGF-I expression vector was developed by King et al. (46). The Quikchange 
site-directed mutagenesis kit was used to incorporate a G to A mutation in the IGF-
I coding sequence at position 130 using the following oligonucleotides: Val44Met 
forward 5’ CCG CAG ACC GGA ATC ATG GAT GAA TGC TGC 3’, Val44Met reverse 
5’ GCA GCA TCC ATC CAT GAT TCC GGT CTG CGG 3’. The Val44Met IGF-I-coding 
sequence was then subcloned using HpaI and HindIII restriction enzymes into the 
pGH (1-11) expression vector (46).  
Recombinant IGF-I and Val44Met IGF-I production
IGF-I and Val44Met IGF-I were expressed and purified essentially as described by 
Shooter et al. (23). 15N labeled Val44Met IGF-I was expressed in minimal medium 
supplemented with 15N-labeled NH4Cl essentially as described previously (47). The 
purified proteins were analyzed by mass spectroscopy and N-terminal sequencing 
and were shown to have the correct masses (93% incorporation of 15N) and to be 
greater than 95%  pure. Quantitation of proteins was performed by comparing 
analytical C4 HPLC profiles with profiles of standard long-[Arg3]IGF-I prepara-
tions (48). 
Binding analysis of Val44Met IGF-I to the IGF1R and IR isoforms
Receptor binding affinities were measured using an assay similar to that described 
for analyzing epidermal growth factor binding to the epidermal growth factor 
receptor (49) and outlined by Denley et al. (9). Briefly, R-IR-A, R-IR-B or P6 cells 
were lysed with lysis buffer (20 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 10% 
(vol/vol) glycerol, 1% (vol/vol) Triton X-100, 1 mM EGTA, 1mM phenylmethylsul-
fonylfluoride, pH 7.5) for 1 h at 4°C. Lysates were centrifuged for 10 min at 3500 
rpm at 4°C, then 100 µl were added per well to a white Greiner Lumitrac 600 
plate previously coated with anti-IR antibody 83-7 (50) or anti-IGF1R antibody 
24-31 (51). Approximately 100,000 fluorescent counts of Eu-insulin or Eu-IGF-I 
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were added to each well along with various amounts of unlabeled competitor and 
incubated for 16 h at 4°C. Wells were washed with 20 mM Tris, 150 mM NaCl, and 
0.05% (vol/vol) Tween 20 (TBST) and DELFIA enhancement solution (100 µl/well) 
was added. Time-resolved fluorescence was measured using 340-nm excitation 
and 612-nm emission filters with a BMG Lab Technologies Polarstar Fluorometer 
(Mornington, Australia). 
IR and IGF1R phosphorylation assays
Receptor phosphorylation was detected essentially as described by Denley et al. 
(9). R-IR-A, R-IR-B cells or P6 cells (2.5 x 104
 
cells/well; Falcon 96-well, flat-bottom 
plate) were washed for 4 h in serum-free medium before treating with IGF-I, IGF-II, 
insulin or Val44Met-IGF-I in 100µl DMEM with 1% BSA for 10 min at 37°C, 5% CO2. 
Lysis buffer containing 2 mM Na3VO4 and 1 mg/ml NaF was added to cells, and 
receptors from lysates were captured on 96-well plates pre-coated with antibody 
83-7 or 24-31 and blocked with 1x TBST/0.5% BSA. After overnight incubation at 
4°C, the plates were washed with 1 x TBST. Phosphorylated receptor was detected 
with Eu-antiphosphotyrosine antibody PY20 (10 ng/well; room temperature, 2 h). 
DELFIA enhancement solution (100 µl/well) was added and time-resolved fluores-
cence was detected as described above. 
Cell culture, [3H]thymidine incorporation assay, and Western blot 
[3H]Thymidine incorporation assays and Western blotting were performed using 
fibroblast cultures, which were established from skin biopsies of the patient and an 
age- and sex-matched normal subject, as described in detail previously (52, 53). 
BIAcore analysis of IGFBP binding
Coupling of IGFBPs to CM5 BIAsensor chips via amine group linkage was achieved 
using standard coupling procedures (54-56). Briefly, IGFBPs were coupled to 
activated surfaces (2 µg IGFBP/210 µl in 10 mM sodium acetate, pH 4.5) at 5 µl/
min. Unreacted groups were inactivated with 35 µl 1 M ethanolamine-HCl, pH 8.5. 
A sensor surface with 600 response units (RU) coupled IGFBP-2 would routinely 
result in a response of approximately 100 RU with 100 nM IGF-I. In addition, a 
surface with 470 RU IGFBP-6 would result in a response of 70 RU, and a surface 
with 400 RU IGFBP-3 would result in a response of 45 RU with 100 nM IGF-I. 
Kinetic studies with 6.25, 12.5, 25, 50, and 100 nM IGF-I or Val44Met IGF-I were 
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determined at a flow rate of 40 µl/min to minimize mass transfer effects and by 
allowing 300 sec for association and 900 sec for dissociation. IGFBP biosensor 
surfaces were regenerated with 10 mM HCl. Analysis of kinetic data was performed 
with BIAevaluation 3.2 software (Uppsala, Sweden). For each binding curve, the 
response obtained using control surfaces (no protein coupled) was subtracted. 
IGF-I binding fitted a 1:1 Langmuir binding model using global fitting. This model 
describes a simple reversible interaction of two molecules in a 1:1 complex. 
Goodness of fit measured as a χ2 value was not greater than 5 for all experiments. 
All binding experiments were repeated at least in duplicate, and biosensor chips 
coupled at different times yielded surfaces with identical binding affinities. The 
binding affinities of IGF-I to IGFBP-2 (Kd = 0.7 nM), IGFBP-3 (Kd = 0.75 nM), 
and IGFBP-6 (Kd = 6.6 nM) were comparable to the binding affinities reported 
by Hobba et al. (57) and Wong et al. (58) for bovine IGFBP-2 (Kd = 0.3 nM) and 
human IGFBP-2 (Kd = 0.45 nM) respectively, Heding et al. (59) for IGFBP-3, (Kd = 
0.23 nM), and were 5-fold higher than those of Marinaro et al. (60) for IGFBP-6 
(Ka = 0.028 nM
-1) using BIAcore technology.  
NMR structural analysis
Lyophilized, uniformly 15N-enriched Val44Met IGF-I was dissolved in 95% H2O / 
5% 2H2O containing 10 mM sodium acetate-
2H4 and 0.02 % sodium azide. The 
protein concentration was approximately 0.9 mM, and the pH was adjusted to 
5.1 without correcting for the deuterium isotope effect. The after-spectra were 
recorded at 37°C on a DRX-600 spectrometer (Bruker, Karlsruhe, Germany) using 
a triple-resonance probe equipped with triple-axis gradients: two-dimensional 1H-
15N-HSQC, three-dimensional 1H-15N-NOESY-HSQC with a 150 msec mixing time, 
and 15N T1, T2, and NOE measurements. A series of 
1H-15N-HSQC spectra was 
recorded at temperatures of 15,  20, and 37°C on a Bruker Avance500 spectrom-
eter equipped with a cryoprobe. Two-dimensional 1H-15N-HSQC and three-dimen-
sional 1H-15N-NOESY-HSQC spectra were also run at 600 MHz and 37°C on native 
IGF-I (0.5 mM, pH 4.9, in 95% H2O/5% 
2H2O containing 10 mM sodium acetate). 
Water was suppressed using the Watergate pulse sequence (61). All spectra were 
processed in XWINNMR, version 3.5 (Bruker) and analyzed with XEASY, version 
1.4 (62). 1H chemical shifts were referenced to sodium 4,4-dimethyl-4-silapen-
tane-1-sulphonate at 0 ppm via the H2O signal, and 
15N chemical shifts were ref-
erenced indirectly using the 15N/1H γ-ratios (63). 15N relaxation rates R1 and R2 
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were determined by fitting these measured peak intensities, respectively, to three- 
and two-parameter single-exponential decay curves using the program CURVEFIT 
(64). Steady-state 1H-15N NOE values were calculated from peak intensity ratios 
obtained from spectra acquired in the presence and absence of proton saturation. 
The SD of NOE values was determined from the background noise level of the 
spectra as described by Farrow et al. (65). 
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Figure S1. Contour plots of 600 MHz 2D 1H-15N-HSQC spectra with V44M IGF-I in 
red and native IGF-I in blue. The V44M IGF-I spectrum was acquired using a 0.9 mM 
sample at 37 C and pH 5.1 in 95% H2O/5% 2H2O containing 10mM acetate-2H4 and 
0.02% sodium azide, while the IGF-I spectrum was acquired on a 0.5 mM sample at 
37 C and pH 4.9 in 95% H2O/5% 2H2O containing 10mM sodium acetate. 
Resonances are labelled with the corresponding sequence positions and side-chain 
amide resonances (Asn and Gln) are connected with a line. Other side chain 
resonances are labelled with a “sc” sign. Unlabelled peaks are not assigned. 
Figure S1. Contour plots of 600 MHz 2D 1H-15N-HSQC spectra with V44M IGF-I in red and native 
IGF-I in blue. The V44M IGF-I spectrum was acquired using a 0.9 mM sample at 37 °C and pH 5.1 in 
95% H2O/5% 2H2O containing 10mM acetate- 
2H4 and 0.02% sodium azide, while the IGF-I spectrum 
was acquired on  0.5 mM sample at 37°C and pH 4.9 in 95% H2O/5% 2H2O containing 10mM 
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with a “sc” sign. Unlabelled peaks are not assigned.
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Table S1. Residues showing significant differences in 1H and 15N chemical shifts (∆δav>0.3) between 
V44M IGF-I and IGF-I plus F1 peptide (8), where ∆δav=(∆δNH
2 + 0.17∆δN
2)1/2 (66). Chemical shifts for 
these residues in long-[Arg3] IGF-I (10) and long-[Leu60] IGF-I (11) are also included. The residues 
implicated in F1 peptide binding actions (8) are shown in black and others shaded in gray. 
residue V44M IGF-I IGF-I plus F1 Long-[Arg3]IGF-I Long-[Leu60] IGF-I
NH N NH N NH N NH N
Cys 6 8.25 120.2 8.47 118.0 8.38 119.7 8.33 118.3
Gly7* ------- ------- 8.86 109.7 7.74 110.0 7.63 108.3#
Ala8* 8.49 126.5 8.77 128.5 8.98 130.3 8.83 128.2
Glu9 7.61 114.5 7.80 115.5 8.00 118.1 7.94 115.1#
Leu10* ------- ------- 6.74 119.9 6.88 121.7 6.87 120.3
Val11 7.59 115.7 7.18 118.1 7.29 119.3 7.38 117.9
Phe16 7.71 119.0 8.29 121.2 7.84 120.6 7.38 117.9#
Phe25 7.93 117.3 8.53 116.9 8.48 119.6 7.86 120.3#
Ile43 7.91 120.4 7.58 121.5 7.89 122.4 7.74 121.4
Phe49 7.45 115.9 7.70 116.1 7.72 117.3 7.89 113.7#
Arg50 7.93 116.5 7.42 117.1 7.53 119.9 7.95 119.4
Ser51 7.90 112.9 7.75 110.7 7.83 113.3 7.81 112.9
Leu54 7.73 122.6 8.67 127.0 7.59 123.6 7.57 122.5#
Arg55 7.80 118.0 8.22 117.5 7.86 119.9 7.92 119.4
Glu58* ------- ------- 7.40 112.5 8.09 114.8 8.15 113.7
Tyr60 7.76 115.8 7.81 117.5  7.98 117.0 7.76 117.9
Cys61* ------- ------- 7.09 7.26 116.9 7.22 115.3
* Gly7, Leu10, Glu58 and Cys61 are not found in any spectra of 15˚C, 20˚C and 37˚C in V44M IGF-I.
+ Ala8 has a very weak peak in 2D HSQC. 
# Chemical shifts show significant differences among the three published IGF-I data sets. 
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Table S2. NOE intensities observed in Val44Met IGF-I compared with inter-proton distances for the 
mutated residue 44 in A) long-[Arg3] IGF-I (12) and B) IGF-I plus F1 peptide (8). Relative intensities 
(RI), calculated using the integrated intensity divided by the average noise in the 3D NOESY-HSQC 
spectrum, are designated S (strong, RI>3.5), M (medium, 3.5>RI>2.0) and W (weak, RI<2.0). HN-HN 
and HN-HA NOEs and corresponding distances are shaded in grey. Note that the relative strengths 
of the sequential NOEs to Met44 HN correspond more closely with the distances in the long-[Arg3] 
IGF-I structure. Several backbone-to-backbone NOEs expected from the long-[Arg3] IGF-I structure 
are not seen in spectra of Val44Met IGF-I as follows: HN of Asn26, Gly42, Glu46, Cys47, Cys48 to 
Met44 HN; HN of Leu10, Val11, Glu46, Cys47, Cys48 to Met44 Hα. NOEs expected from the IGF-I+F1 
structure but not seen in spectra of Val44Met IGF-I are: HN of Gly42, Glu46, Cys47, Cys48 to Met44 
HN; HN of Glu46, Cys47, Cys48, Phe49 to Met44 Hα. However, a number of these expected NOEs are 
also not observed in our spectra of native IGF-I, probably as a result of the effects of conformational 
averaging and aggregation.  
A. NOEs observed in 3D 1H-15N-
NOESY-HSQC spectrum of V44M 
IGF-I 
Inter-proton distances in the native IGF-I 
structure (Å) for pairwise interactions giving 
rise to NOEs in the spectrum of Val44Met 
Met44 Val44 
HN  HA HB HG21 HN HA HB HG21 
Ile43 HN W W 2.55-2.84  5.55-5.96 
HA M   3.34-3.45
HG23 S  3.49-4.93
Asp45 HN S S S 1.90-2.18 3.59-3.63 2.79-3.18 
Thr41 HN  M 6.62-9.09
B. NOEs observed in 3D 1H-15N-
NOESY-HSQC spectrum of V44M 
IGF-I 
Inter-proton distances in the native IGF-I 
structure (Å) for pairwise interactions giving 
rise to NOEs in the spectrum of Val44Met 
Met44 Val44 
HN  HA HB HG21 HN HA HB HG21 
Ile43 HN W W 2.06-2.71  4.23-4.94 
HA M   3.49-3.57
HG23 S  2.48-3.96
Asp45 HN S S S 2.76-2.99 3.57-3.59 3.53-3.73 
Thr41 HN  M 7.13-9.92
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Figure S2.  Deviations from random coil chemical shifts for 15N, NH and Hα resonances in Val44Met 
IGF-I. Random coil values were taking from published data (16). Residues Gly1, Gly7, Leu10, Glu58 
and Cys61 were not assigned. Residues 2, 28, 39, 63 and 66 are proline and the other gaps are calcu-
lated to be zero. The locations of the three helices of native IGF-I are indicated above the plot. 
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Figure S2.  Deviations from random coil chemical shifts for 15N, NH and H
resonances in Val44Met IGF-I. Random coil values were taking from published data 
(16). Residues Gly1, Gly7, Leu10, Glu58 and Cys61 were not assigned. Residues 2, 
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Figure S3. Summary of 15N backbone relaxation parameters R1, R2 and steady-state 1H-15N NOE 
for V44M IGF-I. Residues Gly1, Gly7, Leu10, Glu58 and Cys61 were not assigned. Residues Glu3, Ala8, 
Asp12, Gly22, Arg56 and Ser69 are not shown due to poor fitting and overlap. Residues Glu9, Phe23 
and Lys27 are not shown in the R2 plot because of their very short T2 values. Residues 2, 28, 39, 63 
and 66 are proline. The locations of the three helices of native IGF-I are indicated above the plot.  
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1H-15N NOE for V44M IGF-I. Residues Gly1, Gly7, Leu10, Glu58 and Cys61 were not 
assigned. Residues Glu3, Ala8, Asp12, Gly22, Arg56 and Ser69 re no  shown du  
to poor fitting and overlap. Resid es Glu9, Phe23 and Lys27 are not shown in the R2
plot because of their very short T2 values. R sidues 2, 28, 39, 63 and 66 are proline. 
The locations of the thr e helices of n tive IGF-I are indicated above the plot.  

A variable degree of intrauterine and postnatal 
growth retardation in a family with a missense 
mutation in the IGF-I receptor
8
Marie J.E. Walenkamp1, Hetty J. van der Kamp1, Alberto M. Pereira2, Sarina G. Kant3, 
Hermine A. van Duyvenvoorde1,2, M.Femke Kruithof1, Martijn H. Breuning3, Johannes 
A. Romijn2, Marcel Karperien1,2 and Jan M. Wit1
1 Department of Pediatrics, 2Department of Endocrinology and Metabolic Disorders, 3Center for Human and 
Clinical Genetics 
 Leiden University Medical Center, Leiden, The Netherlands
The Journal of Clinical Endocrinology and Metabolism 2006;91(8):3062-3070
Chapter 8
142
A b st r a c t
Context: The type 1 IGF-I receptor (IGF1R) mediates the biological functions of 
IGF-I. Binding of IGF-I to the IGF1R results in autophosphorylation of the intracel-
lular β-subunit and activation of intracellular signaling. 
Objective: The objective of this study was to evaluate the functional characteristics 
of a novel IGF1R mutation and describe the phenotypic features of two patients 
with this mutation.
Design: The study was performed in a university hospital.
Patients: We describe a 35-yr-old female with mild intrauterine growth failure, 
progressive postnatal growth retardation, severe failure to thrive, and microceph-
aly. Her daughter was born with severe intrauterine growth retardation and also 
showed postnatal failure to thrive and microcephaly. 
Results: We found a heterozygous G3148A nucleotide substitution in the IGF1R-
gene, changing a negatively charged glutamic acid at position 1050 into a positively 
charged lysine residue (E1050K). E1050 is a conserved residue in the intracellu-
lar kinase domain. Dermal fibroblasts of the mother showed normal binding of 
iodinated IGF-I, but autophosphorylation and activation of downstream signaling 
cascades upon challenging with IGF-I was markedly reduced. Consequently, the 
maximal [3H]thymidine incorporation upon a challenge with a dose range of IGF-I 
was reduced compared with a panel of control cells (3.65 ± 1.79 vs. 6.75 ± 4.7-fold 
stimulation (P < 0.01)). These data suggest that the mutation result in the inactiva-
tion of one copy of the IGF1R gene.
Conclusions: These two patients support the key role for IGF-I in intrauterine and 
postnatal growth. The different phenotypes of these and earlier described patients 
may be associated with variability in IGF-I signaling. The degree of intrauterine 
growth retardation may be partially determined by the presence or absence of 
maternal IGF-I resistance.  
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I n t r o d u c t i o n
IGF-I plays a key role in intrauterine development and postnatal growth and metab-
olism. IGF-I deficiency due to a homozygous deletion or mutation of the IGF-I 
gene results in severe intrauterine and postnatal growth failure, mental retarda-
tion and deafness (1, 2). The biological functions of IGF-I are primarily mediated 
through the type 1 IGF receptor (IGF1R). The IGF1R gene is located on the distal 
long arm of chromosome 15 (15q26.3) and has a similar organization compared 
with the insulin receptor (IR) gene, with sequence homology varying from 41-84% 
depending on the domain (3). Both are heterotetrameric (α2β2) transmembrane 
glycoproteins, synthesized as a single chain preproreceptor and consisting of an 
α-subunit that is mainly involved in ligand binding and a β-subunit containing the 
tyrosine kinase domain. Ligand binding to the tyrosine kinase receptor results in 
receptor autophosphorylation on intracellular tyrosine residues and activation of 
the receptor’s intrinsic tyrosine kinase, initiating distinct intracellular signaling 
pathways (4).
Although the IR gene and the IGF1R gene are homologous, genetic disturbances 
lead to a different phenotypical spectrum. Mutations of the IR gene in humans 
present with a heterogeneous phenotype, ranging from mild insulin resistance 
to leprechaunism (5). The clinical features of patients with IGF1R mutations are 
less well defined. So far, no cases have been found with a homozygous IGF1R 
mutation, and observations in mice suggest that such defect is lethal: IGF1R knock 
out mice die within min after birth due to respiratory failure (6). Heterozygous 
IGF1R mutations presenting with intrauterine and postnatal growth retardation 
have been observed in three families (7, 8). Heterozygous mutant mice are pheno-
typically normal (6), but targeted partial invalidation of the IGF1R-gene in mice 
causes postnatal growth deficiency (9).
Abuzzahab et al.(7) described a girl and a boy with mutations in the IGF1R. The girl 
was compound heterozygous for two missense mutations in exon 2, resulting in 
reduced ligand binding and decreased receptor phosphorylation on IGF-I stimula-
tion. The boy had a nonsense mutation in exon 2, resulting in reduced expression 
of IGF1R. Both children had severe intra-uterine growth retardation and postnatal 
growth failure. Recently, a heterozygous mutation in the cleavage site of the prore-
ceptor of IGF1R was reported in a 6 year old Japanese girl and her mother, present-
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ing with mild intrauterine growth retardation and postnatal short stature (8). We 
now describe a mother and her daughter with the first missense mutation in the 
intracellular kinase domain of the IGF1R.
M e t h o d s
Patient A provided written informed consent for herself and her daughter (Patient 
B) for all investigations. The Medical Ethics Committee of the Leiden University 
Medical Center approved the protocol. 
Clinical measurements and auxology
Height and sitting height were determined with a Harpenden stadiometer, and 
head circumference was assessed with a tape measure. Height and head circumfer-
ence were expressed as standard deviation score (SDS) based on Dutch references 
(10). Sitting height and sitting height/height ratio were also expressed as SDS for 
the Dutch population (11).
 
Radiological and sonographic measurements
BMD (g/cm2) of the lumbar spine and total body was measured by dual-energy 
x-ray absorptiometry (DXA) (Lunar, DPXL/PED, Lunar Radiation Corporation, 
Madison, WI). Ancillary DXA-derived data were used to calculate lumbar spine vol-
umetric BMD [bone mineral apparent density (BMAD)] with the model BMAD = 
BMD x [4/( x width)], as validated before (12). BMD and BMAD results were 
compared with age- and sex-matched reference values and expressed as SDS. 
Cardiac ultrasound in patient A was performed (GE System 7 – Vingmed, Milwaukee, 
WI, USA) and routine images (for assessment of left ventricular systolic function) 
and color Doppler data (to detect valvular abnormalities) were obtained. 
Biochemical measurements
Plasma GH in both patients was measured with time resolved IFMA (Wallac/PE, 
Turku, Finland), using the WHO 80/505 as a standard (1 mg = 2.6 IU). Spontane-
ous GH secretion was assessed in case A after an overnight fast by sampling every 
20 min from 0900-1200 (3-hr GH profile). An arginine stimulation test (0.5 g/kg iv 
over 30 min, from 0-30 min) and a combined GH-Releasing-Hormone (GHRH) (1 
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µg/kg iv at 0 min) and arginine test was performed in case A. An arginine stimula-
tion test (0.5 g/kg iv over 30 min) was performed in case B. 
Plasma IGF-I, IGF-II, IGF-binding-protein (IGFBP)-1 and IGFBP-3, were deter-
mined by specific RIAs (13, 14) With the exception of IGFBP-1 smoothed refer-
ences based on the LMS method were available for all parameters allowing conver-
sion of  patients data to SDS values (15). Plasma IGFBP-1 concentration after an 
overnight fast was compared with a reference group of six healthy adult controls. 
A 75-g oral glucose tolerance test performed after a 10-h overnight fast was used to 
classify the patient as having normal glucose tolerance, impaired glucose tolerance, 
or type 2 diabetes on the basis of the American Diabetes Association 1997 criteria 
(16). Glucose was assayed by an automated glucose oxidase method. Plasma 
insulin and C-peptide levels were measured by specific RIAs. The insulin secretion 
ratio or insulinogenic index was calculated as (30- to 0-min plasma insulin)/30-
min glucose, which correlates well with direct measures of stimulated insulin 
secretion (17, 18). The homeostatic model assessment for insulin resistance 
index (HOMA-IR = fasting glucose (mmol/l) × Fasting insulin (mUI/ml)/22.5) was 
used for estimating insulin action. High HOMA-IR index denotes low insulin sensi-
tivity and thus insulin resistance (19). 
Molecular and functional studies
A skin biopsy from patient A was taken, and a culture of dermal fibroblasts was 
established. Total RNA was isolated and reverse transcribed into cDNA. The coding 
regions of the IGF1R were amplified by PCR using overlapping primer combinations 
(Table 1) and subjected to direct sequencing as described previously (2). Genomic 
DNA was isolated from whole blood of the patients and of 87 unrelated individuals 
with proportionate growth retardation, of whom 19 also had intrauterine growth 
retardation. All coding exons of the IGF1R were PCR amplified and subjected to 
direct sequencing. Primer combinations are indicated in Table 2. Fibroblast cultures 
of the patient and of eight healthy donors were used for a thymidine incorporation 
assay in response to IGF-I as described previously (20). Each of these cultures was 
used in at least two independent thymidine incorporation assays performed in qua-
druplicate. The interexperimental variance for each dose of IGF-I varied between 
10 and 25%. For Western blotting, cells were stimulated for 10 min with a dose 
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range of IGF-I, 1 x 10-6 M insulin or 10 ng/ml epidermal growth factor (EGF). Blots 
were probed with an anti-phospho-PKB/Akt, total PKB/Akt, anti-phospho-ERK-1 
and -2, anti-phospho-IGF1R (Biosource International, Camarillo, CA), and a total 
IGF1R β (Cell Signaling technology, Beverly, MA) antibody as described previously 
(21). Binding studies were performed using iodinated IGF-I in the presence of an 
IGF-I analogue that is bound by IGFBPs but not by the IGF1R (Ala 31Leu60-IGF-I, 
GroPep) (22). In short, fibroblasts of the patient and controls were incubated at 
4°C with 30,000 cpm [125I]IGF-I, 250 ng/mL Ala31Leu60-IGF-I and graded amounts 
of unlabeled native IGF-I in 250 µL of HEPES binding buffer (100 mM HEPES 
(pH 7.8), 0.5% fatty-acid-free BSA, 120 mM sodium chloride, 1.2 mM magnesium 
sulfate, 5 mM potassium chloride, 15 mM sodium acetate, and 10 mM dextrose) 
as previously described (7, 22). After 18 h, cells were washed and solubilized in 1 M 
NaOH. Radioactivity was determined using a γ-counter.
Table 1. Overlapping primersets used for PCR amplification and sequencing of the IGF1R cDNA.
Primer Sequence (5’-3’) Nucleotidea
hIGF1R 1 F 5’- TTTGAGAAAGGGAATTTCATCC - 3’     12 - 33
hIGF1R 2 R 5’- AGACACCGGCATAGTAGTAGTGG - 3’   823 - 845
hIGF1R 3 F 5’- TTGCCGCCACTACTACTATGC - 3’   795 - 815
hIGF1R 3 R 5’- GTTATGATGATGCGATTCTTCG - 3’ 1568 - 1589
hIGF1R 4 F 5’- GACATAAACACCAGGAACAACG - 3’ 1471 - 1492
hIGF1R 4 R 5’- CTTCTCGGCTTCAGTTTTGG - 3’ 2172 - 2191
hIGF1R 5 F 5’- ATTGAGGAGGTCACAGAGAACC - 3’ 2083 - 2104
hIGF1R 5 R 5’- GGAAGACGTACAGCATAATCACC - 3’ 2920 - 2942
hIGF1R 6 F 5’- CACATCTCTCTCTGGGAATGG - 3’ 2766 - 2786
hIGF1R 6 R 5’- CCGAGTAAGTGGTGAAGACTCC - 3’ 3625 - 3646
hIGF1R 7 F 5’- TGGAGTCTTCACCACTTACTCG - 3’ 3603 - 3624
hIGF1R 7 R 5’- TAAAGGCCCATGTCAGTTAAGG - 3’ 4390 - 4411
F, Forward; R, Reverse
a The numbers correspond to nucleotide position in the IGF1R mRNA with accession number 
  NM_000875
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Table 2. Primer sets for the amplification and sequencing of the coding exons of the IGF1R.
exon name primer sequence exon name primer sequence
1  ex01-F  aaggggaatttcatcccaaa 11  ex11-F  aagtcatagaaaagacaaaagagg
 ex01-R  aggaaaagttcccgcagtg  ex11-R  ccactaggttgtgaggaagg
2  ex02a-F  tccttctaactgagacgtttacc 12  ex12-F  gaacccaaatccaactttgt
 ex02a-R  gcatttttctcaatcctgatg  ex12-R  catatgctgtcaatggatgg
2  ex02b-F  ttctacaactacgccctggt 13  ex13-F  ctgcattcatgggaaattg
 ex02b-R  cagaagagaagggaggtcaa  ex13-R  accctgctttcagttttacc
3  ex03-F  tcatctccgtctctcctctc 14  ex14-F  tgtgaagaaatgaaatgagca
 ex03-R  gggcgggtagtgaccaca  ex14-R  accactcagccacagaaagt
4  ex04-F  cagactcaattatgtgtgtttttg 15  ex15-F  atgtatggaggtggggtttt
 ex04-R  aagcccatattttagtggtga  ex15-R  cttcctttcccaaattagca
5  ex05-F  agcacacagtgacacaatcc 16  ex16-F  cgttctgtctaagggcttgt
 ex05-R  gcacgctgcttattttgtaa  ex16-R  caaaggcaagacaccaaac
6  ex06-F  gcaggtgcgctaacatcg 17  ex17-F  caacgaagcttctgtgatga
 ex06-R  gctgttatcatgatggttgg  ex17-R  tttccttgcagggagattat
7  ex07-F  aagcaagacaggtgcttttc 18  ex18-F  aagaaattggcatggaaaaa
 ex07-R  cgtagccctgtcaacagaat  ex18-R  taatgccaacaaagtcctca
8  ex08-F  tgagggttttgatgtcagag 19  ex19-F  gctccagcgtgtgactct
 ex08-R  caggcatagctcactgctaa  ex19-R  agactgagctggtggaaagt
9  ex09-F  ctgttggcttgccagagtat 20  ex20-F  ttgttcagtccatccctttc
 ex09-R  acaggaatgaacggtcaca  ex20-R  cccaagaaaacaggtatttga
10  ex10-F  gctttcattcccactcttgt 21  ex21-F  agggctgtgttcagtgct
 ex10-R  agtgggttttgccaactg  ex21-R  aggcttgtgaatggattgtt
To facilitate sequence analysis, oligonucleotides included an M13 (tgt-aaa-acg-acg-gcc-agt) or M13 
rev (cag-gaa-aca-gct-atg-acc) sequence primer. 
F, Forward and R, Reverse
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R e s u l t s
Case reports
Patient A was born after 40 wk gestation as the second daughter of a nonconsan-
guineous marriage. This pregnancy was complicated by hyperemesis gravidarum. 
Her birth weight was 2.6 kg (-2.1 SDS), and birth length was 49 cm (-0.34 SDS) 
(23). The height of her father was 171.5 cm (-1.0 SDS) and of her mother 158.0 
cm (-1.3 SDS). Her target height was 162.8 cm (-1.2 SDS) (10). Postnatally severe 
failure to thrive and poor appetite were noticed. She needed nasogastric tube 
feeding during the first year of life. Psychomotor development was normal. At 3.3 
yr of age her height was 88 cm (-2.9 SDS) and her weight was 9.9 kg (weight for 
height, – 3.3 SDS). Additional investigations excluded hypothyroidism and renal 
failure. A normal female karyotype (46 XX) was found. In 1975, an arginine stimu-
lation test was performed with a maximum GH response of 62 mU/liter. In 1981, 
an exercise test showed a peak GH concentration of 109 mU/liter. Bone age was 10 
yr at the chronological age of 12.1 yr. 
Recently, she came again to our attention through her daughter, who had similar 
problems (patient B). At present, patient A is 35 yr of age. At physical examina-
tion her height was 144.6 cm (-4.0 SDS), weight 47 kg ( -1.7 SDS), sitting height/
height ratio 0.52 (-0.1 SDS), body mass index 22.5 kg/m2 and head circumference 
50.2 cm (-3.0 SDS) (10, 11). Blood pressure was 135/85 mm Hg. There were no 
dysmorphic features (Fig. 1). Cardiovascular, respiratory and abdominal examina-
tions were all normal. Menarche had occurred at 18 yr. She has worked as adminis-
trative assistant after completing high school. Neuropsychological tests showed an 
above average intelligence. Biochemical characteristics are summarized in Table 3. 
Plasma IGF-I was in the upper normal range and IGFBP-1 was low. Ingestion of 75 
g glucose suppressed GH secretion (GH nadir, 0.2 mU/liter). Glucose tolerance 
was slightly impaired: fasting glucose, 4.8 mmol/liter; 2-h glucose, 8.5 mmol/
liter; fasting insulin, 14 mU/liter. Stimulated insulin secretion, as reflected by the 
insulinogenic index, was normal: 12.3 (mU/liter x mmol/liter-1).  HOMA-IR index 
indicated mild insulin resistance: index: 3.1 (mU/liter x mmol/liter-1) 
BMD at the lumbar spine (L2-L4) was 1.07 gr/cm2 (-0.5 SDS), BMAD (L3) was 
0.43 gr/cm3 (+1.3 SDS). Abdominal ultrasound revealed no abnormalities of  liver, 
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Table 3. Biochemical characteristics of case A at 35 yr of age and case B at 15 months of age.
Case A Case B
Variable Value SDS Value SDS
GH max. (mU/liter) after arginine stimulation 62a 222
GH max. (mU/liter) in 3-h GH profile 3.4
GH max. (mU/liter) after GHRH/arginine 131
Total IGF-I (ng/ml) 239 1.6 145b 2.9
IGF-II (ng/ml ) 656 -0.5 430 0.9
IGFBP-1 (ng/ml) < 5 c  21c
IGFBP-3 (µg/ml) 2.63 0.1 1.9 1.0
a performed at the age of 5.7 yr
b Before placing the gastrostoma, IGF-I was 68 ng/ml (-0.1 SDS)
c  Normal range for nonfasting subjects is 24-58 ng IGFBP-1/ml. After overnight fasting, there is an 
average 5-fold rise in normal individuals.
spleen, kidneys, pancreas, uterus, and ovaries. Cardiac ultrasound was normal. 
Patient B, the daughter of patient A, was born after 39 + 1/7 wk gestation. Her 
father was from Hindoestani descent. This pregnancy was complicated by hyper-
emesis gravidarum and oligohydramnion. Birth weight was 2100 g (-3.3 SDS), 
length 42 cm (-4.2 SDS) (23),  and placental weight was 290 gr. (-2.4 SDS) (24). 
Head circumference was 33.3 cm at 2 months of age (-5.6 SDS). At physical exami-
nation, she had a triangular face, brachycephaly, mild hypotelorism, a small mouth 
with thin lips, and prominent ears (Fig. 1). Because of extremely poor appetite a 
percutaneous gastrostoma was positioned at the age of 10 months. Failure to thrive 
persisted (Fig. 2). Biochemical characteristics at 16 months of age are summarized 
in Table 3. Most noteworthy is the elevated plasma IGF-I after realimentation and 
the low IGFBP-1. An arginine stimulation test was performed at 14 months of age. 
Bone age was 1.5 yr at the chronological age of 1.05 yr and 1.75 yr at the age of 1.6 
yr . Psychomotor development was determined with the Bayley test at 9 months 
and showed a motor delay of 3 months. After feeding through the gastrostoma 
and with physical therapy, motor skills progressed rapidly. At the age of 15 months 
a normal mental and slightly delayed motor development was found. 
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Figure 2. A, Length for age of patient B, with the pink area showing the normal distribution (-2 to +2 
SDS) and the blue area showing the target range; B, weight for age.
    A B
Figure 1. Patient A at the age of 35 yr and her daughter at the age of 4.5 months (patient B).
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Mutational analysis
Considering the increased IGF-I levels in both patients, we hypothesized that the 
clinical symptoms could be caused by a deletion or an inactivating mutation in 
the IGF1R-gene. IGF1R cDNA was isolated by RT-PCR from fibroblasts of patient 
A. Sequence analysis showed, besides a known polymorphism, a heterozygous 
G >A nucleotide substitution at position 3148, changing glutamic acid to lysine at 
position 1050 of the mature IGFIR protein (E1050K) (Fig. 3). No other mutations 
were found after sequence analysis of all coding exons of the IGF1R-gene. In 
genomic DNA of patient B, the same mutation was found. Patient B did not carry 
the polymorphism. In addition, we sequenced all coding exons of a panel of 87 
growth-retarded patients of whom 19 also had intrauterine growth retardation. 
In none of these patients was the G3148A substitution or another mutation in the 
IGF1R  present. This excluded that the G3148A substitution was a common poly-





Figure 3. Sequence analysis of IGF1R cDNA of patient A (top) and genomic DNA of patient B (bottom). 
The asterisk indicates the polymorphism. The arrow indicates the heterozygous GA nucleotide altera-
tion. The wild-type and mutant alleles are both expressed in fibroblasts of patient A.
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Figure 4. IGF-I binding studies.
A. Equal amounts of cells of patient A and four controls were seeded in 24-well plates. At conflu-
ency, cells were incubated with [125I]IGF-I in the presence of 250 ng Ala31Leu60 IGF-I and increasing 
amounts of unlabeled IGF-I. After 18 h, cells were washed and binding of  [125I]IGF-I was deter-
mined. Data represent the mean of four quadruplicate experiments and are expressed as percent-
age of total binding in the absence of competition with unlabeled IGF-I, which was set to 100% 
after correction for nonspecific binding. The displacement curve of the patient’s cells was indistin-
guishable from controls.
B. Scatchard analysis was performed, with GraphPad for Windows, for the calculation of the binding 
affinity (Kd) and binding capacity  (Bmax) of the patient’s cells and controls. Both values were in the 
























Kd ± sd Bmax ± sd
Patient A 2.5 ± 0.63 × 10-9 10 ± 4.6 × 10-11
Control A 2.2 ± 0.58 × 10-9 7.7 ± 1.8 × 10-11
Control B 3.8 ± 1.40 × 10-9 8.8 ± 3.2 × 10-11
Control D 1.5 ± 0.17 × 10-9 11 ± 3.0 × 10-11
Control E 1.6 ± 0.53 × 10-9 3.8 ± 1.9 × 10-11
B
A Figure 4 
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Functional analysis
E1050 is a highly conserved amino acid residue located in the intracellular tyrosine 
kinase domain. The charge change induced by the amino acid substitution is 
presumed to result in inactivation of the IGF1R. Based on PCR and sequence 
analysis, both mutant and wild-type alleles were equally well expressed in fibro-
blasts of patient A (Fig. 3). In addition, we did not observe a difference in the 
expression of the IGF1R mRNA in the patient’s vs. control cells (data not shown). 
Binding studies showed that the mutation did not affect binding affinity or total 
binding of iodinated IGF-I to patient’s cells in comparison with a panel of control 
cell lines (Fig. 4). Western blot demonstrated a comparable level of total IGF1R 
protein expression in the patient compared with controls; however, autophos-
phorylation of the IGF1R and activation of PKB/Akt upon a challenge with IGF-I 
for 10 min were markedly reduced (Fig. 5, A and B).  Stimulation with a dose range 
of IGF-I also showed that autophosphorylation of the IGF1R and activation of 
the downstream targets PKB/Akt and to a lesser extent Erk1/2 were reduced in 
cells of the patient compared with an age- and sex-matched healthy control (Fig. 
5C). This reduction in activation of intracellular signal transducers was specific for 
IGF-I, because it was not seen when EGF or insulin were used as stimuli (Fig. 5D), 
excluding global unresponsiveness of the cells of the patient. Finally we determined 
the incorporation of [3H]thymidine after a challenge with a dose range of IGF-I and 
compared the response in the patient’s cells with the average response in a panel 
of fibroblast cultures of eight non-growth-retarded individuals. As shown in Fig. 
5E, the maximal response was almost 50%  reduced compared with controls (3.65 
± 1.79 vs. 6.75 ± 4.7-fold stimulation (P< 0.01). These results are in line with the 
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Figure 5. The E1050K missense mutation results in partial IGF-I resistance.
A. Dermal fibroblasts of patient A and controls were stimulated with 10 ng/ml IGF-I for 10 min. Protein lysates 
were collected and 25 µg of protein was used for Western blotting using phosphospecific IGF1R and PKB/Akt 
(Ser473) antibodies and total IGF1R and PKB/Akt antibodies. A representative picture of a triplicate experiment 
is shown.
B. Densitometric quantification of the Western blot shown in A. Data are expressed as a ratio of phosphospecific 
IGF1R or PKB/Akt and total IGF1R or PKB/Akt, respectively. 
C. Activation of PKB/Akt by phosphorylation on Ser473 and of phosphor-Erk-1 and –2 as well as autophosphory-
lation of the IGF1R in fibroblasts of patient A and an age- and sex-matched control was determined by Western 
blot after a challenge with a dose range of IGF-I. Protein lysates were collected after 10-min stimulation. Total 
PKB/Akt was used to check for equal loading. 
D. To exclude global unresponsiveness, fibroblasts of patient A and the age- and sex-matched control were chal-
lenged with 10 ng/ml EGF and 1 x 10-6 M Insulin (Ins). Protein lysates were collected and equal amounts were 
loaded on a gel and subjected to Western blot to determine phosphorylated PKB/Akt. Both stimuli were equally 
potent in activating PKB/Akt in cells of the patient and the control.
E. Fibroblasts of patient A and fibroblasts of eight healthy donors were stimulated with a dose range of IGF-I 
and the incorporation of [3H]-thymidine was determined. The maximal response expressed as fold stimulation 
(Vmax) was calculated by averaging the responses observed at concentrations of IGF-I of 10, 20, 40, and 100 
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D i s c u s s i o n
In this study, we describe two cases, a mother and daughter, with the first hetero-
zygous missense mutation in the intracellular tyrosine kinase domain of the IGF1R. 
This IGF1R mutation results in partial resistance to IGF-I, which presents with 
intrauterine and postnatal growth retardation and failure to thrive. These cases, 
together with the three previously described families with IGF1R mutations (7, 8), 
and two cases with homozygous IGF-I defects (1, 2) have provided a unique oppor-
tunity to study the role of the IGF-I/IGF1R system in human physiology.  
Our patients have a mutation in exon 16, coding for the intracellular tyrosine 
kinase domain of the receptor. The tyrosine kinase (catalytic) domain is part of the 
cytoplasmatic portion of the β-chain of the IGF1R. Binding of IGF-I to the extra-
cellular α-chain induces a conformational change in the structure of the receptor 
leading to autophosphorylation of three tyrosines in the activation loop of the 
catalytic domain of the β chain. Phosphorylation of the tyrosine residues results 
in a dramatic conformational change (25, 26). Glutamic acid at position 1050 
(E1050) is extremely well conserved in all tyrosine kinase domains available in the 
database of the National Center for Biotechnology Information (NCBI) and is 
believed to play an important role in stabilizing the active conformational state.
The equivalent of E1050 in the IR is E1047. Upon binding insulin, the intracellular 
kinase domain is activated and conformational changes are induced. The change 
in three-dimensional structure places E1047 in close proximity of K1030 (K1033 in 
the IGF1R). This lysin residue is also highly conserved in tyrosine kinase domains 
and is located in the ATP-binding site. Hydrogen bonding between the negatively 
charged E1047 and the positively charged K1030 is believed to stabilize the structure 
of the activated receptor upon binding of insulin (25). Similarly, hydrogen bonding 
between E1050 and K1033 is believed to stabilize the active conformation of the 
IGF1R upon IGF-I binding. Due to the charge change induced by the E1050K substi-
tution, it seems likely that the mutant receptor cannot preserve its active conforma-
tion. Consequently, the substitution should result in inactivation. This was confirmed 
by functional studies showing a dramatic reduction in autophosphorylation of IGF1R 
and in activation of downstream signaling pathways in cells of patient A compared 
with a panel of controls upon a challenge with IGF-I. The mutation did not have an 
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effect on IGF-I binding or on IGF1R mRNA and protein expression. Compared with 
the PKB/Akt pathway, the reduction in activation of the Erk1/2 pathway was less 
pronounced. This can be explained by assuming that less kinase activity is required 
to saturate activation of the Erk1/2 pathway compared with the PKB/Akt pathway. 
Finally, the maximal response determined in a [3H]thymidine incorporation assay 
was almost 50% reduced compared with a panel of fibroblasts derived from healthy 
controls. Taken together, these data are fully in line with the inactivation of one copy 
of the IGF1R as a result of  the E1050K substitution and suggests that the IGF-I 
resistance in our patients is caused by IGF1R haploinsufficiency. They furthermore 
confirm the important function of E1050 in stabilizing the active conformation of 
the tyrosine kinase domain as predicted by structural models (25, 26).
Although we believe that the best explanation of the phenotype observed in our 
two patients is the heterozygous IGF1R mutation leading to partial IGF-I resis-
tance, we acknowledge that the results cannot be viewed as definitive proof. Even if 
one accepts that the mutated IGF1R must be dysfunctional based on its structure 
and that in in vitro studies of cultured fibroblasts stimulation of the the PKB/Akt 
pathway is reduced, one still has to assume that one functional allele is not suffi-
cient for a full biological activity, at least with respect to growth of the skull, trunk, 
and extremities. Clinical observations on more patients, combined with detailed in 
vitro studies, are needed before it can be concluded that IGF1R haploinsufficiency 
indeed causes a clinical syndrome of pre- and postnatal growth failure.    
The most striking clinical characteristics of patients with primary IGF-I resis-
tance are intrauterine and postnatal growth retardation. The growth data of the 
reported patients with a mutation of the IGF1R gene are summarized in Table 4. 
Most patients have intrauterine growth retardation, but the degree of growth 
failure is variable. The patients with an affected mother (patients 2A, 2B, and 4B, 
and possibly 1A) seem to be more severely growth retarded than the patients with 
an apparently unaffected mother (patients 2C and 4A). One can hypothesize that 
maternal IGF-I resistance during pregnancy may affect placental size and, as a con-
sequence, fetal growth. This hypothesis is supported by a strongly positive correla-
tion between the rate of IGF-I increase during pregnancy and placental weight (27, 
28) and by the finding that placentas from IUGR pregnancies are characterized by 
decreased expression of IGF1R and signal transduction proteins (29). 
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Postnatally, we saw a stimulated GH response to arginine in patient B, reflecting 
the state of IGF-I resistance. The direct IGF-I independent effects of GH could 
account for the better postnatal than prenatal growth in patient B. Another expla-
nation could be that later in life the body compensates for the lack of IGF-I effect 
by producing more IGF-I receptor per cell. In the adult patient, GH secretion was 
normal, while it had been high in childhood and adolescence. This suggests that 
the GH-IGF-I feedback loop may change with age.   
Concerning puberty, our patient A had a late onset of puberty. In the earlier 
reported patients, timing of puberty was not described in detail, except for the 
compound heterozygous patient in the report of Abuzzahab et al. (7) who had a 
normal pubertal development. The patients with IGF-I deletion and mutation had 
delayed puberty (1, 2). In Laron syndrome puberty is delayed, more so in boys than 
in girls (30). In patients with ALS deficiency puberty is extremely delayed (31). 
Taking all data together, it appears that IGF-I plays a role in pubertal onset.
So far, all patients with heterozygous IGF1R mutations with a reported head cir-
cumference have been microcephalic (Table 4). This is in line with the severe micro-
cephaly found in both patients with primary IGF-I deficiency (-8 SDS in the case of 
IGF-I mutation and – 5.3 SDS in the case of IGF-I deletion) (1, 2). Carriers of the 
IGF-I mutation had a lower head circumference than noncarriers (-1.0 SDS vs. – 0.4 
SDS) (2). This confirms the important role of IGF-I in intrauterine brain develop-
ment as is known from IGF-I knockout mice (32). In contrast, the findings regarding 
intellectual and emotional development seem to vary substantially (Table 4).
Both our patients needed tube feeding due to poor appetite and failure to thrive, 
so it is tempting to believe that the IGF1R mutation is associated with this phe-
nomenon. Observations in rats lend some support to this speculation: in rats, 
IGF-I receptors are localized in the hypothalamic arcuate nucleus (33), whereas 
the arcuate nucleus integrates signals regulating appetite (34). Insulin is known to 
penetrate the blood-brain barrier, where it acts as an anorexigenic signal, decreas-
ing intake and body weight (34). Although data on the role of IGF-I on appetite are 
limited, we hypothesize that IGF-I has a similar effect. In our case B we observed 
that plasma IGF-I levels can be within the normal range in a state of poor nutrition. 
After restoring the nutritional state by a gastrostoma, IGF-I increased from -0.1 
SDS to 2.9 SDS. 
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In our adult patient, an increased HOMA-IR was found, reflecting a moderate 
degree of insulin resistance, which could not be explained by an increased fat mass, 
since body mass index as well as stimulated insulin secretion were normal. Primary 
IGF-I deficiency is associated with insulin resistance (35) and treatment with 
recombinant human IGF-I improved insulin sensitivity in a patient with homozy-
gous IGF-I mutation (36). Administration of recombinant human IGF-I to patients 
with severe insulin resistance and to patients with type 2 diabetes improves insulin 
sensitivity (37). These observations support the hypothesis that IGF-I is necessary 
for normal insulin sensitivity.
Comparing the phenotypes of the affected individuals in the four families with 
an IGF1R mutation, the degree of mental performance, dysmorphic features, 
and failure to thrive varies substantially (Table 4). This may reflect a spectrum of 
remaining IGF-I signaling activity. This is supported by our finding in patient A, 
that [3H]thymidine can be incorporated in fibroblasts that are stimulated with high 
doses of IGF-I, although the maximal response is significantly reduced compared 
with controls. With regard to therapy, this in vitro response to high-dose IGF-I is 
an important argument for the potential benefits of GH or IGF-I treatment. Our 
patient B has just started GH treatment (1.4 mg/m2/day). 
In conclusion, the novel heterozygous mutation in the intracellular tyrosine kinase 
domain of the IGF1R leads to intrauterine and postnatal growth retardation to 
a similar extent as the previously described mutations in the extracellular ligand 
binding part of the receptor. The degree of remaining IGF-I signaling may explain 
the different phenotypes seen in patients with IGF1R mutations. Maternal IGF-I 
resistance may affect placental size and explain part of the variance in birth weight 
of carriers of an IGF1R mutation. Heterozygous IGF1R mutations can be expected 
in patients born small for gestational age with a small head circumference in the 
presence of relatively high levels of IGF-I. Genetic analysis in such patients may 
provide important information on genotype-phenotype relations and the role of the 
IGF-I system in intrauterine and postnatal growth and development in human. 
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A b st r a c t
Context: Microscopically visible heterozygous terminal 15q deletions encompassing 
the IGF1R gene are rare and invariably associated with intrauterine growth retar-
dation and short stature. The incidence of submicroscopic deletions is unknown, 
as well as the effect of growth hormone therapy in this condition. 
Objective: To describe the use of a novel genetic technique [multiplex ligation 
probe amplification (MLPA)] to detect haploinsufficiency of the IGF1R gene in a 
patient suspected of an IGF1R gene defect and evaluate the effect of long-term GH 
therapy.  
Patient: We describe a 15 yr old adolescent, born small for gestational age, who 
showed persistent postnatal growth retardation, mild developmental delay and 
elevated IGF-I levels. She had been treated with GH since the age of 5 yr.
Methods: Mutation analysis of the IGF1R gene was performed by DNA sequenc-
ing followed by MLPA and array Comparative Genomic Hybridization (aCGH) to 
examine gene copy number changes. Dermal fibroblast cultures were used for func-
tional analysis.
Results: Sequence analysis revealed no abnormalities in the IGF1R gene. With 
MLPA, a deletion of one copy of the IGF1R gene was detected, which was defined 
by aCGH to a loss of 15q26.2qter. In concordance with IGF1R haploinsuffi-
ciency, IGF1R mRNA expression was decreased and activation of IGF1R and PKB/
Akt after a challenge with IGF-I was decreased in the patient’s fibroblasts, though 
to a lesser extent. IGF-I binding assays showed normal binding affinity and maximal 
binding of the IGF1R. GH treatment resulted in a good growth response and final 
height within the normal range.
Conclusions: The phenotype of a heterozygous terminal 15q deletion resembles 
that of a heterozygous inactivating IGF1R mutation with respect to intrauterine 
growth retardation, microcephaly, short stature, and elevated IGF-I levels. Long 
term growth hormone therapy is well tolerated and causes growth acceleration in 
childhood resulting in a normal adult height. MLPA and aCGH are useful tools to 
detect submicroscopic deletions of the IGF1R gene in patients born small for ges-
tational age with persistent growth failure.
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I n t r o d u c t i o n
Insulin-like growth factor I (IGF-I) is required for normal intrauterine and postnatal 
growth. The biological functions of IGF-I are mediated through the type 1 IGF 
receptor (IGF1R). The IGF1R gene is located on the distal long arm of chromo-
some 15 (15q26.3). Heterozygous inactivating mutations of the IGF1R gene result 
in a phenotype of intrauterine and postnatal growth failure and microcephaly, with 
a variable degree of psychomotor retardation (1-4). Mild dysmorphic features 
have been described in some cases (1, 3). An isolated homozygous or heterozygous 
deletion of the IGF1R gene has not yet been described. 
Heterozygous terminal deletions of the distal long arm of chromosome 15, including 
the IGF1R, have been reported in only a few cases: 6 patients with a15q26.1  
15qter deletion (5-9) and 2 patients with a 15q26.215qter deletion (10-12). 
Intrauterine growth retardation (IUGR) is present in almost all cases, with a birth 
weight varying between -1.8 SDS and –5.6 SDS and a birth length between -1.3 
SDS and -5.5 SDS. In all cases, except one, the karyotype was abnormal, showing 
the terminal deletion of 15q. 
We report a female patient with pre- and postnatal growth failure and elevated 
plasma IGF-I levels. The karyotype was normal. This clinical picture resembles the 
presentation of patients with a heterozygous mutation in the IGF1R gene (1-4). 
However, sequencing of the IGF1R gene did not reveal any abnormalities. Since 
the clinical picture may also be caused by haploinsufficiency of the IGF1R gene, we 
performed multiplex ligation-dependent probe amplification (MLPA) and found 
loss of one copy of the IGF1R gene. The borders of the deletion were mapped using 
array-comparative genomic hybridization (aCGH).  15q26.2qter was deleted, 
including IGF1R gene. We show that long term growth hormone therapy in a 
patient with IGF1R haploinsufficiency improves growth considerably and leads to 
a normal adult height without notable side-effects.  
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M e t h o d s
The patient and her parents provided written informed consent 
Clinical measurements and auxology
Height and sitting height were determined with a Harpenden stadiometer, and 
head circumference was assessed with a tape measure. Height and head circumfer-
ence were expressed as standard deviation score (SDS) based on Dutch references 
(13). Sitting height and sitting height/height ratio were also expressed as SDS for 
the Dutch population (14).
Bone Mineral Density (BMD)
BMD (g/cm2) of the lumbar spine and total body was measured by dual-energy x-ray 
absorptiometry (DXA) (Lunar, DPXL/PED, Lunar Radiation Corporation, Madison, 
WI). Ancillary DXA-derived data were used to calculate lumbar spine volumetric 
BMD [bone mineral apparent density (BMAD)] with the model BMAD = BMD x 
[4/( x width)], as validated before (15). BMD and BMAD results were compared 
with age- and sex-matched reference values and expressed as SDS (16, 17).
Biochemical measurements
Plasma GH was measured with Plasma GH was measured with Immulite 2000 a 
solid-phase, two-site chemiluminescent immunometric assay (DPC, Los Angeles, 
CA) using the WHO NIBSC 1st international standard 80/505 (1mg=2.6 IU). An 
arginine stimulation test was performed with 0.5 g/kg arginine iv over 30 min and 
blood samples at 0 and 30 min. A clonidine stimulation test was performed with 
0.15 mg/m2 clonidine orally, collecting blood samples every 30 minutes until 150 
min. 
Plasma IGF-I, IGF-II, IGF-binding-protein (IGFBP)-1 and IGFBP-3 were deter-
mined by specific RIAs (18, 19). With the exception of IGFBP-1 smoothed refer-
ences based on the LMS method were available for all parameters allowing conver-
sion of patients data to SDS values (20). Plasma IGFBP-1 concentration after an 
overnight fast was compared with a reference group of 6 healthy adult controls. An 
IGF-I generation test was performed with 1 mg/m2 body surface GH (Humatrope, 
Lilly) during 4 days, followed by 2 mg/m2 during 3 days. 
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Genetic analysis
Fluorescence In Situ Hybridization (FISH)
Fluorescence in situ hybridization (FISH) was performed on cultured dermal fibro-
blasts according to standard procedures. The probes used were the 15q subtelo-
meric PAC clone 154P1 (GS-154P1, (21) and the BAC clone 342L10 (RP11-342L10, 
“Cancer_1E9”, located in 15q26.3, BACPAC Resource Center (http://bacpac.
chori.org/order.php).
Sequence analysis
Total RNA was isolated from cultured fibroblasts and reverse transcribed into 
cDNA. The coding regions of the IGF1R were amplified by PCR using overlapping 
primer combinations and subjected to direct sequencing as described previously 
(22). Genomic DNA was isolated from whole blood according to the salting out 
procedure described by Miller et al (23). All coding exons of the IGF1R were PCR 
amplified and subjected to direct sequencing as described previously (3).
 
Multiplex ligation-dependent probe amplification (MLPA)
MLPA probes for the IGF1R were designed according to the criteria described by 
White et al (24) and were directed to exons 2, 8 and 18 of the IGF1R gene, which 
are conserved exons in different species (Table 1). The oligonucleotide probes 
were ordered from Illumina Inc. (San Diego, CA) and used without purification. 
Table 1. Sequence of the MLPA probes. 
Gene exon
Upstream (U) /







IGF1R 2 U GATGTGTGAGAAGACCACCATCAACA 44 92 HEX
  D ATGAGTACAACTACCGCTGCTGGACCACAA 48
 8 U CTACATGGGCTGAAGCCCTGGACTCAG 45 94 HEX
  D TACGCCGTTTACGTCAAGGCTGTGACCCTCA 49
 18 U CAGTCCTAGCACCTCCAAGCCTGAGCA 45 90 HEX





All reagents for the MLPA were obtained from MRC Holland (Amsterdam, the 
Netherlands). Reactions were performed according to White et al. (24) and the 
manufacturer’s instructions. In short, 50 ng of genomic DNA in a final volume 
of 1 µl was heated at 98ºC for 5 min and subsequently cooled at 25ºC. 0.375 µl 
probe mix (4 fmol/µl), 0.25 µl H2O and 0.375 µl SALSA MLPA buffer were added 
to each sample, heat denatured at 95ºC for 2 minutes and followed by hybridiza-
tion at 60ºC for 2.5-3 hours. Samples were kept at 54ºC and 8 µl Ligase-65 mix 
(0.75 µl buffer A, 0.75 µl buffer B, 0.25 µl Ligase and 6.25 µl H2O) was added to 
each sample. After 10-15 min, the reaction was stopped by heat inactivation at 
98ºC for 5 min and cooled at 4ºC. The MLPA product (10 µl) was added to 20 
µl PCR mix at 60ºC and 33 cycles of 20 sec. 95ºC, 30 sec at 62ºC and 60 sec. at 
72ºC were carried out. From each PCR reaction 2 µl of product was mixed with 15 
µl deionized formamide and 0.5 µl ROX-500 Genescan. Product separation was 
performed using capillary electrophoresis on an ABI 310 (Applied Biosystems). 
The data analysis was performed as described by White et al. (24).
Array comparative genomic hybridization (aCGH) 
To determine the boundaries of the deletion we performed array-based comparative 
genomic hybridization (aCGH) using the 44B Human Genome CGH Microarrays 
(Agilent, Santa Clara, CA). These arrays contain 43x103 60-mer oligonucleotide 
probes (mostly exonic) that span the human genome with an average spacing of 
35 Kb. aCGH analysis was performed according to the manufacturer’s protocols. 
After hybridization and washing, slides were dried and scanned using a microar-
ray scanner (Agilent, Santa Clara, CA).  Images were analyzed with Agilent’s CGH 
Analytics software. 
Functional analysis
Real Time PCR was performed with the Biorad iQ5 multicolor real-time PCR 
detection system using Hs_IGF1R_SG Quantitect Primer Assay primers (Qiagen, 
Valencia, CA). Fibroblast cultures of the patient and of two healthy donors were 
used for Western blotting. Cells were stimulated for 10 min with or without 10 ng/
ml IGF-I. Blots were probed with an anti-phospho-PKB/Akt, total PKB/Akt (Cell 
Signaling Technology, Beverly, MA), anti-phospho-IGF1R (Biosource International, 
Camarillo, CA) and total IGF1R (Cell Signaling Technology, Beverly, MA) antibod-
ies as described previously (22). Binding studies were performed using iodinated 
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IGF-I in the presence of an excess of an IGF-I analog that is bound by IGFBPs but 
not by the IGF1R (Ala31Leu60-IGF-I, GroPep, Adelaide, Australia) (23). In short, 
fibroblasts of the patient and controls were incubated at 4ºC with 30,000 cpm 
[125I]IGF-I, 250 ng/ml Ala31Leu60-IGF-I, and graded amounts of unlabeled native 
IGF-I in 250 µl HEPES binding buffer (100 mM HEPES (pH 7.8), 0.5% fatty-acid-
free BSA, 120 mM sodium chloride, 1.2 mM magnesium sulfate, 5 mM potassium 
chloride, 15 mM sodium acetate, and 10 mM dextrose) as previously described 
(23). After 18 h, cells were washed and solubilized in 1 M NaOH. Radioactivity was 
determined using a γ-counter.
R e s u l t s
Case report
A 4.5 year old girl presented to the growth clinic of the Sophia Children’s Hospital 
with severe growth retardation. She was born after 39 wk gestation as the third 
child of healthy  unrelated parents. The pregnancy was uneventful. Her birth weight 
was 2.1 kg (-3.0 SDS), birth length was 47 cm (-1.3 SDS), and head circumference 
33 cm (-2 SDS)(25). Father’s height was 182 cm (-0.3 SDS) and the height of her 
mother was 165.5 cm (-0.8 SDS). Her target height corrected for secular trend 
(4.5 cm per generation) was 171.8 (0.2 SDS) (13). Her sister’s height was 0 SDS, 
her brother’s height was +1.3 SDS. Motor development was normal: she started 
sitting at the age of 10 months and walking at 17 months. Speech development 
was slow.
At the age of 4.5 yr her height was 93.5 cm (-3.5 SDS) (Fig. 1), weight 14.8 kg 
(weight for height +0.7 SDS), BMI 17 kg/m2 (1.0 SDS), sitting height 51.6 cm 
(sitting height/ height ratio 0.55 = 0.1 SDS). At physical examination she had a 
puppet face and a high-pitched voice. Her upper legs were strikingly muscular 
and there was increased abdominal fat distributed in a lobular pattern. She wore 
strong glasses because of extreme myopia (-10 and -7.5). There were no dysmor-
phic features and no abnormalities at further physical examination. 
IgG and IgA anti-gliadin antibodies were negative, virtually excluding celiac disease. 
Thyroid function was normal. The karyogram showed a normal female pattern 
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(46,XX). IGF-I was 203 ng/ml (+2.5 SDS), IGFBP-3 2.49 mg/l (+0.8 SDS), IGFBP-
1 46.6 ng/ml (normal). GH stimulation tests were performed with clonidine and 
arginine on separate days, resulting in peak GH concentrations of 8.4 and 25 IU/
liter, respectively. At the start of the IGF-I generation test IGF-I was 224 ng/ml, 
after 4 days of GH injections (1 mg/m2 body surface) IGF-I was 375 ng/ml, after 
another 3 days of GH (2 mg/m2) IGF-I was 480 ng/ml (normal range 115-329 
ng/ml). 
Bone age was delayed by 2.5 years. BMD was 0.56 g/cm2 (-1.80 SDS), BMAD was 
0.25 g/cm3 (-1.09 SDS) and total body BMD was 0.77 g/cm2 (-1.39 SD). Lean 
body mass SDS was –2.45 and percentage body fat SDS was 0.75.
At the age of 5.3 years GH therapy was started in a dosage of 1 mg/m2.day sc 
(Humatrope, Lilly) (equivalent to 0.26 mg/kg body weight/week). A rapid catch-
up growth occurred, followed by a stabilisation at -2 SDS (Fig. 1). During GH 
GH
Figure 1 
  IGF-I (ng/ml)   203      717     277   932    795 
  IGF-I (SDS)   2.5      3.6     0.2   3.3    3.3 
  IGFBP-3 (mg/l)  2.5      5.0     4.0   6.1    3.5 
  IGFBP-3 (SDS)  0.8      1.6     1.3   2.5    0.4 
Figure 1. Growth curve 
The black dots represent height measurements, the gray squares the bone age, M2 indicates Tanner 
breast stage 2. The black horizontal lines indicate the periods of GH treatment. 
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therapy IGF-I was elevated (Fig. 1). BMD and lean body mass SDS increased. After 
two years of GH-treatment lumbar spine BMD SDS was –1.55, BMAD SDS –0.62, 
total body BMD SDS –0.95, and lean body mass SDS –0.96. GH therapy was inter-
rupted at the age of 10.8 years for 6 months, resulting in a decrease in height 
velocity and IGF-I level (Fig. 1). Puberty started at the age of 12.8 years and final 
height was reached at 15 years (157 cm, -1.6 SDS), 1.8 SD lower than target height 
SDS. Head circumference was 53 cm (-1.1 SDS). She had a regular menstrual cycle. 
She has recently completed high school. 
 
Genetic and functional analysis
Sequence analysis revealed no mutation in the coding exons of the IGF1R gene. 
MLPA showed a heterozygous deletion of the three exons (2, 8 and 18) of the 
IGF1R gene that were included in the MLPA assay (Fig. 2). This deletion was not 
present in the DNA of the parents. FISH confirmed the IGF1R deletion, together 
with a deletion of the 15q telomere. aCGH revealed that the deletion comprises 5.2 
Mb of the terminal part of the long arm of chromosome 15 (15q26.2  15qter), 




Figure 2. Genescan of the MLPA analysis of the IGF1Rgene.
The arrows in the lower panel show the lower peaks of the 3 IGF1R probes in the patient compared 
with the control in the upper panel, indicating a deletion of IGF1R. 
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Figure 3. Functional analysis
A.  Expression of three IGF1R mRNA fragments 
(P = patient, C = control). Cultured dermal 
fibroblasts showed decreased expression 
of IGF1R mRNA in the patient vs a random 
control.
B. Equal amounts of cells of the patient and 
four controls were seeded in 24-wells plates. 
At confluency, cells were incubated with 
[125I]IGF-I in the presence of 250 ng/ml 
Ala31Leu60-IGF-I and increasing amounts of 
unlabeled native IGF-I. After 18 h, cells were 
washed and binding of  [125I]IGF-I was deter-
mined. Data represent the mean of two qua-
druplicate experiments and are expressed as 
percentage of total binding in the presence of 
competition with the lowest concentration 
IGF-I (0.05 ng/ml), which was set to 100% 
after correction for non-specific binding. 
The displacement curve of the patient’s cells 
was indistinguishable from controls.
 Scatchard analysis was performed for the 
calculation of the binding affinity (Kd) and 
binding capacity (Bmax) of the patient’s cells 
and controls. The Kd and Bmax of our patient 
showed no significant differences compared 
with various controls. Values represent the 
mean of two quadruplicate experiments ± 
SD.
C. Dermal fibroblasts of the patient and 
controls were stimulated with 10 ng/ml IGF-
I for 10 min. Protein lysates were collected 
and 25 µg of protein was used for Western 
blotting using phosphospecific IGF1R and 
PKB/Akt (Ser473) antibodies and total 
IGF1R and PKB/Akt antibodies (picture 
not shown). Densitometric quantification 
of the Western blots was performed. Data 
are expressed as a ratio of phosphor specific 
IGF1R or PKB/Akt and total IGF1R or PKB/
Akt, respectively. The ratio of the unstimu-
lated lysates was set at 100%. The activation 
of the IGF1R and PKB/Akt tended to be 
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RT-PCR analysis using various fragments of the IGF1R gene showed decreased 
expression of IGF1R mRNA in fibroblasts of the patient versus a normal control 
(Fig. 3A). This was confirmed by quantitative PCR (qPCR) showing an approxi-
mately 5 times reduction in IGF1R mRNA expression compared to a panel of 
normal controls (data not shown). Binding studies showed normal binding affinity 
and a trend towards decreased total binding (not significant) of iodinated IGF-I to 
patient’s cells in comparison with a panel of control cell lines (Fig. 3B). Western 
blot demonstrated a comparable level of total IGF1R protein expression in the 
patient compared with controls (data not shown); however, autophosphorylation 
of the IGF1R and activation of PKB/Akt upon a challenge with 10 ng/ml IGF-I for 
10 min were reduced (Fig. 3C), although this did not reach significance. 
D i s c u s s i o n
Partial IGF-I resistance due to heterozygous deletions or inactivating mutations of 
the IGF1R gene is a rare cause of short stature. We present a girl with a hetero-
zygous terminal deletion of the long arm of chromosome 15, including the IGF1R 
gene. 
The IGF1R is a tyrosine kinase receptor, consisting of a heterotetrameric (α2β2) 
transmembrane glycoprotein. Binding of IGF-I to the receptor results in autophos-
phorylation of three intracellular tyrosine residues and activation of the receptor’s 
intrinsic tyrosine kinase. Subsequently, distinct intracellular signaling pathways are 
activated, which induce amongst others protein synthesis and glucose transport 
and regulate cell proliferation, differentiation and apoptosis (26). A deletion of 
one copy of the IGF1R may result in haploinsufficiency due to lower expression 
of IGF1R mRNA and protein. Indeed, in dermal fibroblasts of the patient IGF1R 
mRNA expression was decreased compared with a panel of controls. However, this 
resulted not in reduced protein expression, diminished IGF-I binding or decreased 
activation of downstream signaling upon a challenge with IGF-I. Maximal binding 
and phosphorylation of IGF1R and PKB/AKT tended to be lower but this did not 
reach significance. Also others have reported inconsistent results regarding IGF1R 
haploinsufficiency due to a 15q deletion in dermal fibroblasts and it was suggested 
that dermal fibroblasts were less suited to study the functional consequences of 
IGF1R haploinsufficiency (6, 10). This contrasts findings in a family with a missense 
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mutation in the intracellular kinase domain of the IGF1R, which resulted in strongly 
decreased activation of downstream signaling in dermal fibroblasts (3). It may well 
be that the consequences of haploinsufficiency are cell type dependend, with little 
effect in dermal fibroblasts but strong effects in growth plate chondrocytes that 
are responsible for longitudinal growth.
A pure terminal deletion of 15q, without the presence of a ring chromosome, has 
only been described in a few cases (5-11). In all cases, except one, the deletion was 
detected by regular karyotyping. Pinson et al. diagnosed a patient with a terminal 
15q deletion unexpectedly: looking for a maternal 15q11-q13 deletion to exclude 
Angelman syndrome, they accidently observed that the specific telomeric control 
probe on one chromosome 15 was missing. In our case the deletion was not 
diagnosed with regular karyotyping, but detected through the MLPA technique. 
We have developed a MLPA probe-mixture directed against 3 different exons of the 
IGF1R and several other genes for the evaluation of children with unexplained short 
stature. In our patient MLPA proved successful in detecting the IGF1R deletion, 
which was further characterized with aCGH. Since the MLPA assay can be easily 
extended to include as many as at least 40 different probe sets, this technique 
is ideally suited for the evaluation of copy number changes of multiple genomic 
regions simultaneously. We, therefore, expect that these techniques will signifi-
cantly contribute to the elucidation of genetic causes of unexplained short stature 
in the future. 
Some of the phenotypical features can be attributed to the loss of one copy of the 
IGF1R gene, while other features are probably the result of the absence of other 
genes in the deleted region. 
In all cases of terminal 15q deletion, except in one child with a diabetic mother 
(9),  IUGR was present. IUGR is also a common feature in patients with inactivat-
ing IGF1R mutations (1-4), indicating that IGF1R haploinsufficiency is responsible 
for the poor prenatal growth. Also, the postnatal growth pattern in our patient 
and in other cases with this condition is comparable with the growth in patients 
with a heterozygous inactivating mutation in the IGF1R gene, suggesting that the 
growth retardation in patients with terminal 15q deletion is the result of  partial 
IGF-I resistance. 
Succesful GH therapy in IGF1R haploinsufficiency
175
Another common feature in patients with partial IGF-I resistance is microcephaly 
with or without delayed psychomotor development. The normal development in 
our patient, our earlier observations of a normal intellectual development in an 
adult woman with a heterozygous missense mutation (3), in combination with the 
normal intelligence reported for three other cases with IGF1R missense mutations 
(1, 2, 4) suggest that the degree of developmental delay is predominantly deter-
mined by the deletion of other genes on 15q26.2qter. 
The dysmorphic features described in the patients with terminal 15q deletion, 
including our own patient, mainly include craniofacial characteristics and anomalies 
of hand and feet. These features are uncommon in patients with IGF1R mutations 
and probably result from the loss of other genes in the gene-rich 15q subtelomeric 
region. Our patient had extreme myopia, which has not been reported in other 
patients with IGF-I resistance. Although the IGF1R is expressed in the lens (27), it is 
unlikely that myopia is the result of IGF-I resistance, as one would expect to find this 
more frequently in other patients with IGF-I resistance. We have now shown that the 
absence of major dysmorphic features does not exclude a terminal 15q deletion. 
We have shown that the growth retardation caused by IGF1R haploinsufficiency 
can successfully be treated with GH: height at start of therapy was -3.5 SDS and 
final height was -1.6 SDS, within the population range, but 1.8 SD below target 
height. This observation is partially consistent with the effects of GH therapy in 
two patients with IGF1R haploinsuffiency (6, 10). One of them (6) was treated 
from 3.5 years onwards during three periods with different dose regimes. During 
the first two periods catch-up growth was observed, but this was not sustained 
and at the age of 12 years height was -5.5 SDS, similar to height SDS at start. 
Okubo et al. (10) treated a patient with 1.7 U/day from the age of 22 months 
resulting in improved growth (-4.9 SDS to -3.2 SDS at the age of 9 years). The 
result of two years of GH treatment (30 µg/kg/day) administered to a patient with 
an inactivating mutation of the IGF1R gene was reported by Raile et al (28). Height 
SDS increased from -2.5 to -1.5. Thus, we conclude that patients with partial IGF-
I resistance due to heterozygous IGF1R deletions or mutations may benefit from 
GH therapy in terms of longitudinal growth, possibly due to the direct effect of 
increased concentrations of GH in combination with strongly elevated plasma IGF-
I levels that may partially overcome the decreased IGF-I sensitivity. 
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In conclusion, the characteristics of a heterozygous terminal 15q deletion are 
dominated by partial IGF-I resistance, due to IGF1R haploinsufficiency, while the 
dysmorphic features and the developmental delay are probably the result of hap-
loinsufficiency of other genes in this chromosomal region. GH treatment consider-
ably improves growth during childhood and leads to a normal adult height, though 
still below the genetic target. A normal karyogram in patients with features sugges-
tive for IGF-I resistance does not exclude small deletions. MLPA followed by aCGH 
is a powerful diagnostic strategy to detect submicroscopic deletions in children 
with short stature.
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A b st r a c t
Animal knockout experiments have offered the opportunity to study genes that 
play a role in growth and development. In the last few years, reports of patients 
with genetic defects in the GH-IGF-I axis have greatly increased our knowledge of 
genetically determined causes of short stature. In the various chapters of this thesis, 
patients are described with a genetic defect in the GHRH receptor, the GH signaling 
pathway, IGF-I or the IGF-I receptor, all of which are components of the GH-IGF-I 
axis. In this final chapter the animal data and human reports of genetic disorders in 
the GH-IGF-I axis will be reviewed, in order to describe the role of the GH-IGF-I axis 
in intrauterine and postnatal growth. In addition, the effects of the GH-IGF-I axis 
on development and function of different organ systems as brain, inner ear, eye, 
skeleton, glucose homeostasis, gonadal function and the immune system will be 
discussed. The number of patients with genetic defects in the GH-IGF-I axis is small 
and a systematic diagnostic approach and selective genetic analysis in a patient 
with short stature are essential to identify more patients. Finally, the implications 
of a genetic defect in the GH-IGF-I axis for the patient and the therapeutic options 
will be discussed.   
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I n t r o d u c t i o n
Reports of patients with genetic defects in the growth hormone – Insulin-like 
Growth Factor-I (GH-IGF-I) axis, in addition to animal knockout experiments, have 
increased our knowledge on the role of the GH-IGF-I axis in growth and develop-
ment throughout life considerably. By means of these reports we will describe the 
factors playing a role in intrauterine as well as postnatal growth and the effect of 
the GH-IGF-I axis on the development and function of different organs. Finally, the 
tools for the diagnostic approach for the physician and the clinical implications for 
the patients will be discussed. 
I n t r a u t e r i n e  g r ow t h
The first evidence that intrauterine growth is determined by GH-independent IGF-I 
secretion, comes from animal experiments. Mice with severe GH deficiency due to 
spontaneous mutations in the genes encoding GHRHR (little mouse), Pit 1 (Snell 
dwarf) and Prop-1 (Ames dwarf) have a normal birthweight (1). The GH insensitive 
Laron mouse is born with a normal body size and weight (2). In contrast, IGF-I and 
IGF1R knockout mice have birthweights of 60% and 45% of normal, respectively. 
From these observations it was concluded that IGF-I is a growth determinant factor 
for intrauterine growth, independently of GH (3-5). The effects of IGF-I are mediated 
through the IGF-I receceptor (IGF1R), which is in line with the observation that the 
IGF1R -/- mice and the IGF1R-/- IGF-I-/- mice are equally growth retarded at birth 
(45 % of normal) (3). IGF1R-/- knockout mice die within minutes after birth due to 
respiratory failure (3). IGF1R+/- mice are phenotypically normal (3). Disruptions in 
the IGF-I signaling pathway as described in mice deficient in Akt1, insulin receptor 
substrate-1 (IRS-1) or IRS-2 result in reduced intrauterine growth (6-9).
In the human, GH deficiency and insensivity result in a normal birth size (10-
12). In contrast, an IGF-I gene deletion or mutation results in severe intrauterine 
growth retardation as is demonstrated in the patient described by Woods et al. 
(birth weight and length –3.9 SDS and –5.4 SDS, respectively), Walenkamp et al. 
(birth weight and length –3.9 SDS and –4.3 SDS, respectively) and Bonapace et al. 
(birth weight and length –4 SDS and –6.5 SDS, respectively) (13-15). The finding 
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that genetically determined low IGF-I levels, due to polymorphisms in the IGF-I 
promoter region, result in a reduced birth weight and length support the role of 
IGF-I in fetal growth (16, 17). 
There are also indications of an IGF-I dose effect on intrauterine growth. IGF-I 
heterozygous mouse are 10-20% smaller at birth (4) and in the human we found 
that carriers of an IGF-I missense mutation have a 10% lower birth weight than 
non-carriers (14). 
In contrast to the observations in mice, heterozygous mutations of the IGF1R 
result in intrauterine growth retardation in the human (18-22). The degree of 
IUGR varies between -1.5 SDS and  -3.5 SDS for birth weight and between -0.3 
SDS and -5.8 SDS for birth length. The different mutations result in a variable 
degree of remaining IGF-I signaling, which may explain the wide range of birth 
size. Another hypothesis is that maternal IGF-I resistance during pregnancy in the 
mothers with a heterozygous IGF1R mutation contribute to more severe growth 
retardation. This is supported by the finding that children with an affected mother 
are more growth retarded at birth than children with an apparently non-affected 
mother (22).
IGF1R haploinsufficiency is associated with a variable degree of intrauterine growth 
retardation (-1.8 SDS to –5.6 SDS) as is demonstrated in patients with a terminal 
15q deletion, including the IGF1R gene (23-30). The report of a patient with three 
copies of the IGF1R gene supports the concept that a gene dose effect plays a 
role in intrauterine growth. This patient is born at 42 weeks gestational age with 
a birth weight of 5140 gr, a birth length of 60 cm and a head circumference 38.5 
cm (28).
So far, genetic defects of the IGF-I signaling pathway are not described in human. 
However, in a recent study of Laviola et al. the IRS-2 and Akt pathway were down-
regulated in human placentas from pregnancies complicated by IUGR, indicating 
an important role for IGF-I signaling in the appropiate development of the fetopla-
cental unit (31).    
ALS (acid-labile subunit) forms a ternary complex with IGF-I or IGF-II and with 
IGFBP-3 or IGFBP-5 in the circulation to increase the half-life of the IGFs. ALS defi-
ciency appears to have no effect on fetal growth in ALS knockout mice (32). Data 
on intrauterine growth of ALS deficient patients are limited, as the first described 
patient is adopted and gestational age is not available. At the age of one week 
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weight was 2500 gr and length was 47 cm, which is considered normal (33). Also 
from the second patient no data regarding gestation, birth weight and length are 
available (34). As expression of ALS occurs late in fetal life (35), severe effects on 
intrauterine growth are unlikely.
Although this review focuses on genetic defects of the GH-IGF-I axis, the impor-
tance of the role of IGF-II in intrauterine growth cannot be left unmentioned.  IGF-
II acts as an important modulator of placental cell proliferation and maturation 
(36). A positive correlation has been demonstrated between cord blood IGF-II 
and placental weight (37). However, controversy exists with regard to the relation 
between fetal serum IGF-II levels and fetal growth. Some studies report reduced 
cord blood IGF-II levels in IUGR babies (38-40), others report similar levels of 
IGF-II in IUGR and normal fetuses (41). Human mutations in the gene encoding 
IGF-II, located on 11p15, have not been identified sofar. However, alterations in 
imprinting status of the IGF-II gene are associated with severe IUGR as part of 
the Silver Rusell syndrome (a condition characterized by severe IUGR, postnatal 
growth failure, dysmorphic facial features and body assymetry). The IGF-II gene 
is paternally expressed. A maternal duplication of 11p15 or demethylation of the 
telomeric imprinting centre ICR1 on 11p15, resulting in under-expression of IGF-II 
is found in 50 % of patients with Silver Russell syndrome (42-44). 
Po st n a t a l  g r ow t h
The first two weeks of postnatal life growth of the Snell dwarf, the Ames dwarf, 
the little and Laron mouse is indistinguishable from the wild type littermates (1). 
However, at postnatal day 40, their size is about 50% of normal, which confirms 
the increasing role of GH in postnatal life. The size of the IGF-I knockout mice 
decreases progressively from 60% of normal at birth to 30% of normal at 8 weeks. 
Double knockout mice (GHR-/- and IGF-I-/-) have a postnatal growth pattern of 
17% of normal (45). These findings demonstrate that GH dependent IGF-I action 
is the main determinant of postnatal growth, but that GH and IGF-I have also 
independent effects (45). Targeted gene deletion of liver-specific IGF-I and ALS 
(LID/ALSO mouse), resulting in a 85-90% reduction of circulating IGF-I, shows a 
20% lower body weight than control mice.  This implicates that, while endocrine 
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IGF-I is important in postnatal growth, tissue IGF-I also plays a role since the total 
IGF-I-/- mouse is more growth retarded (46). 
The classical heterozygous IGF1R-/+ mice are phenotypically normal, with normal 
expression of IGF1RmRNA, suggesting that the intact wild-type allele is up-
regulated and implying that a single functional IGF1R allele is sufficient to assure 
normal growth (3). However, later experiments inducing reduced availability of the 
IGF1R (41% less than normal) showed a growth deficit of 13% in males and of 6% 
in females, implying that a partial reduction in IGF-I signaling reduces the growth 
potential, at least in the male mouse (47).
In the human, severe isolated GH deficiency leads to a final height ranging from 
-3.9 to -6.1 SDS (mean -4.7 SDS) (48). GH deficiency due to GHRHR mutations 
results in a mean final height of –7.2 SDS (49). Patients with GH insensitivity due 
to a GHR mutation reach a final height varying from -3.2 SDS to -12 SDS (12, 50, 
51) and due to a STAT5b mutation from -5.9 SDS to -7.8 SDS (52-54). Complete 
IGF-I deficiency due to a deletion of the IGF-I gene results in a final height of -6.9 
SDS (13). The final height of the patient with an inactivating mutation of the IGF-I 
gene is -8.5 SDS (14). The height of a patient with a mutation resulting in extremely 
low IGF-I levels at the age of 19 months is -6.2 SDS (15). These results show that 
GH deficiency results in a similar growth pattern as primary IGF-I deficiency, which 
emphasizes the predominant role of GH dependent IGF-I production in postnatal 
growth. Treating GH deficient patients with GH results in a better growth response 
than treating GH insensitive patients with recombinant human (rh)IGF-I, suggest-
ing that a direct GH effect is necessary for optimal postnatal growth (55). 
GH insensitivity caused by a STAT5b mutation results in severe postnatal growth 
retardation in males and females. In contrast, the homozygous ablation of STAT5b 
in mice results in loss of the sexual dimorphism in body growth: the postnatal 
growth curves of female wild type, female STAT5b-/-  and male STAT5b-/- mice 
show no significant difference (56). STAT5b gene disruption in mice leads to a 
loss of the sexually dimorphic pituitary pulsatile GH secretion pattern and liver 
gene expression. It is uncertain how this difference with regard to the interaction 
between sex steroids and the GH-STAT5b-IGF-I axis in mouse vs human is can be 
explained. One explanation may be that in the mouse the growth promoting effect 
of the typical male pattern of GH secretion (high GH peaks, low throughs) is trans-
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mitted by STAT5B, while the irregular GH profile of female rats, with lower peaks 
and higher troughs, is primarily transmitted by another signal transduction route. 
Knocking out STAT5B in the mouse can then be expected to abolish the sexual 
dimorphism in growth in the rat. In the human, the GH profile is not different 
between sexes, and is similar to the pattern of GH secretion seen in male rats. 
A STAT5B defect would then be expected to have a similar effect in both sexes 
56, 57)
Patients with IGF-I insensitivity due to IGF1R mutations show more variety in 
postnatal growth (-0.9 SDS to -4.8 SDS) than patients with IGF-I deficiency. The 
phenotypical variability in IGF-I insensitivity is most probably caused by differences 
in remaining IGF-I signaling or by a compensatory mechanism that up-regulates 
the expression of the normal IGF1R allele. In addition, a gene dose effect seems to 
play a role in postnatal growth as is demonstrated by the severe postnatal growth 
failure (-3.5 SDS to –6.3 SDS) of patients with IGF1R haploinsufficiency due to a 
terminal 15q deletion, including the IGF1R gene (23, 25, 26, 28-30). The finding 
that trisomy of terminal 15q resulting in duplication of the IGF1R gene is associ-
ated with tall stature supports this hypothesis (58).
Two patients with ALS deficiency due to a mutation in the ALS gene have been 
described (33, 34) and we have recently reported two affected sibs (59). They 
present with a variable degree of growth retardation: height at 14.6 years of age 
–2.05 SDS and final height -0.8 SDS in the patient described by Domene et al, -2.1 
SDS at 15.5 years of age in the patient described by Hwa et al, final height was -
4.2 SDS in one of the sibs and height was -4.3 SDS at the age of 16.5 years in the 
other sib. Extremely low IGF-I and IGFBP-3 levels is a common finding in all these 
patients. A high flux of free IGF-I into the tissues and rapid proteolysis of IGF-I 
can explain this feature. Another possibility is that paracrine and autocrine IGF-I 
effects, stimulated by increased GH production, compensate for the deficiency of 
circulatory IGF-I (34).
R e g u l a t i o n  o f  G H  s e c r e t i o n 
The regulation of GH secretion is complex. Shortly, GHRH stimulates GH synthesis 
and determines the amplitude of the pulses, while the intermittent withdrawal of 
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somatostatin regulates the timing of the GH pulses. The low amplitude spontane-
ous GH release in patients with a GHRHR mutation supports this hypothesis (60). 
The autofeedback mechanism of GH and IGF-I suppresses GHRH and stimulates 
somatostatin expression. 
Age, gender, sex hormones and adiposity influence the magnitude of GH secretion 
(61). Ghrelin, a hormone predominantly produced in the stomach, stimulates GH 
release and appetite. Ghrelin -/- mouse have a normal phenotype, suggesting that 
ghrelin itself is not required for growth (62). Human mutations have not yet been 
described. Ghrelin acts via the GH secretagogue receptor (GHSR). Recently, two 
families with a GHSR missense mutation resulting in impairment of the constitutive 
activity of the receptor were identified. The heights of the homozygous probands 
were –3.7 SDS and –3.2 SDS, supporting the hypothesis that ghrelin signaling via 
the GHSR plays a role in the GH-IGF-I axis (63).   
In patients with GH insensitivity low IGF-I levels result in loss of negative feedback 
and as a consequence increased GH secretion. IGF-I therapy restores GH secretion 
to normal, implying that the sensitivity of the feedback mechanism is intact in 
these patients (64). In addition to the increased GH secretion, prolactin levels are 
slightly elevated in patients with GHI due to a GHR mutation (65). This may be the 
result of increased GHRH secretion as a consequence of the diminished negative 
feedback of IGF-I and GH, which also stimulates the prolactin secretion from 
somatolactotroph cells in the pituitary. Indeed, the elevated prolactin levels are 
suppressed upon IGF-I administration, in line with the inhibitory action of IGF-I on 
hypothalamic GHRH neurons (65). In patients with a STAT5b mutation prolactin 
levels are even more elevated (52, 54, 66). This can be explained by the obligatory 
role of STAT5b in mediating the negative feedback action of prolactin on tuberoin-
fundibular dopamine neurons; in the absence of STAT5b the signal transduction in 
the hypothalamic dopamine neurons is impaired (67).
 
Patients with IGF-I insensitivity are characterized by elevated IGF-I levels as a result 
of increased GH production due to pituitary and hypothalamic IGF1R deficiency. 
This is supported by the finding that IGF1R-/- mice exhibit signs of somatotropic 
stimulation in the pituitary (61). However, in patients with poor caloric intake IGF-
I can be in the normal range, which should be considered as relatively high for a 
malnourished infant or child. Restoring the nutritional status increases the IGF-I 
level above the normal range (22).
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Patients with IGF1R haploinsufficiency have normal or elevated IGF-I levels (23, 
25, 26, 30). Stimulated GH secretion was normal in all tested patients (24, 26, 28-
30). Apparently, IGF1R haploinsufficiency has no major impact on GH and IGF-I 
secretion.
IG F  b i n d i n g  p r ot e i n s
IGF-I is secreted in the circulation and associated with soluble high-affinity binding 
proteins, the IGFBPs. IGFBP-3 and IGFBP-5 form a complex with IGF-I and ALS. 
This ternary complex slows the clearance of IGF-I. Changes in IGFBP expression 
have an important role in modulating the growth-promoting actions of the IGFs.
In mice, reports of IGFBP knockout models are limited and demonstrate only few 
phenotypic manifestations (68). Overexpression of IGFBP-1 in transgenic mice 
result in a modest and transient impairment of fetal growth. Also maternal IGFBP-
1 excess is associated with reduced fetal growth indicating placental insufficiency 
(69). In human there is a striking inverse correlation between maternal and fetal 
circulating levels of IGFBP-1 and fetal size (39, 44, 70, 71). It is postulated that 
IGFBP-1 inhibits the growth promoting effect of IGF-I by binding fetal IGF’s in 
IUGR.  Indeed, IGFBP-1 levels and mRNA expression are markedly elevated in the 
umbilical cord blood of babies with profound and prolonged hypoxia, which is con-
sidered as a leading cause of IUGR (72). In a recent study the key role for IGFBP-1 
in mediating the effects of hypoxia on fetal growth was confirmed in zebrafish, 
suggesting this is a conserved physiological mechanism to restrict IGF stimulated 
growth under hypoxic conditions (73). 
IGFBP-1 is synthesized in the liver, where its expression is under control of insulin 
which suppresses its production (74). It has also been suggested that GH directly 
regulates IGFBP-1 secretion (75). In the patient with the IGF-I deletion IGFBP-
1 was low. This patient was severely insulin resistant and a combination of high 
insulin levels, the absence of IGF-I and increased GH levels probably contributes to 
the low IGFBP-1 levels. Treatment of this patient with rhIGF-I resulted in beneficial 
effects on insulin resistance, decreased GH secretion and higher IGFBP-1 levels 
(76). The patient with the inactivating mutation of the IGF-I gene was not severely 
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insulin resistant and had also low IGFBP-1 levels, suggesting an important role for 
a direct suppressive effect of GH on IGFBP-1 (14). The patient with ALS deficiency 
also had low IGFBP-1 levels, which can also be attributed to stimulated GH levels 
(33).
IGFBP-2 levels were low in the patient with the IGF-I gene deletion. rhIGF-I 
treatment increased the IGFBP-2 levels (76). IGFBP-2 in the patient with the IGF-I 
mutation was -1 SDS (14). The patient with ALS deficiency had low IGFBP-2 levels 
(33). These data suggest that GH plays a role in regulating IGFBP-2 production. 
In the absence of ALS,  IGFBP-3 is cleared very fast, resulting in extremely low 
serum concentrations (33, 77). The transcription of IGFBP-3 is induced by activa-
tion of the GH signal transduction pathway, including STAT5b. Therefore, IGFBP-3 
is a valuable biochemical parameter in differentiating a GH receptor or postrecep-
tor defect from an IGF-I or IGF1R defect. In the latter IGFBP-3 levels are normal 
(13, 14, 22), while in patients with a GHR defect or a STAT5b mutation IGFBP-3 
is low (51, 52, 54, 77).
T h e  G H - I G F - I  a x i s  b r a i n  d e ve l o p m e n t
IGF-I plays  a key role  in the development of the central nervous system, stimulat-
ing neurogenesis and synaptogenesis, facilitating oligodendrocyte development, 
promoting neuron and oligodendrocyte survival and stimulating myelination (78). 
In addition, IGF-I appears to be a potent agent for rescuing neurons from apoptosis. 
As systemic IGF-I is not readily transported through the blood-brain-barrier local 
production of IGF-I is considered to be responsible for these effects (79).
Psychomotor development is normal in patients with GH deficiency or insensitivity 
(80). Patients with primary IGF-I deficiency due to a deletion or mutation of the 
IGF-I gene are severely mentally retarded and microcephalic with a head circumfer-
ence at birth of -4.9 SDS (13) and -5.7 SDS (15) and in adulthood of -5.3 SDS (13) 
and -8 SDS (14), emphasizing the essential role of GH-independent IGF-I produc-
tion for prenatal brain development. The head circumference of carriers of the 
inactivating IGF-I mutation is within the normal range. However, carriers have a 
lower head circumference than non-carriers (-1 SDS vs 0.5 SDS).  Microcephaly is 
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a common feature in patients with IGF-I insensitivity due to a heterozygous IGF1R 
mutation, however less severe than in complete IGF-I deficiency (-3 SDS to -5.6 
SDS)(22). Psychomotor development in these patients varies from retarded with 
an IQ of 60 to completely normal. Head circumference in patients with IGF1R 
haploinsufficiency due to a terminal 15q deletion is not well documented. In two 
patients head circumference was measured: -5.3 SDS (25) and -3 SDS (26). In 
most cases psychomotor development was delayed, but the possible contribu-
tion of other genes in the deleted region makes conclusions on a causal relation 
difficult.
H e a r i n g
Recently, the role of IGF-I in auditory function was evaluated. Auditory brainstem 
responses were analized in IGF-I-/- mice, showing an all-frequency involved 
bilateral sensorineural hearing loss. The delayed response to acoustic stimuli along 
the auditory pathway indicates the contribution of the central nervous system to 
the hearing loss in IGF-I deficiency (81). At a cellular level a significant decrease in 
number and size of auditory neurons, increased apoptosis of cochlear neurons, a 
significant reduced volume of the cochlea and cochlear ganglion result in abnormal 
differentiation and maturation of the cochlear ganglion cells and abnormal inner-
vation of the sensory cells in the organ of Corti (82).
Audiograms of the three patients with complete IGF-I deficiency due to a homozy-
gous deletion or mutation of the IGF-I gene demonstrate severe bilateral sensori-
neural deafness (13-15). This is confirmed by absent brain stem evoked potentials 
in one of the patients (14). Seven of the 21 family members of the patient with the 
inactivating IGF-I mutation, including 9 carriers of the inactivating IGF-I mutation, 
revealhearing abnormalities. However, no significant association with the carrier-
ship could be detected (14). In patients with GH deficiency or insensitivity or het-
erozygous IGF1R receptor mutations hearing problems have not been reported. 
In conclusion, IGF-I is a key factor in development and postnatal differentiation 
and maturation of the inner ear. 
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V i s i o n
In a recent study, the ocular dimensions of patients with Laron syndrome were 
compared with reference values. Patients with Laron syndrome have significantly 
shorter axial length of the eye and shallower anterior chambers. Treatment with 
IGF-I increases the axial length of the eye (83). The patient with an inactivating 
IGF-I mutation, has a shallow anterior chamber, suggesting that IGF-I may play a 
role in ocular growth (14).
Retinal vascularization is significantly reduced in patients with defects of the GHR, 
IGF-I and IGF1R indicating that IGF-I plays an important role in this phenomenon 
(84). A strong association has been found between reduced IGF-I levels in preterm 
children and development of retinopathy of prematurity. Deficient IGF-I levels after 
premature birth result in initial poor retinal vascular development and a large area 
of avascular retina (85).
 
S ke l e t a l  f e a t u r e s
Limited elbow extensibility is seen in 85% of patients with Laron syndrome over 5 
years of age, with increasing severity with age (50). In addition, 6 of 8 patients with 
GH deficiency due to a PROP1 mutation show symmetrical limitation of elbow 
extensibility, correlated with age (86). In the patient with the inactivating mutation 
of the IGF-I gene we also found this feature but it was not described in the other 
patients with IGF-I defects at 19 months and 15.5 years, suggesting that IGF-I 
plays a role in elbow extensibility later in life. The mechanism is unknown. 
Micrognathia is a striking feature in two patients with IGF-I defects. Diewert et al. 
found that major growth movements and developmental changes in craniofacial 
tissues take place between 7 and 12 weeks of gestation (87). Significant altera-
tions in growth during this period may produce significant irreversible effects on 
postnatal craniofacial morphology. One can hypothesize that prenatal IGF-I defi-
ciency may disturb this process and result in micrognathia.
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B o n e  M i n e r a l  D e n s i t y
Studies on skeletal structure in IGF-I -/- mice show a 17% decrease in cortical bone 
but an increase in trabecular bone (23% in male and 88% in female) (88). This phe-
nomenon is also observed in IGF-I deficient double knockout mice (liver-specific 
IGF-I and ALS deletion) (89). Yakar et al. postulated that the ternary complex 
(IGF-I, IGFBP-3 and ALS) influences bone acquisition in a compartment-specific 
manner (i.e.cortical vs trabecular bone). The finding that IGF-I deficient mice 
exhibit greater impairment in bone accretion than GH deficient mice, implies a 
GH-independent effect of IGF-I on bone formation during postnatal growth (90). 
Dual-energy X-ray absorptiometry (DEXA) is a method to assess BMD (in g per 
cm2). However, the method does not correct for antero-posterior depth and is 
therefore greatly influenced by bone size. Bone mineral apparent density (BMAD) 
calculates volumetric density to minimize the effect of bone size on BMD values 
(91). This method  greatly contributes to the interpretation of BMD in patients 
with short stature. 
Patients with GH deficiency due to GHRHR mutations or GH insensitivity due to 
GHR mutations have a normal BMAD (92-94). BMAD in the patient with an IGF-I 
gene deletion is mildly reduced. Treatment with rhIGF-I resulted in a 7% increase of 
BMAD, compared to a 17% increase of BMD, suggesting that the increase in BMD 
is partly attributable to an increase in bone size (95). In contrast, severe osteopo-
rosis is demonstrated in the patient with an inactivating IGF-I mutation (14). Two 
patients with a heterozygous mutation of the IGF1R gene have a normal BMD (18, 
22). In one patient with ALS deficiency severe osteoporosis is found at the age of 
16 years (BMD at lumbar spine -4.6 SDS), with a partial recovery at 19 years of 
age (BMD at lumbar spine –2.1 SDS)  (96). In the patient we recently described a 
similar pattern was observed with an increasing BMD from -5.2 to -4.1 and -2.5 
SDS at the age of 16, 17 and 19 years, respectively. This suggests that sex steroids 
can reduce the osteoporotic effects of ALS deficiency during puberty.  
G l u c o s e  h o m e o st a s i s
It has been well documented that GH exerts direct effects on insulin secretion as 
well as indirect effects through increased lipolysis, resulting in elevated free fatty 
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acid (FFA) levels and impaired insulin sensitivity, the “lipotoxic effect” (97). Acute 
administration of GH has an insulin-like effect, mediated by the JAK-2 signaling 
pathway. Activation of insulin receptor substrate (IRS)-1 and IRS-2 leads to recruit-
ment of PI3 kinase and, analogous to the post-receptor events for insulin, results 
in increased glucose uptake (98). GH therapy is often associated with impaired 
insulin sensitivity. Prevention of lipolysis by coadministration of GH with FFA 
regulators can partially prevent the deterioration of insulin sensitivity, indicating 
that insulin resistance is a consequence of enhanced GH-induced lipolysis (99). In 
addition, the GH plus FFA regulator combination treatment significantly enhances 
linear body growth in SGA and control rats. The precise mechanism of this obser-
vation remains to be elucidated (100). Chronic excess of GH, as in acromegaly, is 
associated with insulin resistance and impairment of insulin receptor signal trans-
duction. Treatment of acromegalic patients with somatostatin analogues improves 
insulin resistance (101). Post receptor cross talk between the insulin receptor and 
GH receptor signaling pathway is believed to play a key role in this process (102). 
IGF-I, which has 48% amino acid sequence identity with proinsulin, enhances 
insulin sensitivity. Epidemiological studies have demonstrated that lower baseline 
IGF-I levels are associated with a higher risk of insulin resistance (103). Genetically 
determined low IGF-I levels are associated with an increased risk of insulin resis-
tance (104). Treatment with rhIGF-I improves insulin sensitivity in normal individu-
als (105), in patients with insulin resistance (106) and in those with diabetes type I 
(107) or type II (108). The patient with IGF-I deficiency due to an IGF-I deletion had 
severe insulin resistance, which improved with rhIGF-I treatment (76). Patients with 
a heterozygous inactivating mutation of the IGF-I gene had higher fasting insulin 
levels than non-carriers (14). Two patients with a heterozygous IGF1R mutation 
had a moderate degree of insulin resistance (22, 109). The first described patient 
with ALS deficiency was insulin resistant (33). These results demonstrate a role for 
IGF-I in glucose homeostasis. Whether IGF-I directly affects insulin sensitivity or by 
regulating endogenous GH levels is a topic of intense research.  
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B o d y  c o m p o s i t i o n
GH is known to have a lipolytic effect, which is illustrated by the finding that GH 
treatment in GH reduces adiposity and improves lipid profiles (110). Patients with 
GH resistance have a markedly decreased ratio of lean mass to fat mass, indicating 
the lack of the direct antilipolytic effect of GH (50). In the patient with the IGF-I 
gene deletion, in whom the direct GH effects are intact, a low body fat content was 
found (19.9%), which is in line with a direct antilipolytic effect of GH (95). Total 
body fat content increased in this patient after 1 year of treatment with rhIGF-I, 
which can be explained by the fall in GH levels induced by rhIGF-I. IGF-I has no 
direct effects on lipolysis or lipogenesis. 
P u b e r t y  a n d  g o n a d a l  f u n c t i o n
Puberty is delayed in all conditions associated with IGF-I deficiency: GH deficiency 
due to a GHRHR mutation (49), GH insensitivity caused by a GHR mutation (50, 
111), or a STAT5b mutation (54),  IGF-I gene deletion (76) and an inactivating IGF-
I mutation (14). One female with a heterozygous IGF1R mutation had menarche at 
the age of 18 years (22), but one of the patients described by Abbuzahab et al. had 
a normal onset of puberty (18). The first patient with a mutation of the ALS gene 
had a delayed onset of puberty (112), but a later report showed a normal onset of 
puberty (34). These findings suggest that IGF-I plays a role in pubertal onset. 
The pubertal growth spurt is decreased in patients with GH deficiency or resistance 
with normal testosterone levels. This was initially interpreted by speculating that 
testosterone needs the presence of normal GH secretion to exert its full growth 
promoting effect (113). Later, evidence was provided that the growth stimulat-
ing effect of testosterone in puberty may be primarily caused by conversion to 
estrogens and that estrogens are responsible for the pubertal growth spurt and 
epiphysial closure (114).
IGF-I-/- mice are infertile. Males have drastically reduced testosterone levels, 
caused by a significant developmental delay of Leydig cells. Females fail to ovulate 
and possess an infantile uterus with hypoplastic endometrium (115). It is difficult 
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to hypothesize on the role of GH and IGF-I in reproductive function in the human, 
as most reported patients with GH-IGF-I defects are too young. Patients with 
GHRHR mutations (116) and GHR mutation are reported to be fertile. Gonadal 
function of a 30 year old patient with STAT5b mutation was normal (54). The 
55 year old patient with an inactivating IGF-I gene mutation had a small testicu-
lar volume, low inhibin B levels and elevated FSH levels, indicating compromised 
Sertoli cell function and impaired spermatogenesis (14). The role of IGF-I defi-
ciency in the partial gonadal failure is unclear, as this patient underwent  a bilateral 
inguinal hernia operation, with possible damage to the testicles. Patients with a 
heterozygous deletion or mutation of the IGF-I (13, 14) or IGF1R gene (22) are 
fertile. More patients and accurate follow-up at adult age will contribute to unravel 
the role of IGF-I in human reproduction. 
I m m u n e  s y st e m
It has been well established that GH and IGF-I affect the development and function 
of the immune system (117). Most defects of the GH-IGF-I axis are not associated 
with immune disorders, except the STAT5b mutation. STAT proteins are involved 
in the signaling pathway of cytokine receptors (118) and STAT5b-/- mouse exhibit 
a severe immunologic phenotype (119). So far, 5 females and 1 male with a STAT5b 
mutation have been reported (52-54, 66, 77). Five patients have signs of immune 
deficiency. Clinically this results in lymphoid interstitial pneumonia due to Pneu-
mocystis carinii (52),  recurrent pulmonary infections (53, 77), and recurrent 
infections of skin and respiratory tract, severe chronic lung disease and herpetic 
keratitis (66). One patient suffers from juvenile idiopathic arthritis (53). The 30 
year old male patient has no history or signs of immune deficiency (120). Thus, in 
the human an intact STAT5b is not obligatory for a normal immune phenotype. 
We have described a patient with partial GH insensitivity and severe immune defi-
ciency due to a mutation of I-γBγ, disturbing the NF-γB signaling pathway (121). 
In vitro studies have shown that GH binding to the GHR can promote the NF-γB 
signaling pathway (122). Another patient with severe combined immunodeficiency 
(SCID) and GH insensitivity has been described (123). This patient has a mutation 
of the IL2Rγ chain gene, suggesting a common underlying pathogenic mechanism 
for the endocrinological and  immunological problems. 
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More reports on patients with combined growth and immune disorders are needed 
to increase our knowledge on the interaction between the immune system and the 
GH-IGF-I axis.  
L o n ge v i t y
Several lines of evidence suggest an inverse relationship between body size and 
lifespan in mice (124). For example, Laron mice live up to 55% longer than normal 
mice (125). Genetic studies in various experimental models suggest that the ageing 
process is regulated by genes that encode proteins from the GH-IGF-I axis. Exciting 
studies in IGF1R +/-  mice with 50% reduction in receptor level, show that females 
live 33% longer and males 16% longer. The longer lifespan could not be attributed 
to other factors and the authors conclude that IGF-I may be a central regulator of 
mammalian lifespan (126). At a cellular level, fibroblasts with a reduced number of 
receptors are better able to survive to oxidative stress. By causing damage to DNA, 
protein, lipids and cellular components oxidative stress  is the major determinant 
of the ageing process.. At a molecular level the intracellular signaling pathway is 
downregulated. Repressing intracellular signals of insulin and IGF-I is an evolution-
arily conserved mechanism for extending lifespan. 
Caloric restriction also has a positive effect on lifespan. Mild food restriction in 
normal and the Ames dwarf mice demonstrates changes in the expression of genes 
related to insulin and IGF-I signaling pathways (127) . These changes may cause 
the animals to become more sensitive to insulin. Since insulin sensitive mutant 
animals live longer, it is suggested that these genes may play a role in aging and life 
span determination. Studies in the human are limited.
D i a g n o st i c  a p p r o a c h
The number of patients with defects in the GH-IGF-I axis is still small, but we believe 
that they represent a tip of the iceberg. Future studies aimed at detecting known or 
unknown molecular defects in patients with short stature will undoubtedly make 
the tip of the iceberg grow. 
The diagnostic process to reveal an abnormality in the GH-IGF-I axis begins with an 
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alert physician, who is not satisfied with the diagnosis of idiopathic short stature. 
The medical history should include birth weight, length and head circumference, as 
low values of these parameters for gestational age are features of a genetic defect 
in IGF-I, the IGF1R or a not yet described IGF-I signaling disorder. It cannot be 
stressed enough that measurement of length at birth is very important to detect 
underlying pathology and the fear that stretching the legs could be harmful for the 
hip joint is unjustified (128). Careful evaluation of milestones in development is 
necessary  to have an impression of the psychomotor development. Family history 
should include height of other family members and if possible birth data. The 
presence of hearing abnormalities in a family should alert the physician to consider 
an IGF-I defect. 
After excluding organic and systemic disorders like celiac disease and Turner 
syndrome the IGF-I and IGFBP-3 level will determine the follow up. We recently 
presented guidelines for the diagnostic process of patients with severe short stature 
of unknown origin (129). 
The procedure for detailed functional and genetic analysis of a patient with short 
stature and a possible defect in the GH-IGF-I axis depends on the local setting. In 
the Leiden University Medical Center the Leiden Growth Genetics Working group, 
consisting of pediatric and adult endocrinologists, clinical and molecular geneti-
cists, molecular biologists and interested physicians meet to discuss the locally, 
nationally and internationally referred patients. The referring physician is asked to 
complete a form (Appendix A) to register all the information that is necessary to 
make a presumptive diagnosis, including phenotypic features of the patient and 
his or her family and biochemical measurements (IGF-I, IGFBP-3, GH stimula-
tion test). One of the members of the group assesses the information and can 
advise on additional testing, for example an IGF-I generation test, measurement 
of other binding proteins, GH-binding protein or ALS. After presentation of the 
patient and discussion the decision for the next diagnostic step is made, which can 
be sequencing a specific gene, Multiplex Ligation-dependent Probe Amplification 




I m p l i c a t i o n s  f o r  t h e  p a t i e n t
Idiopathic short stature is an unsatisfactory diagnosis for the physician as well as 
for the patient. To find the cause of short stature is important for the patient for 
several reasons. First, with a definite diagnose the often long-lasting diagnostic 
process will come to an end. Second, it will be possible to give information on the 
specific defect and accompanying problems. For example, life style advices in case 
of higher risk of insulin resistance in patients with a heterozygous IGF1R mutation 
or prevention of osteoporosis in patients with ALS deficiency . Finally, therapeutic 
options can be discussed. It has been reported that GH therapy in patients with 
a heterozygous IGF1R mutation or deletion improves growth and head circumfer-
ence(18, 30, 109, 130). In the late 1980’s trials with rhIGF-I started in patients with 
GHR defects. Approximately 60 children have been treated with rhIGF-I injections 
for 2 years or longer. Height SDS increases, although not as much as GH treatment 
in GH deficient patients (131). The explanation for the modest growth response to 
rhIGF-I is probably the absence of direct GH effects at the level of the growth plate, 
including enhancement of local IGF-I production. Recently an rhIGF-I-rhIGFBP-3 
complex, with a longer half life, has been developed as therapeutic agent. Trials in 
patients with GH insensitivity are currently in progress (132). 
Fu t u r e  p e r s p e c t i ve s
Future research should be focused on identifying patients with established defects 
in the GH-IGF-I axis and to evaluate carefully the clinical and biochemical features. 
Genetic defects in the GH-IGF-I axis are rare and international collaboration will 
increase the knowledge on the role of the GH-IGF-I axis in growth and develop-
ment. Finally, it will be a challenge to find new defects in the GH-IGF-I axis in order 
to unravel the  molecular mechanisms that are responsible for the effects of GH 
and IGF-I on pre-and postnatal growth and development.  
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Growth is a complex process, regulated by multiple external and internal factors. 
Deviation from the normal growth pattern can be one of the first manifestations of 
an underlying disorder, disrupting the normal growth process. The GH-IGF-I axis 
plays a key role in regulating the growth process. This thesis focuses on growth 
disorders as a result of genetic defects in the GH-IGF-I axis.  
The aim of this thesis is to study the genotype-phenotype relationship in patients 
with a documented genetic defect in a component of the GH-IGF-I axis and to 
unravel the role of the GH-IGF-I axis in the complex process of growth and devel-
opment throughout life. 
Chapter 1 describes the milestones in the history of the GH-IGF-I axis that lead the 
basis for our current knowledge. In addition, the present view on the GH-IGF-I axis 
is summarized.   
Chapter 2 gives an overview of the clinical aspects and biochemical parameters of 
the various genetic defects in the GH-IGF-I axis. Classical GH deficiency, resulting 
in decreased or absent pituitary GH secretion, can be the result of a mutation 
in the GH releasing hormone receptor (GHRH-R) gene, a defect in the ontogen-
esis of the GH producing cells or a mutation or deletion of the GH1 gene. Since 
the first paper that showed the etiology of Laron syndrome, many mutations in 
the GH receptor have been identified. Several patients have been described with 
a STAT5b mutation, which disrupts the GH signal transduction. More recently, 
genetic defects in the IGF-I gene or the IGF-I receptor gene have been described. 
All these defects result in proportionate short stature. Therefore, in the workup of 
a patient with proportionate short stature genetic analysis is essential. However, 
careful selection of the patients is a prerequisite for optimal results. Therefore, we 
developed flowcharts, based on the described patients in combination with theo-
retical considerations. These flowcharts can be used as guidelines in the diagnostic 
process of patients with idiopathic short stature.   
Chapter 3 describes a brother and sister with a mutation of the GHRH-R gene. They 
presented with a height of -5.8 SDS and -7.6 SDS at an advanced age of 16 and 
14.9 years, respectively, and an advanced pubertal stage. Genetic analysis revealed 
a homozygous single base pair transition at the splice donor site of intron 7. Both 





GH with postponing puberty and delaying skeletal maturation, GH treatment was 
combined with the administration of a gonadotropin-releasing hormone analog 
(GnRHa). This combination treatment was highly effective in increasing final 
height. Sitting height/height ratio decreased in both patients during treatment. 
Although this ratio was within the normal population range, one could conclude 
that combined treatment with GH and GnRHa may result in relatively longer legs. 
Bone mineral density was in the lower normal range in both patients at adult age. 
However, both patients developed severe vitamin D deficiency as adults, which 
confounds the effects of GnRHa treatment on the acquisition of peak bone mass. 
GH insensitivity can be caused by defects in the GH receptor (Laron’s syndrome) 
or a defect in the postreceptor signaling pathway. Recently, reports on two female 
patients with severe postnatal growth retardation, pulmonary problems and 
immunodeficiency were published. These patients had a homozygous defect in the 
STAT5b gene. In chapter 4 and 5 of this thesis the first male patient is described 
with a homozygous frameshift mutation in the STAT5b gene, resulting in an 
inactive truncated protein, lacking most of the DNA binding and SH2-domain. 
The phenotype consisted of severe short stature (final height -5.9 SDS), delayed 
puberty and high body fat percentage (40%), but no history or signs of pulmonary 
problems or immunodeficiency. Biochemically extremely low levels of IGF-I (-6.9 
SDS), IGFBP-3 (-12 SDS), and ALS (-7.5 SDS) were present. In addition, prolactin 
levels were elevated. 24-h GH and prolactin secretion characteristics were assessed. 
The GH secretory parameters were comparable with healthy male controls. 
However, one could hypothesize that GH secretion is severely suppressed by his 
visceral adiposity. Prolactin secretion was increased by six-fold. High doses of GH 
in the IGF-I generation test showed a response of  IGF-I to levels approaching 
reference range values. Evaluation of the monocyte and T-cell function revealed no 
abnormalities. The heterozygous family members of the patient showed no signs 
of GH insensitivity.
In conclusion, STAT5b deficiency causes a disruption of the GH signaling pathway, 
resulting in severe short stature. Although STAT5b plays a role in signaling 
processes in immune cells, apparently, immunodeficiency is not an obligatory 




Chapter 6 reports on the first patient with an inactivating homozygous missense 
mutation of the IGF-I gene. The phenotype consisted of severe intrauterine growth 
retardation (birth weight -3.9 SDS and birth length -4.3 SDS), reflecting the GH-
independent IGF-I secretion in utero. Severe mental retardation, microcephaly 
(head circumference -8 SDS) and sensorineural deafness were observed and con-
sidered as a consequence of  IGF-I defciency on intrauterine brain development. 
The postnatal growth pattern was comparable with untreated GH deficient or GH-
insensitive patients (final height -8.5 SDS), which is in line with the hypothesis that 
IGF-I secretion in childhood is mainly GH-dependent. Apparently IGF-I deficiency 
is well tolerated after adolescence, considering the relative healthy condition of the 
55-yr-old patient. Biochemically, the patient had high IGF-I levels (+7.3 SDS) and a 
stimulated GH secretion in the upper normal range. 
In addition, 24 relatives of the patient were studied: nine heterozygous carriers 
were identified, which had a significantly lower birth weight, final height and head 
circumference than the noncarriers. 
The structural and functional characterization of the IGF-I mutation is described in 
detail in chapter 7. The mutation lead to the expression of IGF-I with an aminoacid 
substitution of methionine instead of a valine at residue 44 of the protein(val44met 
IGF-I). Val44met IGF-I exhibited a 90-fold decrease in IGF1R binding compared 
with wild type IGF-I. An indirect argument for the important role of this part of 
the molecule is provided by observations that a point mutation in the insulin gene 
(valA3leu insulin, also termed insulin Wakayama, corresponding with Val44 of IGF-I.) 
result in hyperinsulinemia due to severely defective insulin receptor binding. Activa-
tion of downstream signaling by val44met IGF-I was reduced, corresponding with 
the reduced affinity for the IGF1R. Also, val44met IGF-I was unable to stimulate 
DNA synthesis. Binding or activation of both insulin receptor isoforms was not 
detectable. However, val44met IGF-I bound IGFBP-2, IGFBP-3 and IGFBP-6 with 
equal affinity to IGF-I, suggesting the maintenance of the overall structure. Nuclear 
magnetic resonance studies confirmed retention of near-native structure with only 
local side-chain disruptions.  
In chapter 8 we describe a mother and daughter with a heterozygous missense 
mutation in the intracellular tyrosine kinase domain of the IGF1R. The phenotype 
of the mother consisted of mild intrauterine growth retardation (birth weight -
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2.1 SDS, birth length -0.3 SDS) and progressive postnatal growth failure (final 
height -4 SDS), microcephaly (head circumference -3 SDS) and failure to thrive. 
The daughter suffered from severe intrauterine growth retardation (birth weight 
-3.3 SDS, birth length -4.2 SDS), microcephaly (head circumference -5.2 SDS) and 
postnatal growth failure. In both patients IGF-I levels were elevated (+1.6 SDS and 
+2.9 SDS, respectively). Functional characterization revealed normal binding of 
IGF-I to the IGF1 receptor, but marked reduction of autophosphorylation and acti-
vation of the downstream signaling cascade, suggesting inactivation of one copy of 
the IGF1R gene. A summary of the clinical features of the other patients described 
in the literature leads to the hypothesis that the degree of intrauterine growth retar-
dation may be determined by the presence or absence of maternal IGF-I resistance. 
In chapter 9 the phenotype of a heterozygous terminal 15q deletion is described, 
consisting of intrauterine growth retardation, postnatal growth retardation, micro-
cephaly, and elevated IGF-I levels. These phenotypic features are similar to the 
features found in patients with an inactivating IGF1R mutation and can therefore 
be ascribed to the loss of one copy of the IGF1R gene. This was diagnosed with a 
novel genetic technique: multiplex ligation-dependent probe amplification (MLPA). 
Subsequently, array comparative genomic hybridization was used to define the 
deleted area, which was 15q26.2->qter. The patient was effectively treated with 
GH, reaching a final height of -1.8 SDS, which is within the population range, 
although not in her genetic target range. 
Chapter 10 reviews the reports of patients with a genetic defect in the GH-IGF-I 
axis and summarizes the data of animal knockout experiments. The role of the GH-
IGF-I axis in intrauterine and postnatal growth is described. In addition, the effects 
of the GH-IGF-I axis on the development and function of different organ systems 
as brain, eye, skeleton, glucose homeostasis, gonadal function and immune system 
are discussed. In this chapter a systematic diagnostic approach and selective 
genetic analysis in a patient with short stature is advocated in order to identify 
more patients with a genetic defect in the GH-IGF-I axis and thereby increasing the 







Groei is een complex proces, dat wordt gereguleerd door verschillende externe en 
interne factoren. Een afwijking van het normale groeipatroon kan een aanwijzing 
zijn voor een onderliggende afwijking, die het normale groeiproces verstoort. De 
groeihormoon (GH)-Insuline-achtige groeifactor I (IGF-I) as speelt een belang-
rijke rol in de regulatie van groei. Dit proefschrift is gericht op groeistoornissen als 
gevolg van een genetisch defect in de GH-IGF-I as. 
Het doel van dit proefschrift is genotype-fenotype relaties te beschrijven in patiënten 
met een genetisch defect in één van de componenten van de GH-IGF-I as en om de 
rol van de GH-IGF-I as in het complexe proces van groei en ontwikkeling gedurende 
het leven te bestuderen. 
In Hoofdstuk 1 worden de mijlpalen in de geschiedenis van de GH-IGF-I as beschre-
ven, die hebben geleid tot onze huidige kennis. Tevens wordt de meest recente kijk 
op de GH-IGF-I as samengevat. 
Hoofdstuk 2 geeft een overzicht van de klinische aspecten en de biochemische para-
meters van de verschillende genetische defecten in de GH-IGF-I as. Klassieke GH 
deficiëntie, met als gevolg verminderde of afwezige hypofysaire GH secretie, kan 
het gevolg zijn van een mutatie in het  GH releasing hormoon receptor (GHRH-R) 
gen, een defect in de ontogenese van de GH producerende cellen of een mutatie of 
deletie van het GH1 gen. Sinds het eerste artikel dat de etiologie van het syndroom 
van Laron aantoonde zijn er vele mutaties in de GH receptor beschreven. Er zijn 
meerdere patiënten beschreven met een mutatie in het STAT5b gen, waardoor de 
GH signaaltransductie wordt verstoord. Meer recent zijn er genetische defecten in 
het IGF-I gen of het IGF-I receptor gen beschreven. Al deze defecten resulteren in 
geproportioneerde kleine lengte. In de evaluatie van een patiënt met geproportio-
neerde kleine lengte is genetische analyse dan ook een essentieel onderdeel. Echter, 
zorgvuldige selectie van de patiënt is van belang voor een optimaal resultaat. Tevens 
worden flow-diagrammen gepresenteerd, gebaseerd op de beschreven patiënten 
in combinatie met theoretische overwegingen. Deze flow-diagrammen kunnen als 
richtlijn worden gebruikt in het diagnostisch proces van patiënten met idiopathisch 
kleine gestalte. 
Hoofdstuk  3 beschrijft een broer en zus met een mutatie van het GHRH-R gen. 
Zij presenteerden zich met een lengte van -5,8 SDS en -7,6 SDS op de leeftijd van 
Chapter 12
218
respectievelijk 16 en 14,9 jaar in een vergevorderd puberteitstadium. Genetische 
analyse toonde een homozygote transitie van een enkel basepaar aan, ter hoogte 
van intron 7.  Beide patiënten werden behandeld met groeihormoon. Om het 
groeibevorderend effect van groeihormoon te combineren met het uitstellen van 
de puberteit en daarmee het vertragen van de botrijping, werd een gonadotropine 
releasing hormoon analoog (GnRHa) toegevoegd aan de GH behandeling. Deze 
combinatie leidde tot een positief effect op de eindlengte. 
GH ongevoeligheid kan het gevolg zijn van een defect in de GH receptor, zoals in 
Laron syndroom of een defect in de postreceptor signaaltransductie. Recent werden 
twee artikelen gepubliceerd waarin vrouwelijke patiënten werden beschreven met 
ernstige postnatale groeivertraging, pulmonale problemen en immuundeficiëntie. 
Deze patiënten hadden een homozygoot defect in het STAT5b gen. 
In hoofdstuk 4 en 5 van dit proefschrift wordt de eerste mannelijke patiënt beschre-
ven met een homozygote frameshift mutatie in het STAT5b gen, leidend tot een 
inactief, getrunceerd eiwit, waarbij het grootste deel van het DNA bindend domein 
en het gehele SH2 domein ontbreekt. Het fenotype van de patiënt bestond uit 
extreem kleine lengte (eindlengte -5.9 SDS), late puberteit en een hoog percentage 
lichaamsvet (40%), maar er waren geen aanwijzingen voor pulmonale problemen 
of immuundeficiëntie. Biochemisch had hij extreem lage IGF-I waarden (-6,9 SDS), 
IGFBP-3 (-12 SDS) en ALS (-7. SDS). Tevens had hij verhoogde prolactine waarden. 
Bij deze patient werden ook 24-uurs groeihormoon en prolactine profielen verricht. 
De GH secretie was vergelijkbaar met gezonde mannelijke controles. In het licht van 
het verhoogde vetpercentage in de patiënt zou deze normale secretie als verhoogd 
kunnen worden beschouwd, aangezien bekend is dat de GH secretie wordt onder-
drukt door visceraal vet. De prolactine secretie was zesvoudig verhoogd. Hoge 
dosis GH in de IGF-I generatietest liet een respons van IGF-I zien tot bijna normale 
referentiewaarden. Evaluatie van de monocyt en T-cel functie liet geen afwijkin-
gen zien. De heterozygote familieleden van de patiënt lieten geen aanwijzingen zien 
voor GH ongevoeligheid. Concluderend veroorzaakt STAT5b deficiëntie een ver-
storing in de GH signaaltransductie, leidend tot kleine lengte. Hoewel STAT5b een 
rol speelt in de signaaltransductie van immuuncellen, is immuundeficiëntie geen 
obligaat symptoom van STAT5b deficiëntie. Hyperprolactinemie, daarentegen, 
lijkt een essentieel onderdeel van een STAT5b defect. 
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In hoofdstuk 6 wordt de eerste patiënt beschreven met een inactiverende homozy-
gote missense mutatie van het IGF-I gen. Het fenotype bestond uit ernstige intrau-
teriene groeivertraging (geboortegewicht -3,9 SDS en geboortelengte -4,3 SDS). 
Deze bevinding reflecteert de GH-onafhankelijke IGF-I secretie in utero. Verder 
bestond het fenotype uit ernstige mentale retardatie, microcefalie (hoofdomtrek 
-8 SDS) en perceptiedoofheid. Deze kenmerken zijn het gevolg van IGF-I deficiëntie 
op de intrauteriene hersenontwikkeling. De postnatale groei was vergelijkbaar met 
die van onbehandelde GH-deficiënte of GH-resistente patiënten (eindlengte was 
-8,5 SDS). Dit is overeenkomstig de hypothese dat IGF-I secretie na de geboorte 
voornamelijk GH-afhankelijk is. Blijkbaar wordt IGF-I deficiëntie goed verdragen in 
de rest van het leven, gezien de relatief gezonde conditie van deze 55 jarige patiënt. 
Biochemisch had de patiënt zeer hoge IGF-I waarden (+7,3 SDS) en een gestimu-
leerde GH secretie in de hoog normale range. 
Tevens werden 24 familieleden van de patiënt onderzocht, waarvan negen familie-
leden heterozygoot waren voor de mutatie. Zij hadden een significant lager geboor-
tegewicht, eindlengte en hoofdomtrek dan de familieleden die geen drager waren. 
De structurele en functionele eigenschappen van de IGF-I mutatie worden gedetail-
leerd beschreven in hoofdstuk 7. De mutatie leidt tot de expressie van IGF-I met een 
methionine in plaats van een valine op positie 44 (val44met IGF-I). val44met IGF-I 
heeft een 90-voudig verminderde capaciteit om aan de IGF1R te binden, vergeleken 
met wild type IGF-I. Een indirect argument voor de belangrijke rol van dit deel van 
het molecuul is dat een punt mutatie in het insuline gen (valA3leu insulin, ook wel 
bekend als insuline Wakayama, dat overeenkomt met Val44 van IGF-I.) resulteert in 
hyperinsulinisme als gevolg van een verminderde binding aan de insuline receptor. 
Activatie van de signaaltransductie-route door val44met IGF-I was verminderd, 
overeenkomend met de verminderde affiniteit voor de IGF1R. Tevens was val44met 
IGF-I niet in staat om DNA synthese te stimuleren. Ook was er geen binding en 
activatie van de insuline receptor detecteerbaar. Echter, val44met IGF-I was wel in 
staat IGFBP-2, IGFBP-3 en IGFBP-6 te binden, met dezelfde affiniteit als IGF-I. Dit 
suggereert dat de globale structuur behouden is gebleven. Dit werd bevestigd met 
nucleaire magnetische resonantie studies, waarbij de oorspronkelijke structuur 
onveranderd was en alleen locale veranderingen in de zijketen werden gezien. 
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In hoofdstuk 8 beschrijven wij een moeder en haar dochter met een heterozygote 
missense mutatie in het intracellulaire tyrosine kinase domein van de IGF1R. Het 
fenotype van de moeder bestaat uit milde intrauteriene groeiretardatie (geboortege-
wicht -2,1 SDS, geboortelengte -0,3 SDS), progressieve postnatale groeivertraging 
(eindlengte -4 SDS), microcefalie (hoofdomtrek -3 SDS) en slechte gewichtstoe-
name (“failure to thrive”). Haar dochter werd geboren met een geboortegewicht 
van -3,3 SDS en een geboortelengte van -4,2 SDS, dus een ernstige intrauteriene 
groeivertraging. In beide patiënten was het IGF-I verhoogd (respectievelijk +1,6 
SDS en +2,9 SDS). Functionele karakterisatie liet een normale binding van IGF-
I zien aan de IGF-I receptor, maar een duidelijk verminderde autofosforylatie en 
activatie van de signaaltransductie cascade. Dit suggereert inactivatie van één 
kopie van het IGF1R gen. De overige patiënten die in de literatuur beschreven zijn, 
worden samengevat in dit hoofdstuk, waarbij geconcludeerd wordt dat de mate 
van intrauteriene groeivertraging ten dele afhankelijk zou kunnen zijn van de aan- 
dan wel afwezigheid van maternale IGF-I resistentie. 
In hoofdstuk 9 wordt het fenotype beschreven van een patiënte met een hetero-
zygote deletie van het terminale deel van chromosoom 15q. Dit fenotype bestaat 
uit intrauteriene groeiretardatie, postnatale groeivertraging, microcefalie en 
verhoogde IGF-I waarden. Dit fenotype is gelijk aan het fenotype dat beschre-
ven is bij de inactiverende IGF1R mutatie en kan dus worden toegeschreven aan 
de afwezigheid van één kopie van het IGF1R gen. Dit werd gediagnosticeerd met 
een nieuwe genetische techniek: multiplex ligatie-afhankelijke probe amplificatie 
(MLPA). Vervolgens werd door middel van array comparatieve genomische hybri-
disatie de grootte van het missende deel vastgesteld: 15q26.2->qter. De patiënt 
werd behandeld met groeihormoon met goed resultaat. Zij bereikte een eindlengte 
van -1.8 SDS. Dit is binnen de populatierange, maar niet binnen haar genetisch 
bepaalde lengte. 
In hoofdstuk 10 worden de publicaties over patiënten met een genetische afwijking 
in de GH-IGF-I as beschreven en de data van dierexperimenteel onderzoek samen-
gevat. De rol van de GH-IGF-I as in intrauteriene en postnatale groei wordt 
beschreven. Tevens worden de effecten van de GH-IGF-I as op ontwikkeling en 
functie van verschillende orgaansystemen als hersenen, ogen, skelet, glucose-meta-
bolisme, gonadale functie en immuunsysteem bediscussieerd. In dit hoofdstuk 
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wordt een systematische diagnostische benadering en selectieve genetische analyse 
van patiënten met een groeistoornis voorgesteld om zo meer patiënten met een 
genetisch defect in de GH-IGF-I as te kunnen identificeren. Hierdoor zal de kennis 
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